


**CUMULATIVE
SUPPLEMENT 3
March 2026**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

**Cumulative Supplement 3
March 2026**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT	vi
1.3	LEVOTHYROXINE SODIUM	vii
1.4	AVAILABILITY OF THE EDITION.....	viii
1.5	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	ix
1.6	CUMULATIVE SUPPLEMENT LEGEND.....	x
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

46th EDITION

CUMULATIVE SUPPLEMENT 3
March 2026

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at orangebook@fda.hhs.gov.

1.3 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2025</u>	<u>MAR</u> <u>2026</u>	<u>JUN</u> <u>2026</u>	<u>SEP</u> <u>2026</u>	<u>DEC</u> <u>2026</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	24120 2765 (11.5%)	24441 2813 (11.5%)			
MULTISOURCE	21355 (88.5%)	21628 (88.5%)			
THERAPEUTICALLY EQUIVALENT	21260 (87.1%)	21534 (88.1%)			
NOT THERAPEUTICALLY EQUIVALENT	95 (0.4%)	94 (0.4%)			

EXCEPTIONS ⁴	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	19	41
NUMBER OF APPLICANTS	1198	1198

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CPOT Change. Potency amount/unit.
CRLD Change. Reference Listed Drug
CHRS Change. Reference Standard
CTEC Change. Therapeutic Equivalence Code.
CTNA Change. Trade Name.
DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABARELIX

POWDER; INTRAMUSCULAR
PLENAXIS

@ SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003 Jan CDFR

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

>A> AB APPCO 333MG A218984 001 Mar 16, 2026 Mar NEWA

ACARBOSE

TABLET; ORAL
ACARBOSE

>D> @ DASH PHARMS 25MG A091053 001 Jan 06, 2011 Mar CAHN
>D> @ 50MG A091053 002 Jan 06, 2011 Mar CAHN
>D> @ 100MG A091053 003 Jan 06, 2011 Mar CAHN
>A> @ NATCO PHARMA USA 25MG A091053 001 Jan 06, 2011 Mar CAHN
>A> @ 50MG A091053 002 Jan 06, 2011 Mar CAHN
>A> @ 100MG A091053 003 Jan 06, 2011 Mar CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTAPAP

>D> AA ! ANDA REPOSITORY 325MG; 50MG A089987 001 Oct 26, 1992 Mar CAHN
>A> AA ! MIKART 325MG; 50MG A089987 001 Oct 26, 1992 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA INGENUS PHARMS LLC 300MG; 50MG; 40MG A215047 001 Nov 17, 2021 Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D> @ LANNETT CO INC 300MG; 5MG A207171 001 Jun 20, 2017 Mar CMFD
>A> AA 300MG; 5MG A207171 001 Jun 20, 2017 Mar CMFD
>D> @ 300MG; 7.5MG A207171 002 Jun 20, 2017 Mar CMFD
>A> AA 300MG; 7.5MG A207171 002 Jun 20, 2017 Mar CMFD
>D> @ 300MG; 10MG A207171 003 Jun 20, 2017 Mar CMFD
>A> AA 300MG; 10MG A207171 003 Jun 20, 2017 Mar CMFD
>D> @ 325MG; 5MG A207172 001 Jun 22, 2017 Mar CMFD
>A> AA 325MG; 5MG A207172 001 Jun 22, 2017 Mar CMFD
>D> @ 325MG; 7.5MG A207172 002 Jun 22, 2017 Mar CMFD
>A> AA 325MG; 7.5MG A207172 002 Jun 22, 2017 Mar CMFD
>D> @ 325MG; 10MG A207172 003 Jun 22, 2017 Mar CMFD
>A> AA 325MG; 10MG A207172 003 Jun 22, 2017 Mar CMFD
@ STRIDES PHARMA INTL 325MG; 5MG A040655 001 Jan 19, 2006 Jan DISC
@ 325MG; 7.5MG A040656 001 Jan 19, 2006 Jan DISC
@ 325MG; 10MG A040355 001 May 31, 2000 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA LANNETT CO INC 325MG; 5MG A207333 001 Sep 25, 2017 Feb CMFD
AA 325MG; 10MG A207333 002 Sep 25, 2017 Feb CMFD

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION
TUDORZA PRESSAIR

>A> +! AZURITY 0.4MG/INH N202450 001 Jul 23, 2012 Mar CAHN
>D> +! COVIS 0.4MG/INH N202450 001 Jul 23, 2012 Mar CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION
DUAKLIR PRESSAIR

>A> +! AZURITY 0.4MG/INH; 0.012MG/INH N210595 001 Mar 29, 2019 Mar CAHN
>D> +! COVIS 0.4MG/INH; 0.012MG/INH N210595 001 Mar 29, 2019 Mar CAHN

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

@	STRIDES PHARMA INTL	400MG	A074946	001	Nov 19, 1997	Jan	DISC
@		800MG	A074946	002	Nov 19, 1997	Jan	DISC

ADAPALENE

SOLUTION; TOPICAL

ADAPALENE

AB	WAYLIS THERAP	0.1%	A203981	001	Sep 23, 2016	Jan	CAHN
AB		0.1%	A204593	001	Jan 05, 2016	Jan	CAHN

ALBUTEROL SULFATE

TABLET; ORAL

ALBUTEROL SULFATE

>D>	AB	DASH PHARMS NATCO	EQ 2MG BASE	A072894	002	Jan 17, 1991	Mar	CAHN
>D>	AB	!	EQ 4MG BASE	A072894	001	Jan 17, 1991	Mar	CAHN
>A>	AB	NATCO PHARMA USA	EQ 2MG BASE	A072894	002	Jan 17, 1991	Mar	CAHN
>A>	AB	!	EQ 4MG BASE	A072894	001	Jan 17, 1991	Mar	CAHN

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

AB	+	LXO IRELAND	EQ 150MG BASE	N021985	001	Mar 05, 2007	Jan	CAHN
AB	+	!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Jan	CAHN

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@	STRIDES PHARMA INTL	0.25MG	A090248	001	Sep 17, 2010	Jan	DISC
@		0.5MG	A090248	002	Sep 17, 2010	Jan	DISC
@		1MG	A090248	003	Sep 17, 2010	Jan	DISC
@		2MG	A090248	004	Sep 17, 2010	Jan	DISC

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

>D>	@	COSETTE	375MG/VIAL	N020221	002	Sep 10, 1999	Mar	CAHN
>D>	@	+	500MG/VIAL	N020221	001	Dec 08, 1995	Mar	CAHN
>A>	@	LEGACY PHARMA	375MG/VIAL	N020221	002	Sep 10, 1999	Mar	CAHN
>A>	@	+	500MG/VIAL	N020221	001	Dec 08, 1995	Mar	CAHN
>A>	@	+	500MG/VIAL	N020221	001	Dec 08, 1995	Mar	CMFD

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

>D>	AP	GEN ILAC	250MG/ML	A215374	001	Aug 28, 2025	Mar	CAHN
>A>	AP	ZENARA	250MG/ML	A215374	001	Aug 28, 2025	Mar	CAHN

SOLUTION; ORAL

AMINOCAPROIC ACID

AA	CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Feb	CAHN
----	----------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

AMINOCAPROIC ACID

AB	CARNEGIE	500MG	A213928	001	Feb 12, 2021	Feb	CAHN
AB		1GM	A213928	002	Feb 12, 2021	Feb	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

>D>	@	AUROBINDO PHARMA USA	10MG	A086009	002		Mar	CMFD
>A>	AB		10MG	A086009	002		Mar	CMFD
>D>	@		25MG	A086009	003		Mar	CMFD
>A>	AB		25MG	A086009	003		Mar	CMFD
>D>	@		50MG	A086009	001		Mar	CMFD
>A>	AB		50MG	A086009	001		Mar	CMFD
>D>	@		75MG	A086009	004		Mar	CMFD
>A>	AB		75MG	A086009	004		Mar	CMFD
>D>	@		100MG	A086009	005		Mar	CMFD
>A>	AB		100MG	A086009	005		Mar	CMFD
>D>	@		150MG	A086009	006		Mar	CMFD
>A>	AB		150MG	A086009	006		Mar	CMFD

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL

SDAMLO

	+	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Jan CMFD
	+		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Jan CMFD
	+		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Jan CMFD

TABLET;ORAL

AMLODIPINE BESYLATE

AB		GRAVITI PHARMS	EQ 2.5MG BASE	A201380	003	Feb 17, 2026	Feb NEWA
AB		TEVA PHARMS INC	EQ 2.5MG BASE	A219686	001	Jan 22, 2026	Jan NEWA
AB			EQ 5MG BASE	A219686	002	Jan 22, 2026	Jan NEWA
AB			EQ 10MG BASE	A219686	003	Jan 22, 2026	Jan NEWA

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL

WIDAPLIK

>D>	@	+	AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Mar CMFD
>A>		+		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Mar CMFD
>D>	@	+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Mar CMFD
>A>		+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Mar CMFD
>D>	@	+		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Mar CMFD
>A>		+		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Mar CMFD

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

@		LUPIN LTD	EQ 5MG BASE;40MG	A201586	001	Jan 08, 2014	Jan DISC
@			EQ 5MG BASE;80MG	A201586	003	Jan 08, 2014	Jan DISC
@			EQ 10MG BASE;40MG	A201586	002	Jan 08, 2014	Jan DISC
@			EQ 10MG BASE;80MG	A201586	004	Jan 08, 2014	Jan DISC
@		MYLAN	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Feb CMFD
@			EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Jan DISC
@			EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Feb CMFD
@			EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Jan DISC
@			EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Feb CMFD
@			EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Jan DISC
@		!	EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Feb CMFD
@			EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Jan DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

!		WA UNIV SCH MED	37.5mCi-800mCi/10ML (3.75-80mCi/ML)	A204506	002	Feb 13, 2026	Feb NFTG
---	--	-----------------	-------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB		PADAGIS ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	Jan CHRS
AB	!	SUN PHARMA CANADA	EQ 12% BASE	A075883	001	Apr 10, 2003	Jan CHRS
AB		ZYDUS LIFESCIENCES	EQ 12% BASE	A217815	001	Feb 12, 2026	Feb NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Jan CTEC
AB	+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Jan CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

@		INGENUS PHARMS LLC	5MG	A213763	001	Aug 24, 2020	Feb CAHN
@			10MG	A213763	002	Aug 24, 2020	Feb CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@		EUROFARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Feb CAHN
@			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Feb CAHN

APREPITANT

EMULSION; INTRAVENOUS

APONVIE

>D>	AB	+	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Mar	CTEC
>A>		+		32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Mar	CTEC
	AB	+		32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Feb	CFTG

APREPITANT

>D>	AB		MYLAN	32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Mar	DISC
>A>		@		32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Mar	DISC
	AB			32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Feb	NFTG

ARIPIPIRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

ARIPIPIRAZOLE

	AB		AUROBINDO PHARMA	10MG	A216208	001	Feb 18, 2026	Feb	NEWA
	AB			15MG	A216208	002	Feb 18, 2026	Feb	NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

	AB		COREPHARMA	50MG	A201514	001	Mar 25, 2019	Jan	CMFD
	AB			150MG	A201514	002	Mar 25, 2019	Jan	CMFD
	AB			250MG	A201514	003	Mar 25, 2019	Jan	CMFD

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

	AP		INGENUS PHARMS LLC	1MG/ML	A209315	001	Nov 15, 2018	Feb	CAHN
		@		2MG/ML	A209315	002	Jan 14, 2021	Feb	CAHN

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYKLX

@ + AM GENOMICS

EQ 8% BASE

N218643	001	Aug 15, 2025	Feb	DISC
---------	-----	--------------	-----	------

ASENAFINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

>A>	AB	+	ABBVIE	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Mar	CAHN
>A>	AB	+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Mar	CAHN
>A>	AB	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Mar	CAHN
>D>	AB	+	ALLERGAN	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Mar	CAHN
>D>	AB	+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Mar	CAHN
>D>	AB	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Mar	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

	AB		IPCA LABS LTD	25MG	A077877	001	Dec 27, 2006	Jan	CMFD
	AB			50MG	A077877	002	Dec 27, 2006	Jan	CMFD
	AB			100MG	A077877	003	Dec 27, 2006	Jan	CMFD

ATOMOXETINE HYDROCHLORIDE

SOLUTION; ORAL

ATONCY

@ +! MAP77

EQ 4MG BASE/ML

N220320	001	Mar 20, 2026	Mar	NEWA
---------	-----	--------------	-----	------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ QUAGEN

0.025MG; 2.5MG

A210571	001	Aug 31, 2018	Feb	CAHN
---------	-----	--------------	-----	------

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

@ CARLSBAD

EQ 250MG BASE

A211317	001	Jul 26, 2022	Feb	CAHN
---------	-----	--------------	-----	------

	AB			EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CAHN
--	----	--	--	---------------	---------	-----	--------------	-----	------

AZTREONAM

	INJECTABLE; INJECTION							
	AZTREONAM							
	@	HIKMA	1GM/VIAL	A207069	001	Feb 05, 2026	Feb	DISC
AP			1GM/VIAL	A207069	001	Feb 05, 2026	Jan	NEWA
	@		2GM/VIAL	A207069	002	Feb 05, 2026	Feb	DISC
AP			2GM/VIAL	A207069	002	Feb 05, 2026	Jan	NEWA

BACITRACIN

	OINTMENT; OPHTHALMIC							
	BACITRACIN							
>D>	!	PADAGIS US	500 UNITS/GM	A061212	001		Mar	DISC
>A>	@		500 UNITS/GM	A061212	001		Mar	DISC

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC							
	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE							
>D>	!	PADAGIS US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Mar	DISC
>A>	@		400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Mar	DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC							
	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC							
>D> AT		PADAGIS US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Mar	DISC
>A>	@		400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Mar	DISC

BACITRACIN ZINC; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC							
	BACITRACIN ZINC AND POLYMYXIN B SULFATE							
>D> AT	!	BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	Mar	CTEC
>A>	!		500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	Mar	CTEC
>D> AT		PADAGIS US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Mar	DISC
>A>	@		500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Mar	DISC

BACLOFEN

	GRANULES; ORAL							
	LYVISPAH							
	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Jan	CAHN
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jan	CAHN
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jan	CAHN
	TABLET; ORAL							
	BACLOFEN							
AB		RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jan	CHRS

BALSALAZIDE DISODIUM

	CAPSULE; ORAL							
	BALSALAZIDE DISODIUM							
AB		CARNEGIE	750MG	A219422	001	Apr 03, 2025	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET; ORAL							
	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
>D> AB		APOTEX	5MG; 6.25MG	A078794	001	Aug 21, 2014	Mar	DISC
>A>	@		5MG; 6.25MG	A078794	001	Aug 21, 2014	Mar	DISC
>D> AB			10MG; 12.5MG	A078794	002	Aug 21, 2014	Mar	DISC
>A>	@		10MG; 12.5MG	A078794	002	Aug 21, 2014	Mar	DISC
>D> AB			20MG; 12.5MG	A078794	003	Aug 21, 2014	Mar	DISC
>A>	@		20MG; 12.5MG	A078794	003	Aug 21, 2014	Mar	DISC
>D> AB			20MG; 25MG	A078794	004	Aug 21, 2014	Mar	DISC
>A>	@		20MG; 25MG	A078794	004	Aug 21, 2014	Mar	DISC
AB	!	SANDOZ	20MG; 25MG	A076631	004	Feb 11, 2004	Jan	CHRS
	LOTENSIN HCT							
AB	+	VALIDUS PHARMS	20MG; 25MG	N020033	003	May 19, 1992	Jan	CHRS

BENDAMUSTINE HYDROCHLORIDESOLUTION;INTRAVENOUS
BENDAMUSTINE HYDROCHLORIDE

>A>	+	AVYXA HOLDINGS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Mar CAHN
>D>	@ +	DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Mar CAHN

BENZONATATECAPSULE;ORAL
BENZONATATE

>A>	AA	MARKSANS PHARMA	100MG	A220298	001	Mar 30, 2026	Mar NEWA
>A>	AA		200MG	A220298	002	Mar 30, 2026	Mar NEWA

BETAMETHASONE DIPROPIONATECREAM;TOPICAL
BETAMETHASONE DIPROPIONATE

AB		AUROBINDO PHARMA LTD	EQ 0.05% BASE	A219348	001	Jan 26, 2026	Jan NEWA
----	--	----------------------	---------------	---------	-----	--------------	----------

BETAMETHASONE VALERATEAEROSOL, FOAM;TOPICAL
BETAMETHASONE VALERATE

@		INGENUS PHARMS LLC	0.12%	A207144	001	May 24, 2017	Feb CAHN
---	--	--------------------	-------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

AT		EUROFARMA	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Feb CAHN
----	--	-----------	--------------	---------	-----	--------------	----------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Feb CAHN
----	--	--------------------	-------------------	---------	-----	--------------	----------

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATE

>D>	@	DASH PHARMS NATCO	5MG	A075831	001	Dec 14, 2005	Mar CAHN
>D>	@		10MG	A075831	002	Dec 14, 2005	Mar CAHN
AB		MICRO LABS	5MG	A218303	001	Mar 09, 2026	Feb NEWA
AB			10MG	A218303	002	Mar 09, 2026	Feb NEWA
>A>	@	NATCO PHARMA USA	5MG	A075831	001	Dec 14, 2005	Mar CAHN
>A>	@		10MG	A075831	002	Dec 14, 2005	Mar CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDETABLET;ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA LTD	2.5MG;6.25MG	A217922	001	Jan 21, 2026	Jan NEWA
AB			5MG;6.25MG	A217922	002	Jan 21, 2026	Jan NEWA
AB			10MG;6.25MG	A217922	003	Jan 21, 2026	Jan NEWA
>A>	AB	UNIQUE PHARM	2.5MG;6.25MG	A219489	001	Mar 24, 2026	Mar NEWA
>A>	AB		5MG;6.25MG	A219489	002	Mar 24, 2026	Mar NEWA
>A>	AB		10MG;6.25MG	A219489	003	Mar 24, 2026	Mar NEWA

BORTEZOMIBINJECTABLE;INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

>D>	AP	CAPLIN ONE LABS	3.5MG/VIAL	A203654	001	Jul 26, 2022	Mar DISC
>A>	@		3.5MG/VIAL	A203654	001	Jul 26, 2022	Mar DISC
AP			3.5MG/VIAL	A203654	001	Jul 26, 2022	Jan CAHN

BOSENTANTABLET, FOR SUSPENSION;ORAL
BOSENTAN

AB		ZYDUS PHARMS	32MG	A213981	001	Feb 17, 2026	Feb NEWA
----	--	--------------	------	---------	-----	--------------	----------

BRIGATINIBTABLET;ORAL
ALUNBRIG

+	!	TAKEDA PHARMS USA	90MG	N208772	002	Apr 28, 2017	Jan CHRS
+			180MG	N208772	003	Oct 02, 2017	Jan CHRS

BRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

AB	GLAND	0.1%	A219219	001	Mar 11, 2026	Feb	NEWA
----	-------	------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATE; CARBACHOLSOLUTION/DROPS;OPHTHALMIC
YUVEZZI

	+! VISUS	0.1%;2.75%	N220142	001	Jan 28, 2026	Jan	NEWA
--	----------	------------	---------	-----	--------------	-----	------

BRIVARACETAMSOLUTION;INTRAVENOUS
BRIVARACETAM

AP	HAINAN POLY	50MG/5ML (10MG/ML)	A218249	001	Feb 23, 2026	Feb	NFTG
AP	MICRO LABS	50MG/5ML (10MG/ML)	A214880	001	Feb 23, 2026	Feb	NFTG
AP	MSN	50MG/5ML (10MG/ML)	A214924	001	Feb 23, 2026	Feb	NFTG

BRIVIACT

AP	+! UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	Feb	CFTG
----	------------	--------------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

BRIVARACETAM

AA	ALKEM LABS LTD	10MG/ML	A219772	001	Feb 23, 2026	Feb	NEWA
>D>	AA	INDOCO	A220385	001	Feb 23, 2026	Mar	CAHN
	AA		A220385	001	Feb 23, 2026	Feb	NEWA
	AA	LUPIN	A220164	001	Feb 23, 2026	Feb	NEWA
	AA	MSN	A214922	001	Feb 19, 2026	Feb	NFTG
>A>	AA	REGCON HOLDINGS	A220385	001	Feb 23, 2026	Mar	CAHN
	AA	ZHEJIANG POLY PHARM	A218494	001	Feb 23, 2026	Feb	NEWA

BRIVIACT

AA	+! UCB INC	10MG/ML	N205838	001	May 12, 2016	Feb	CFTG
----	------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

BRIVARACETAM

AB	APOTEX	10MG	A214875	001	Feb 23, 2026	Feb	NEWA
AB		25MG	A214875	002	Feb 23, 2026	Feb	NEWA
AB		50MG	A214875	003	Feb 23, 2026	Feb	NEWA
AB		75MG	A214875	004	Feb 23, 2026	Feb	NEWA
AB		100MG	A214875	005	Feb 23, 2026	Feb	NEWA
AB	AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Jan	CMFD
AB		100MG	A214848	002	Jan 06, 2023	Jan	CMFD
AB	CENTAUR PHARMS PVT	10MG	A220470	001	Feb 23, 2026	Feb	NEWA
AB		25MG	A220470	002	Feb 23, 2026	Feb	NEWA
AB		50MG	A220470	003	Feb 23, 2026	Feb	NEWA
AB		75MG	A220470	004	Feb 23, 2026	Feb	NEWA
AB		100MG	A220470	005	Feb 23, 2026	Feb	NEWA
AB	SUNSHINE	10MG	A214748	001	Jun 09, 2022	Jan	CMFD
AB		25MG	A214748	002	Jun 09, 2022	Jan	CMFD
AB		50MG	A214748	003	Jun 09, 2022	Jan	CMFD
AB		75MG	A214748	004	Jun 09, 2022	Jan	CMFD
AB		100MG	A214748	005	Jun 09, 2022	Jan	CMFD

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

@ +	PHARMOBEDIENT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jan	DISC
-----	---------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDESUSPENSION;INHALATION
PULMICORT RESPULES

AN	+! ASTRAZENECA	0.25MG/2ML	N020929	001	Aug 08, 2000	Jan	CHRS
AN	+!	0.5MG/2ML	N020929	002	Aug 08, 2000	Jan	CHRS

BUMETANIDEINJECTABLE;INJECTION
BUMETANIDE

AP	ANTHEA PHARMA	0.25MG/ML	A220427	001	Feb 26, 2026	Feb	NEWA
----	---------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

BUMETANIDE

AB	MSN	0.5MG	A215362	001	Feb 05, 2026	Jan	NEWA
AB		1MG	A215362	002	Feb 05, 2026	Jan	NEWA
AB		2MG	A215362	003	Feb 05, 2026	Jan	NEWA

BUPRENORPHINESOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
BRIXADI

>D>	+	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	Mar	CHRS
>A>	+	!	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	Mar	CHRS
>D>	+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	Mar	CHRS
>A>	+	!	16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	Mar	CHRS
>D>	+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	Mar	CHRS
>A>	+	!	24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	Mar	CHRS
>D>	+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	Mar	CHRS
>A>	+	!	32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	Mar	CHRS
>D>	+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	Mar	CHRS
>A>	+	!	64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	Mar	CHRS
>D>	+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	Mar	CHRS
>A>	+	!	96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	Mar	CHRS

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	EQ 2MG BASE;EQ 0.5MG BASE	A219850	001	Jan 21, 2026	Jan	NEWA
AB			EQ 4MG BASE;EQ 1MG BASE	A219850	002	Jan 21, 2026	Jan	NEWA
AB			EQ 8MG BASE;EQ 2MG BASE	A219850	003	Jan 21, 2026	Jan	NEWA
AB			EQ 12MG BASE;EQ 3MG BASE	A219850	004	Jan 21, 2026	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB		SENORES PHARMS	75MG	A075584	001	Feb 07, 2000	Feb	CAHN
AB			100MG	A075584	002	Feb 07, 2000	Feb	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

@ MYLAN

7.5MG

A076008 002 Jul 08, 2013 Feb DISC

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

>D>	!	ANDA REPOSITORY	100MG;1MG	A040590	001	Sep 16, 2005	Mar	CAHN
>A>	!	MIKART	100MG;1MG	A040590	001	Sep 16, 2005	Mar	CAHN

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

AP		ZYDUS PHARMS	200 IU/ML	A215864	001	Mar 04, 2026	Feb	NEWA
----	--	--------------	-----------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		HUMANWELL PURACAP	0.25MCG	A219796	001	Feb 27, 2026	Feb	NEWA
AB			0.5MCG	A219796	002	Feb 27, 2026	Feb	NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>D>	AB	LUPIN LTD	667MG	A202127	001	Jul 09, 2015	Mar	DISC
>A>		@	667MG	A202127	001	Jul 09, 2015	Mar	DISC

TABLET;ORAL

CALCIUM ACETATE

>D>	AB	PADAGIS US	667MG	A091561	001	Apr 13, 2011	Mar	DISC
>A>		@	667MG	A091561	001	Apr 13, 2011	Mar	DISC

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

>D>	AP	SQUARE PHARMS PLC	100MG/ML	A217463	001	Sep 29, 2025	Mar	DISC
>A>		@	100MG/ML	A217463	001	Sep 29, 2025	Mar	DISC

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	SENORES PHARMS	16MG;12.5MG	A202965	001	Jun 03, 2013	Jan	CAHN
AB		32MG;12.5MG	A202965	002	Jun 03, 2013	Jan	CAHN
AB		32MG;25MG	A202965	003	Jun 03, 2013	Jan	CAHN

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	! DR REDDYS	500MG	A204345	002	Dec 04, 2020	Jan	CHRS
	XELODA						
	@ + CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Jan	DISC
	@ +	500MG	N020896	002	Apr 30, 1998	Jan	DISC

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	INGENUS PHARMS LLC	100MG	A216404	001	Dec 02, 2022	Feb	CAHN
AB		200MG	A216404	002	Dec 02, 2022	Feb	CAHN
AB		400MG	A216404	003	Dec 02, 2022	Feb	CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	ALEMBIC	12.5MG;200MG;50MG	A218535	001	Feb 05, 2026	Jan	NEWA
AB		18.75MG;200MG;75MG	A218535	002	Feb 05, 2026	Jan	NEWA
AB		25MG;200MG;100MG	A218535	003	Feb 05, 2026	Jan	NEWA
AB		31.25MG;200MG;125MG	A218535	004	Feb 05, 2026	Jan	NEWA
AB		37.5MG;200MG;150MG	A218535	005	Feb 05, 2026	Jan	NEWA
AB		50MG;200MG;200MG	A218535	006	Feb 05, 2026	Jan	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

	@ SUN PHARM INDS	25MG;100MG	A077828	001	Aug 23, 2007	Feb	DISC
	@	50MG;200MG	A077828	002	Aug 23, 2007	Feb	DISC

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

	@ NOVAST LABS	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Feb	DISC
	@	150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Feb	DISC
	@	450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Feb	DISC
	@	600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Feb	DISC
AP	QILU PHARM HAINAN	50MG/5ML (10MG/ML)	A219999	001	Feb 04, 2026	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A219999	002	Feb 04, 2026	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A219999	003	Feb 04, 2026	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A219999	004	Feb 04, 2026	Jan	NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

CARIPRAZINE HYDROCHLORIDE

	@ AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A213982	001	Dec 16, 2025	Jan	DISC
	@	EQ 3MG BASE	A213982	002	Dec 16, 2025	Jan	DISC
	@	EQ 6MG BASE	A213982	003	Dec 16, 2025	Jan	DISC
	VRAYLAR						
	+! ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CTEC
	+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CTEC
	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CTEC

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	INGENUS PHARMS LLC	350MG	A040823	001	Oct 22, 2008	Feb	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@	LUPIN	3.125MG	A078217	001	Sep 05, 2007	Feb	DISC
@		6.25MG	A078217	002	Sep 05, 2007	Feb	DISC
@		12.5MG	A078217	003	Sep 05, 2007	Feb	DISC
@		25MG	A078217	004	Sep 05, 2007	Feb	DISC

CEFAZOLIN SODIUM

POWDER; INTRAVENOUS

CEFAZOLIN SODIUM

+!	HQ SPCLT PHARMA	EQ 3GM BASE/VIAL	N211413	002	Mar 08, 2024	Feb	NEWA
----	-----------------	------------------	---------	-----	--------------	-----	------

CEFIXIME

CAPSULE; ORAL

CEFIXIME

>A>	AB	AUROBINDO PHARMA LTD	400MG	A217607	001	Mar 23, 2026	Mar	NEWA
-----	----	----------------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

CEFIXIME

!	FDC LTD	400MG	A206358	001	Dec 17, 2024	Jan	CMFD
---	---------	-------	---------	-----	--------------	-----	------

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

CEFTAROLINE FOSAMIL

AP		APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Jan	CMFD
AP			600MG/VIAL	A208075	002	Sep 21, 2021	Jan	CMFD
		TEFLARO						
AP	+!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	Jan	CTEC
AP	+!		600MG/VIAL	N200327	002	Oct 29, 2010	Jan	CTEC

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL

CETIRIZINE HYDROCHLORIDE

AA		RUBICON RESEARCH	5MG/5ML	A220335	001	Feb 25, 2026	Feb	NEWA
>A>	@	TIME CAP LABS	5MG/5ML	A078757	001	Aug 28, 2009	Mar	CAHN
>D>	@	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Mar	CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB		ZYDUS LIFESCIENCES	30MG	A220267	001	Mar 11, 2026	Feb	NEWA
----	--	--------------------	------	---------	-----	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

>D>	AB	BARR	5MG	A084768	001		Mar	CRLD
>A>	AB	+	5MG	A084768	001		Mar	CRLD
>D>	AB		10MG	A083116	001		Mar	CRLD
>A>	AB	+	10MG	A083116	001		Mar	CRLD
>D>	AB	!	25MG	A084769	001		Mar	CRLD
>A>	AB	+!	25MG	A084769	001		Mar	CRLD
		LIBRIUM						
AB	+	BAUSCH	5MG	A085461	001		Feb	CAHN
AB	+		10MG	A085472	001		Feb	CAHN

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

@	+	SALIX PHARMS	250MG/5ML	N011870	001		Jan	DISC
---	---	--------------	-----------	---------	-----	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>		!	PADAGIS US	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Mar	DISC
>A>		@		4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Mar	DISC

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D>	AB	!	GENUS	30MG/ML	A214542	001	Jun 02, 2021	Mar	CTEC
>A>	AA	!		30MG/ML	A214542	001	Jun 02, 2021	Mar	CTEC
>D>	AB	!		100MG/ML	A214542	002	Jun 02, 2021	Mar	CTEC
>A>	AA	!		100MG/ML	A214542	002	Jun 02, 2021	Mar	CTEC
>D>	AB		RUBICON	30MG/ML	A216678	001	Oct 10, 2025	Mar	CTEC
>A>	AA			30MG/ML	A216678	001	Oct 10, 2025	Mar	CTEC
>D>	AB			100MG/ML	A216678	002	Oct 10, 2025	Mar	CTEC
>A>	AA			100MG/ML	A216678	002	Oct 10, 2025	Mar	CTEC
			SONAZINE						
>D>	@		SAPTALIS PHARMS	30MG/ML	A080983	004		Mar	CMFD
>A>	AA			30MG/ML	A080983	004		Mar	CMFD
>D>	@			100MG/ML	A080983	005		Mar	CMFD
>A>	AA			100MG/ML	A080983	005		Mar	CMFD

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP			MSN	25MG/ML	A216092	001	Jan 26, 2026	Jan	NEWA
			TABLET; ORAL						
			CHLORPROMAZINE HYDROCHLORIDE						
AB			ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Jan	CAHN
AB				25MG	A212630	002	Nov 29, 2021	Jan	CAHN
AB				50MG	A212630	003	Nov 29, 2021	Jan	CAHN
AB				100MG	A212630	004	Nov 29, 2021	Jan	CAHN
AB				200MG	A212630	005	Nov 29, 2021	Jan	CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

>D>	AB		ALKEM LABS LTD	50MG	A213412	002	Feb 11, 2020	Mar	CHRS
>A>	AB	!		50MG	A213412	002	Feb 11, 2020	Mar	CHRS

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA			SENORES PHARMS	500MG	A210961	001	Jan 22, 2024	Jan	CAHN
----	--	--	----------------	-------	---------	-----	--------------	-----	------

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB			MICRO LABS	EQ 4GM RESIN/PACKET	A219318	001	Mar 05, 2026	Feb	NEWA
AB			PHARMOBEDIANT	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Jan	CAHN
AB				EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Jan	CAHN
			CHOLESTYRAMINE LIGHT						
>A>	AB		ZYDUS PHARMS	EQ 4GM RESIN/PACKET	A202902	002	Apr 25, 2017	Mar	NEWA

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

AP			SOMERSET THERAPS LLC	EQ 0.004MG CHROMIUM/ML	A218538	001	Nov 18, 2024	Feb	CAHN
----	--	--	----------------------	------------------------	---------	-----	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; NASAL

ZETONNA

>A>	@ +		AZURITY	0.037MG/INH	N202129	001	Jan 20, 2012	Mar	CAHN
>D>	@ +		COVIS	0.037MG/INH	N202129	001	Jan 20, 2012	Mar	CAHN
			SPRAY, METERED; NASAL						
			OMNARIS						
>A>	+!		AZURITY	0.05MG/SPRAY	N022004	001	Oct 20, 2006	Mar	CAHN
>D>	+!		COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006	Mar	CAHN

CICLOPIROX

CREAM; TOPICAL

LOPROX

AB		+!	EUROFARMA	0.77%	N018748	001	Dec 30, 1982	Feb	CAHN
			SUSPENSION; TOPICAL						
			LOPROX						
AB		+!	EUROFARMA	0.77%	N019824	001	Dec 30, 1988	Feb	CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

@	HETERO LABS LTD V	EQ 30MG BASE	A209403	001	Oct 07, 2020	Feb	DISC
@		EQ 60MG BASE	A209403	002	Oct 07, 2020	Feb	DISC
@		EQ 90MG BASE	A209403	003	Oct 07, 2020	Feb	DISC
@	STEVENS J	EQ 30MG BASE	A204364	001	Dec 02, 2021	Feb	CPOT
@		EQ 60MG BASE	A204364	002	Dec 02, 2021	Feb	CPOT
@		EQ 90MG BASE	A204364	003	Dec 02, 2021	Feb	CPOT

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

>D>	AB	AMNEAL	EQ 250MG BASE	A075939	002	Jun 09, 2004	Mar	DISC
>A>		@	EQ 250MG BASE	A075939	002	Jun 09, 2004	Mar	DISC
>D>	AB		EQ 500MG BASE	A075939	003	Jun 09, 2004	Mar	DISC
>A>		@	EQ 500MG BASE	A075939	003	Jun 09, 2004	Mar	DISC
>D>	AB		EQ 750MG BASE	A075939	004	Jun 09, 2004	Mar	DISC
>A>		@	EQ 750MG BASE	A075939	004	Jun 09, 2004	Mar	DISC

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

@	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	DISC
	CISATRACURIUM BESYLATE PRESERVATIVE FREE						
@	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Feb	DISC
@		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Feb	DISC

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

>D>		+! ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Mar	CFTG
>A>	AB	+!	EQ 30MG BASE	N215428	001	Jan 31, 2022	Mar	CFTG
>A>	AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A219985	001	Mar 13, 2026	Mar	NFTG

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

@	AMNEAL PHARMS NY	EQ 10MG BASE	A077289	001	Nov 30, 2006	Feb	DISC
@		EQ 20MG BASE	A077289	002	Nov 30, 2006	Feb	DISC
@		EQ 40MG BASE	A077289	003	Nov 30, 2006	Feb	DISC

CLADRIBINE

TABLET;ORAL

CLADRIBINE

>A>	AB	HOPEWELL PHARMA	10MG	A215547	001	Mar 27, 2026	Mar	NEWA
-----	----	-----------------	------	---------	-----	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D>	AA	PADAGIS US	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Mar	DISC
>A>		@	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Mar	DISC

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

>A>	AB1	AUROBINDO PHARMA LTD	EQ 1% BASE	A218942	001	Mar 18, 2026	Mar	NEWA
	AB1	SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Feb	CAHN

SOLUTION;TOPICAL

CLINDA-DERM

>D>	AT	PADAGIS US	EQ 1% BASE	A063329	001	Sep 30, 1992	Mar	DISC
>A>		@	EQ 1% BASE	A063329	001	Sep 30, 1992	Mar	DISC

CLINDAMYCIN PHOSPHATE

>A>	AT	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Feb	CAHN
		RISING	EQ 1% BASE	A218300	001	Mar 23, 2026	Mar	NEWA

SWAB;TOPICAL

CLINDETS

>D>	AT	PADAGIS US	EQ 1% BASE	A064136	001	Sep 30, 1996	Mar	DISC
>A>		@	EQ 1% BASE	A064136	001	Sep 30, 1996	Mar	DISC

CLOBETASOL PROPIONATE

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

>D>	AT	PADAGIS US	0.05%	A090898	001	Jun 16, 2011	Mar	DISC
>A>	@		0.05%	A090898	001	Jun 16, 2011	Mar	DISC

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB		CHARTWELL RX	0.5MG	A074925	001	Sep 30, 1997	Jan	CMFD
AB			1MG	A074925	002	Sep 30, 1997	Jan	CMFD
AB			2MG	A074925	003	Sep 30, 1997	Jan	CMFD

CLONIDINE

SYSTEM;TRANSDERMAL

CLONIDINE

@ DIFGEN PHARMS

@ 0.1MG/24HR

@ 0.2MG/24HR

@ 0.3MG/24HR

A076157	001	Aug 18, 2009	Feb	CAHN
A076157	002	Aug 18, 2009	Feb	CAHN
A076157	003	Aug 18, 2009	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

>D>		ATHENA	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Mar	CAHN
>D>	@		EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Mar	CAHN
>A>		ROSEMONT	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Mar	CAHN
>A>	@		EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Mar	CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

>A>	!	TP ANDA HOLDINGS	0.05MG	A070923	004	Apr 06, 2026	Mar	NFTG
-----	---	------------------	--------	---------	-----	--------------	-----	------

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

>D>	@	DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987	Mar	CAHN
>D>	@		7.5MG	A071510	001	Oct 19, 1987	Mar	CAHN
>D>	@		15MG	A071511	001	Oct 19, 1987	Mar	CAHN
>A>	@	NATCO PHARMA USA	3.75MG	A071509	001	Oct 19, 1987	Mar	CAHN
>A>	@		7.5MG	A071510	001	Oct 19, 1987	Mar	CAHN
>A>	@		15MG	A071511	001	Oct 19, 1987	Mar	CAHN

COBICISTAT

TABLET;ORAL

TYBOST

>D>	+	!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Mar	DISC
>A>	@	+		150MG	N203094	001	Sep 24, 2014	Mar	DISC

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

>D>	+	JANSSEN PRODS	150MG;EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar	CHRS
>A>	+	!	150MG;EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar	CHRS

TABLET, FOR SUSPENSION;ORAL

PREZCOBIX PED

+! JANSSEN PRODS

90MG;EQ 600MG BASE

N220092	001	Feb 27, 2026	Feb	NEWA
---------	-----	--------------	-----	------

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB		MICRO LABS	0.6MG	A212880	001	Feb 17, 2026	Feb	NEWA
----	--	------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

COLCHICINE

AB		MACLEODS PHARMS LTD	0.6MG	A210633	001	Feb 13, 2026	Feb	NEWA
----	--	---------------------	-------	---------	-----	--------------	-----	------

COPPER HISTIDINATE

POWDER;SUBCUTANEOUS

ZYCUBO

+! SENTYNL THERAPS INC

2.9MG/VIAL

N211241	001	Jan 12, 2026	Jan	NEWA
---------	-----	--------------	-----	------

CUPRIC CHLORIDEINJECTABLE; INJECTION
CUPRIC CHLORIDE

>D>	AP	AMNEAL	EQ 0.4MG COPPER/ML	A217287	001	Jan 26, 2026	Mar	DISC
>A>	@		EQ 0.4MG COPPER/ML	A217287	001	Jan 26, 2026	Mar	DISC
	AP		EQ 0.4MG COPPER/ML	A217287	001	Jan 26, 2026	Jan	NEWA

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

	@	HAINAN POLY	500MG/VIAL	A218632	001	Dec 26, 2024	Jan	DISC
	@		1GM/VIAL	A218632	002	Dec 26, 2024	Jan	DISC
	@		2GM/VIAL	A218632	003	Dec 26, 2024	Jan	DISC

CYCLOSPORINEEMULSION; OPHTHALMIC
CYCLOSPORINE

	AB	TWI PHARMS	0.05%	A209064	001	Jan 21, 2026	Jan	NEWA
--	----	------------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION
CYCLOSPORINE

>D>	AP	PADAGIS US	50MG/ML	A065151	001	Oct 07, 2003	Mar	DISC
>A>	@		50MG/ML	A065151	001	Oct 07, 2003	Mar	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

	AA	ST JOHN PHARM	2MG/5ML	A209108	001	Oct 16, 2018	Jan	CAHN
--	----	---------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	@	ANVI	4MG	A087129	001		Mar	CAHN
	AA	INGENUS PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Feb	CAHN
>D>	@	STRIDES PHARMA INTL	4MG	A087129	001		Mar	CAHN

DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

DALBAVANCIN HYDROCHLORIDE

	AP	LONG GROVE PHARMS	EQ 500MG BASE/VIAL	A218602	001	Feb 26, 2026	Feb	NEWA
--	----	-------------------	--------------------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN

TABLET; ORAL

DAPAGLIFLOZIN

>A>	AB	AIZANT	5MG	A211523	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211523	002	Apr 06, 2026	Mar	NFTG
>A>	AB	AJANTA PHARMA LTD	5MG	A211482	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211482	002	Apr 06, 2026	Mar	NFTG
>A>	AB	ALEMBIC	5MG	A211560	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211560	002	Apr 06, 2026	Mar	NFTG
>A>	AB	ALKEM LABS LTD	5MG	A211545	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211545	002	Apr 06, 2026	Mar	NFTG
>A>	AB	AUROBINDO PHARMA	5MG	A211468	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211468	002	Apr 06, 2026	Mar	NFTG
>A>	AB	BIOCON PHARMA	5MG	A211470	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211470	002	Apr 06, 2026	Mar	NFTG
>A>	AB	CIPLA	5MG	A211535	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211535	002	Apr 06, 2026	Mar	NFTG
>A>	AB	INVENTIA	5MG	A211156	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211156	002	Apr 06, 2026	Mar	NFTG
>A>	AB	LUPIN LTD	5MG	A211531	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211531	002	Apr 06, 2026	Mar	NFTG
>A>	AB	MACLEODS PHARMS LTD	5MG	A211506	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211506	002	Apr 06, 2026	Mar	NFTG
>A>	AB	MICRO LABS	5MG	A211467	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211467	002	Apr 06, 2026	Mar	NFTG
>A>	AB	MSN	5MG	A211478	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211478	002	Apr 06, 2026	Mar	NFTG
>A>	AB	SANDOZ	5MG	A211312	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211312	002	Apr 06, 2026	Mar	NFTG
>A>	AB	TEVA PHARMS USA	5MG	A211541	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG	A211541	002	Apr 06, 2026	Mar	NFTG
>D>	@	ZYDUS PHARMS	5MG	A211582	001	Feb 22, 2022	Mar	NFTG
>A>	AB		5MG	A211582	001	Apr 06, 2026	Mar	NFTG

TABLET;ORAL

DAPAGLIFLOZIN

>D>	@		10MG	A211582	002	Feb 22, 2022	Mar	NFTG
>A>	AB		10MG	A211582	002	Apr 06, 2026	Mar	NFTG
FARXIGA								
>D>	+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CFTG
>A>	AB	+	5MG	N202293	001	Jan 08, 2014	Mar	CFTG
>D>		+	10MG	N202293	002	Jan 08, 2014	Mar	CFTG
>A>	AB	+	10MG	N202293	002	Jan 08, 2014	Mar	CFTG

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE								
>A>	AB	ALKEM LABS LTD	5MG;500MG	A211563	001	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;1GM	A211563	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211563	003	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211563	004	Apr 06, 2026	Mar	NFTG
>A>	AB	AUROBINDO PHARMA	5MG;500MG	A211489	001	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;1GM	A211489	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211489	003	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211489	004	Apr 06, 2026	Mar	NFTG
>A>	AB	CIPLA	5MG;1GM	A211595	001	Apr 06, 2026	Mar	NFTG
>A>	AB	CIPLA LTD	5MG;500MG	A211536	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211536	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211536	003	Apr 06, 2026	Mar	NFTG
>A>	AB	LUPIN LTD	5MG;500MG	A211579	001	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;1GM	A211579	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211579	003	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211579	004	Apr 06, 2026	Mar	NFTG
>A>	AB	MACLEODS PHARMS LTD	5MG;500MG	A211559	001	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;1GM	A211559	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211559	003	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211559	004	Apr 06, 2026	Mar	NFTG
>A>	AB	MICRO LABS	5MG;500MG	A211466	001	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;1GM	A211466	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211466	003	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211466	004	Apr 06, 2026	Mar	NFTG
>A>	AB	MSN	5MG;500MG	A211479	001	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;1GM	A211479	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211479	003	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211479	004	Apr 06, 2026	Mar	NFTG
>A>	AB	SUN PHARM	5MG;1GM	A211491	001	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211491	002	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211491	003	Apr 06, 2026	Mar	NFTG
>A>	AB	TEVA PHARMS USA INC	2.5MG;1GM	A211583	001	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;500MG	A211583	002	Apr 06, 2026	Mar	NFTG
>A>	AB		5MG;1GM	A211583	003	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;500MG	A211583	004	Apr 06, 2026	Mar	NFTG
>A>	AB		10MG;1GM	A211583	005	Apr 06, 2026	Mar	NFTG
XIGDUO XR								
>D>	+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017	Mar	CFTG
>A>	AB	+	2.5MG;1GM	N205649	005	Jul 28, 2017	Mar	CFTG
>D>	+		5MG;500MG	N205649	001	Oct 29, 2014	Mar	CFTG
>A>	AB	+	5MG;500MG	N205649	001	Oct 29, 2014	Mar	CFTG
>D>	+		5MG;1GM	N205649	002	Oct 29, 2014	Mar	CFTG
>A>	AB	+	5MG;1GM	N205649	002	Oct 29, 2014	Mar	CFTG
>D>	+		10MG;500MG	N205649	003	Oct 29, 2014	Mar	CFTG
>A>	AB	+	10MG;500MG	N205649	003	Oct 29, 2014	Mar	CFTG
>D>	+	!	10MG;1GM	N205649	004	Oct 29, 2014	Mar	CFTG
>A>	AB	+	10MG;1GM	N205649	004	Oct 29, 2014	Mar	CFTG

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE									
>A>	AB	!	MSN	10MG;EQ 5MG BASE	A211533	001	Apr 06, 2026	Mar	NFTG
>A>	AB		TORRENT	10MG;EQ 5MG BASE	A211537	001	Apr 06, 2026	Mar	NFTG

DAPSONE

TABLET;ORAL

DAPSONE

AB	ZYDUS LIFESCIENCES	25MG	A220103	001	Feb 26, 2026	Feb	NEWA
AB		100MG	A220103	002	Feb 26, 2026	Feb	NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
DAPTOMYCIN

@	HENGRUI PHARMA	500MG/VIAL	A212022	001	Aug 22, 2019	Jan DISC
---	----------------	------------	---------	-----	--------------	----------

DASIGLUCAGON HYDROCHLORIDESOLUTION; SUBCUTANEOUS
ZEGALOGUE

@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Feb DISC
-----	----------------	---	---------	-----	--------------	----------

ZEGALOGUE (AUTOINJECTOR)

@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Feb DISC
-----	----------------	---	---------	-----	--------------	----------

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

@	NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Feb DISC
---	-------------	-----------	---------	-----	--------------	----------

DEFEROXAMINE MESYLATEINJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

>D>	AP	HIKMA	500MG/VIAL	A078086	001	May 30, 2007	Mar DISC
>A>	@		500MG/VIAL	A078086	001	May 30, 2007	Mar DISC
>D>	AP		2GM/VIAL	A078086	002	May 30, 2007	Mar DISC
>A>	@		2GM/VIAL	A078086	002	May 30, 2007	Mar DISC

DEFLAZACORTSUSPENSION; ORAL
DEFLAZACORT

AB	SUN PHARM INDS INC	22.75MG/ML	A219930	001	Jan 27, 2026	Jan NEWA
----	--------------------	------------	---------	-----	--------------	----------

DEHYDRATED ALCOHOLSOLUTION; INTRA-ARTERIAL
ABLYSINOL

@ +	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jan CAIN
AP	+	99% (5ML)	N207987	002	Jun 21, 2018	Jan CAIN

DEHYDRATED ALCOHOL

AP	ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jan CAIN
AP	BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jan CAIN
AP	INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jan CAIN
AP	XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jan CAIN

SOLUTION; INTRAVENOUS

DEHYDRATED ALCOHOL

+	ROYAL PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Jan CAIN
---	--------------	-----------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

@	HERITAGE	10MG	A207433	001	May 05, 2016	Jan DISC
@		25MG	A207433	002	May 05, 2016	Jan DISC
@		50MG	A207433	003	May 05, 2016	Jan DISC
@		75MG	A207433	004	May 05, 2016	Jan DISC
@		100MG	A207433	005	May 05, 2016	Jan DISC
@		150MG	A207433	006	May 05, 2016	Jan DISC
AB	INGENUS PHARMS LLC	10MG	A204963	001	Dec 26, 2017	Feb CAHN
AB		25MG	A204963	002	Dec 26, 2017	Feb CAHN
AB		50MG	A204963	003	Dec 26, 2017	Feb CAHN
AB		75MG	A204963	004	Dec 26, 2017	Feb CAHN
AB		100MG	A204963	005	Dec 26, 2017	Feb CAHN
AB		150MG	A204963	006	Dec 26, 2017	Feb CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

>D>	@	DASH PHARMS	5MG	A078351	001	Feb 10, 2012	Mar CAHN
>A>	@	NATCO PHARMA USA	5MG	A078351	001	Feb 10, 2012	Mar CAHN

DESMOPRESSIN ACETATEINJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP	CAPLIN	0.004MG/ML	A219981	001	Feb 27, 2026	Feb	NEWA
	SOLUTION; ORAL						
	DESMODA						
	+! ETON	0.05MG/ML	N219873	001	Feb 25, 2026	Feb	NEWA

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

>A>	AB	ANNORA PHARMA	0.15MG; 0.03MG	A219761	001	Mar 18, 2026	Mar	NEWA
-----	----	---------------	----------------	---------	-----	--------------	-----	------

DESOXIMETASONEGEL; TOPICAL
DESOXIMETASONE

>D>	AB	PADAGIS US	0.05%	A077552	001	Jan 09, 2006	Mar	DISC
>A>		@	0.05%	A077552	001	Jan 09, 2006	Mar	DISC

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

>D>	AB	MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Mar	CAHN
>D>	AB		EQ 100MG BASE	A204805	002	May 07, 2019	Mar	CAHN
>A>	AB	PLATINUM	EQ 50MG BASE	A204805	001	May 07, 2019	Mar	CAHN
>A>	AB		EQ 100MG BASE	A204805	002	May 07, 2019	Mar	CAHN
	AB	YICHANG HUMANWELL	EQ 25MG BASE	A220460	001	Mar 10, 2026	Feb	NEWA
	AB		EQ 50MG BASE	A220460	002	Mar 10, 2026	Feb	NEWA
	AB		EQ 100MG BASE	A220460	003	Mar 10, 2026	Feb	NEWA

DEXAMETHASONECONCENTRATE; ORAL
DEXAMETHASONE INTENSOL

+! HIKMA 1MG/ML

A088252 001 Sep 01, 1983 Jan CRLD

TABLET; ORAL
DEXAMETHASONE

>D>		@ PANGEA	0.25MG	A088149	001	Apr 28, 1983	Mar	CMFD
>A>			0.25MG	A088149	001	Apr 28, 1983	Mar	CMFD

DEXAMETHASONE SODIUM PHOSPHATESOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

@ CAPLIN EQ 0.1% PHOSPHATE

A088771 001 Jan 16, 1985 Jan CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

>D>	AT	PADAGIS US	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062938	001	Jul 31, 1989	Mar	DISC
>A>		@	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062938	001	Jul 31, 1989	Mar	DISC

DEXMEDETOMIDINE HYDROCHLORIDEFILM; BUCCAL, SUBLINGUAL
IGALMI

+ BIOXCEL EQ 0.18MG BASE

N215390 002 Apr 05, 2022 Jan CHRS

INJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP	CAPLIN	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Jan	CAHN
AP	DR REDDYS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A220315	001	Feb 25, 2026	Feb	NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A220315	002	Feb 25, 2026	Feb	NEWA
AP	KNACK	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A218675	001	Mar 09, 2026	Feb	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	@	AUROLIFE PHARMA LLC	5MG	A202580	002	Aug 25, 2015	Mar CMS1
>A>	@		10MG	A202580	003	Aug 25, 2015	Mar CMS1
>A>	@		15MG	A202580	004	Aug 25, 2015	Mar CMS1
>A>	@		20MG	A202580	005	Dec 21, 2015	Mar CMS1
>A>	@		25MG	A202580	006	May 04, 2021	Mar CMS1
>A>	@		35MG	A202580	007	May 04, 2021	Mar CMS1
>A>	@		40MG	A202580	008	Aug 25, 2015	Mar CMS1

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

@	STRIDES PHARMA INTL	5MG	A205673	001	Oct 31, 2017	Jan DISC
@		10MG	A205673	002	Oct 31, 2017	Jan DISC
@		15MG	A205673	003	Oct 31, 2017	Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	AA	HETERO LABS LTD III	15MG/5ML;6.25MG/5ML	A218264	001	Mar 12, 2026	Mar NEWA
-----	----	---------------------	---------------------	---------	-----	--------------	----------

DIAZEPAM

TABLET;ORAL

DIAZEPAM

@	STRIDES PHARMA INTL	2MG	A077749	001	Mar 31, 2006	Jan DISC
@		5MG	A077749	002	Mar 31, 2006	Jan DISC
@		10MG	A077749	003	Mar 31, 2006	Jan DISC

DICLOFENAC POTASSIUM

CAPSULE;ORAL

ZIPSOR

AB	+	ASSERTIO SPECLTY	25MG	N022202	001	Jun 16, 2009	Feb CAHN
----	---	------------------	------	---------	-----	--------------	----------

FOR SOLUTION;ORAL

CAMBIA

AB	+	ASSERTIO SPECLTY	50MG	N022165	001	Jun 17, 2009	Feb CAHN
----	---	------------------	------	---------	-----	--------------	----------

TABLET;ORAL

DICLOFENAC POTASSIUM

AB		INGENUS PHARMS LLC	50MG	A215585	001	Oct 08, 2021	Feb CAHN
----	--	--------------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

>D>	AB	AMNEAL	3%	A200936	001	Oct 28, 2013	Mar DISC
-----	----	--------	----	---------	-----	--------------	----------

>A>	@		3%	A200936	001	Oct 28, 2013	Mar DISC
-----	---	--	----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB		INGENUS PHARMS LLC	100MG	A216275	001	Sep 23, 2022	Feb CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

DIFAMILAST

OINTMENT;TOPICAL

ADQUEY

+	ACROTECH BIOPHARMA	1%	N219474	001	Feb 12, 2026	Feb NEWA
---	--------------------	----	---------	-----	--------------	----------

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DIFLUPREDNATE

AB		ALEMBIC	0.05%	A213774	001	Jan 26, 2026	Jan NEWA
----	--	---------	-------	---------	-----	--------------	----------

DIGOXIN

INJECTABLE;INJECTION

LANOXIN

>A>	AP	+	AZURITY	0.25MG/ML	N009330	002	Mar CAHN
-----	----	---	---------	-----------	---------	-----	----------

>D>	AP	+	COVIS	0.25MG/ML	N009330	002	Mar CAHN
-----	----	---	-------	-----------	---------	-----	----------

LANOXIN PEDIATRIC

>A>		+	AZURITY	0.1MG/ML	N009330	004	Mar CAHN
-----	--	---	---------	----------	---------	-----	----------

>D>		+	COVIS	0.1MG/ML	N009330	004	Mar CAHN
-----	--	---	-------	----------	---------	-----	----------

DIHYDROERGOTAMINE MESYLATEINJECTABLE; INJECTION
DIHYDROERGOTAMINE MESYLATE

>D>	AP	PADAGIS US	1MG/ML	A040475	001	Apr 28, 2003	Mar	DISC
>A>	@		1MG/ML	A040475	001	Apr 28, 2003	Mar	DISC

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB3		MACLEODS PHARMS LTD	120MG	A218744	001	Feb 27, 2026	Feb	NEWA
AB3			180MG	A218744	002	Feb 27, 2026	Feb	NEWA
AB3			240MG	A218744	003	Feb 27, 2026	Feb	NEWA
AB3			300MG	A218744	004	Feb 27, 2026	Feb	NEWA
AB3			360MG	A218744	005	Feb 27, 2026	Feb	NEWA

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@		ZYDUS LIFESCIENCES	30MG	A219253	001	Aug 08, 2025	Jan	DISC
@			60MG	A219253	002	Aug 08, 2025	Jan	DISC
@			90MG	A219253	003	Aug 08, 2025	Jan	DISC
@			120MG	A219253	004	Aug 08, 2025	Jan	DISC

DIMETHYL FUMARATECAPSULE, DELAYED RELEASE; ORAL
DIMETHYL FUMARATE

>D>	AB	MYLAN	120MG	A210531	001	Aug 17, 2020	Mar	DISC
>A>	@		120MG	A210531	001	Aug 17, 2020	Mar	DISC
>D>	AB		240MG	A210531	002	Aug 17, 2020	Mar	DISC
>A>	@		240MG	A210531	002	Aug 17, 2020	Mar	DISC

DISULFIRAMTABLET; ORAL
DISULFIRAM

>D>	@	DASH PHARMS	250MG	A203916	001	Mar 04, 2015	Mar	CAHN
>D>	@		500MG	A203916	002	Mar 04, 2015	Mar	CAHN
>A>	@	NATCO PHARMA USA	250MG	A203916	001	Mar 04, 2015	Mar	CAHN
>A>	@		500MG	A203916	002	Mar 04, 2015	Mar	CAHN

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

@		INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Feb	CAHN
@			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb	DISC
AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb	CAHN
@			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb	DISC
AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb	CAHN

DOFETILIDECAPSULE; ORAL
DOFETILIDE

@		INGENUS PHARMS LLC	0.125MG	A212410	001	Dec 27, 2019	Feb	CAHN
@			0.25MG	A212410	002	Dec 27, 2019	Feb	CAHN
@			0.5MG	A212410	003	Dec 27, 2019	Feb	CAHN
@		STRIDES PHARMA INTL	0.125MG	A208519	001	Oct 09, 2018	Jan	DISC
@			0.25MG	A208519	002	Oct 09, 2018	Jan	DISC
@			0.5MG	A208519	003	Oct 09, 2018	Jan	DISC

DONEPEZIL HYDROCHLORIDETABLET; ORAL
DONEPEZIL HYDROCHLORIDE

@		LUPIN LTD	23MG	A202782	001	Oct 30, 2015	Feb	DISC
---	--	-----------	------	---------	-----	--------------	-----	------

DOXEPIIN HYDROCHLORIDECAPSULE; ORAL
DOXEPIIN HYDROCHLORIDE

>D>	AB	PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar	CAHN
>D>	AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar	CAHN
>D>	AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar	CAHN
>D>	AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar	CAHN
>D>	AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar	CAHN
>A>	AB	UNIQUE	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar	CAHN
>A>	AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar	CAHN

CAPSULE;ORAL

DOXEFIN HYDROCHLORIDE

>A>	AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar	CAHN
>A>	AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar	CAHN
>A>	AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		CAPLIN	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan	CAHN
>D>	AP	EUGIA PHARMA	4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Mar	DISC
>A>		@	4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Mar	DISC
>D>	AP	HIKMA	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Mar	DISC
>A>		@	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Mar	DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE

AB		QILU PHARM HAINAN	20MG/10ML (2MG/ML)	A219881	001	Feb 03, 2026	Jan	NEWA
AB			50MG/25ML (2MG/ML)	A219881	002	Feb 03, 2026	Jan	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		AIPING PHARM INC	40MG	A219978	001	Oct 01, 2025	Jan	CAHN
----	--	------------------	------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

		@	AVET LIFESCIENCES	EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb	DISC
AP				EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb	NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

		@	APOTEX	EQ 75MG BASE	A209243	001	Apr 15, 2019	Jan	DISC
		@		EQ 150MG BASE	A209243	002	Apr 15, 2019	Jan	DISC

DRONABINOL

SOLUTION;ORAL

SYNDROS

		@ +	WELLHOUSE PHARMA	5MG/ML	N205525	001	Mar 23, 2017	Jan	CAHN
--	--	-----	------------------	--------	---------	-----	--------------	-----	------

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

>D>	AB		LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Mar	DISC
>A>		@		EQ 400MG BASE	A205904	001	Jan 31, 2024	Mar	DISC
			MULTAQ						
>D>	AB	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Mar	CTEC
>A>		+!		EQ 400MG BASE	N022425	001	Jul 01, 2009	Mar	CTEC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

		+!	ALMATICA	EQ 80MG BASE	N219131	001	Feb 27, 2026	Feb	NEWA
		+		EQ 90MG BASE	N219131	002	Feb 27, 2026	Feb	NEWA
		+		EQ 120MG BASE	N219131	003	Feb 27, 2026	Feb	NEWA

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

>D>		@	AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Mar	CMFD
>A>	AB			1%	A210364	001	Apr 18, 2018	Mar	CMFD

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

	AB		ALEMBIC	10%	A212027	001	Feb 23, 2026	Feb	NEWA
>A>	AB		NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Mar	CAHN
>D>	AB		UMEDICA	10%	A211969	001	Jun 21, 2021	Mar	CAHN

ELETRIPATAN HYDROBROMIDE

TABLET;ORAL

ELETRIPATAN HYDROBROMIDE

@	CARLSBAD	EQ 20MG BASE	A209680	001	Jul 13, 2020	Feb CAHN
@		EQ 40MG BASE	A209680	002	Jul 13, 2020	Feb CAHN

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

@	CIPLA	EQ 84MG BASE	A212369	001	Dec 10, 2024	Feb DISC
---	-------	--------------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB	AMNEAL	EQ 12.5MG ACID	A212884	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A212884	003	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A212884	002	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A212884	004	Jan 14, 2026	Jan NEWA
>A>	DR REDDYS	EQ 12.5MG ACID	A219121	001	Mar 16, 2026	Mar NEWA
>A>		EQ 25MG ACID	A219121	002	Mar 16, 2026	Mar NEWA
>A>		EQ 50MG ACID	A219121	003	Mar 16, 2026	Mar NEWA
>A>		EQ 75MG ACID	A219121	004	Mar 16, 2026	Mar NEWA
AB	MSN	EQ 12.5MG ACID	A220250	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A220250	002	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A220250	003	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A220250	004	Jan 14, 2026	Jan NEWA
AB	SOMERSET THERAPS LLC	EQ 12.5MG ACID	A219638	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A219638	002	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A219638	003	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A219638	004	Jan 14, 2026	Jan NEWA
>A>	ZENARA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Mar NEWA
>A>		EQ 25MG ACID	A220033	002	Apr 08, 2026	Mar NEWA
>A>		EQ 50MG ACID	A220033	003	Apr 08, 2026	Mar NEWA
>A>		EQ 75MG ACID	A220033	004	Apr 08, 2026	Mar NEWA
AB	ZYDUS PHARMS	EQ 12.5MG ACID	A216281	001	Jan 14, 2026	Jan NEWA
AB		EQ 25MG ACID	A216281	002	Jan 14, 2026	Jan NEWA
AB		EQ 50MG ACID	A216281	003	Jan 14, 2026	Jan NEWA
AB		EQ 75MG ACID	A216281	004	Jan 14, 2026	Jan NEWA

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

AB	APOTEX	200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jan NFTG
AB	ODEFSEY					
AB	+! GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jan CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	LAURUS	200MG;EQ 25MG BASE;300MG	A220232	001	Mar 04, 2026	Feb NEWA
----	--------	--------------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

>D>							
>D>	AB	LUPIN LTD	200MG;EQ 25MG BASE	A213926	001	Dec 13, 2024	Mar DISC
>A>	@		200MG;EQ 25MG BASE	A213926	001	Dec 13, 2024	Mar DISC
>A>	AB	MACLEODS PHARMS LTD	200MG;EQ 25MG BASE	A214216	001	Apr 07, 2026	Mar NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

>A>	@	PHARMADAX	0.5MG	A212106	001	Aug 10, 2020	Mar CAHN
>A>	@		1MG	A212106	002	Aug 10, 2020	Mar CAHN
>D>	@	SWISS PHARM	0.5MG	A212106	001	Aug 10, 2020	Mar CAHN
>D>	@		1MG	A212106	002	Aug 10, 2020	Mar CAHN

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
EPHEDRINE SULFATE

>A>	AP2	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A219991	001	Mar 19, 2026	Mar NEWA
-----	-----	--------------------	--------------------	---------	-----	--------------	----------

EPINEPHRINESOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

>A>		+! BAXTER HLTHCARE CORP	1MG/ML (1MG/ML)	N220626	001	Mar 30, 2026	Mar NEWA
>A>		+!	30MG/30ML (1MG/ML)	N220626	002	Mar 30, 2026	Mar NEWA

EPINEPHRINE BITARTRATESOLUTION; INTRAVENOUS
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

>A>		+! BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N218475	002	Mar 16, 2026	Mar NEWA
-----	--	-------------------------	--------------------------------------	---------	-----	--------------	----------

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

SOLUTION; INJECTION

>A>		FLAVALTA					
>A>		+! DEPROCO	EQ 0.017MG BASE/1.7ML (EQ 0.01MG BASE/ML); 34MG/1.7ML (20MG/ML)	N216564	001	Mar 19, 2026	Mar NEWA

ERIBULIN MESYLATESOLUTION; INTRAVENOUS
ERIBULIN MESYLATE

>A>	AP	FORMOSA LABS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar NEWA
>A>	AP	XGEN PHARMS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		CARNEGIE	250MG	A062746	001	Dec 22, 1986	Feb CAHN
----	--	----------	-------	---------	-----	--------------	----------

TABLET; ORAL

ERYTHROMYCIN

AB		CARNEGIE	250MG	A061621	001		Feb CAHN
AB			500MG	A061621	002		Feb CAHN

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

AB		CARNEGIE	250MG	A062298	001		Feb CAHN
AB			333MG	A062298	003	Mar 29, 1982	Feb CAHN
AB		!	500MG	A062298	002		Feb CAHN

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL

E.E.S. 400

BX		@ CARNEGIE	EQ 400MG BASE	A061905	001		Feb CAHN
BX		!	EQ 400MG BASE	A061905	002	Aug 12, 1982	Feb CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX		! CARNEGIE	EQ 400MG BASE	A061904	001		Feb CAHN
----	--	------------	---------------	---------	-----	--	----------

ESTRADIOL

CREAM; VAGINAL

ESTRACE

>A>	AB	+! ABBVIE	0.01%	A086069	001	Jan 31, 1984	Mar CAHN
>D>	AB	+! ALLERGAN	0.01%	A086069	001	Jan 31, 1984	Mar CAHN

GEL; TRANSDERMAL

ESTRADIOL

AB		SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Feb CAHN
AB			0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Feb CAHN
AB			0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Feb CAHN
AB			0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Feb CAHN
AB			0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Feb CAHN
AB		XIROMED	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jan CAHN
AB			0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jan CAHN
AB			0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022	Jan CAHN

GEL, METERED; TRANSDERMAL

ESTRADIOL

AB		LONG GROVE PHARMS	0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026	Jan NEWA
----	--	-------------------	---------------------------	---------	-----	--------------	----------

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINAL
FEMRING

	+	MILLICENT MFG PR	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan CAHN
	+	!	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATEFILM, EXTENDED RELEASE;TRANSDERMAL
COMBIPATCH

>D>	+	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998	Mar CHRS
>A>	+	!	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998	Mar CHRS

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET;ORAL
QUARTETTE

>D>	AB	+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar CAHN
>A>	AB	+	!	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar CAHN

ETODOLACTABLET;ORAL
ETODOLAC

@	SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jan CAHN
---	----------------	-------	---------	-----	--------------	----------

ETOPOSIDECAPSULE;ORAL
ETOPOSIDE

AB	!	MYLAN	50MG	A075635	001	Sep 19, 2001	Jan CTEC
----	---	-------	------	---------	-----	--------------	----------

AB	+	ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jan CMFD
----	---	---------------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION
ETOPOSIDE

>D>	@	DASH PHARMS	20MG/ML	A204927	001	Oct 31, 2017	Mar CAHN
>D>	@	DASH PHARMS NATCO	20MG/ML	A203507	001	Nov 20, 2017	Mar CAHN
>A>	@	NATCO PHARMA USA	20MG/ML	A203507	001	Nov 20, 2017	Mar CAHN
>A>	@		20MG/ML	A204927	001	Oct 31, 2017	Mar CAHN

>D>		INJECTABLE;INTRAVENOUS					
>D>		AVOPEF					
>D>	+	AVYXA HOLDINGS	100MG/5ML (20MG/ML)	N220200	001	Feb 13, 2026	Mar CDFR
	+	!	100MG/5ML (20MG/ML)	N220200	001	Feb 13, 2026	Feb NEWA

>A>		SOLUTION;INTRAVENOUS					
>A>		AVOPEF					
>A>	+	AVYXA HOLDINGS	100MG/5ML (20MG/ML)	N220200	001	Feb 13, 2026	Mar CDFR

EVEROLIMUSTABLET;ORAL
EVEROLIMUS

AB		EUGIA PHARMA	0.25MG	A219533	001	Feb 25, 2026	Feb NEWA
AB			0.5MG	A219533	002	Feb 25, 2026	Feb NEWA
AB			0.75MG	A219533	003	Feb 25, 2026	Feb NEWA
AB			1MG	A219533	004	Feb 25, 2026	Feb NEWA
	@	PH HEALTH	2.5MG	A207934	001	Dec 09, 2019	Jan DISC
	@		5MG	A207934	002	Dec 09, 2019	Jan DISC
	@		7.5MG	A207934	003	Dec 09, 2019	Jan DISC
	@		10MG	A207934	004	Dec 09, 2020	Jan DISC

TABLET, FOR SUSPENSION;ORAL
EVEROLIMUS

AB		BIOCON PHARMA	2MG	A217216	001	Jan 09, 2026	Jan NEWA
AB			3MG	A217216	002	Jan 09, 2026	Jan NEWA
AB			5MG	A217216	003	Jan 09, 2026	Jan NEWA

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

@	WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017	Feb DISC
@		10MG;20MG	A202968	002	Apr 26, 2017	Feb DISC
@		10MG;40MG	A202968	003	Apr 26, 2017	Feb DISC
@		10MG;80MG	A202968	004	Apr 26, 2017	Feb DISC

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Feb	CAHN
AB	CONTRACT PHARMACAL	40MG/5ML	A219603	001	Mar 09, 2026	Feb	NEWA

TABLET;ORAL

FAMOTIDINE

AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan	CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan	CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB	ZYDUS LIFESCIENCES	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb	CAHN
----	--------------------	--------------	---------	-----	--------------	-----	------

FENOFIBRATE

CAPSULE;ORAL

LIPOFEN

@ + CIPHER PHARMS INC 100MG

N021612 002 Jan 11, 2006 Jan CRLD

TABLET;ORAL

FENOFIBRATE

AB	MACLEODS PHARMS LTD	54MG	A210379	001	Jan 21, 2026	Jan	NEWA
AB		160MG	A210379	002	Jan 21, 2026	Jan	NEWA

TRIGLIDE

@ JAGOTEC 50MG

N021350 001 May 07, 2005 Jan CAHN

@ + 160MG

N021350 002 May 07, 2005 Jan CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

>D>	@ + ATHENA	35MG	N022418	001	Aug 14, 2009	Mar	CAHN
-----	------------	------	---------	-----	--------------	-----	------

>D>	@ +	105MG	N022418	002	Aug 14, 2009	Mar	CAHN
-----	-----	-------	---------	-----	--------------	-----	------

>A>	@ + ROSEMONT	35MG	N022418	001	Aug 14, 2009	Mar	CAHN
-----	--------------	------	---------	-----	--------------	-----	------

>A>	@ +	105MG	N022418	002	Aug 14, 2009	Mar	CAHN
-----	-----	-------	---------	-----	--------------	-----	------

FERRIC CITRATE

TABLET;ORAL

AURYXIA

AB	+! KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Feb	CFTG
----	--------------------	---------------	---------	-----	--------------	-----	------

FERRIC CITRATE

AB	TEVA PHARMS USA	EQ 210MG IRON	A212563	001	Mar 11, 2026	Feb	NFTG
----	-----------------	---------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

>D>	AB	DR REDDYS LABS LTD	30MG	A076502	001	Apr 11, 2006	Mar	DISC
-----	----	--------------------	------	---------	-----	--------------	-----	------

>A>	@		30MG	A076502	001	Apr 11, 2006	Mar	DISC
-----	---	--	------	---------	-----	--------------	-----	------

>D>	AB		60MG	A076502	002	Apr 11, 2006	Mar	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>	@		60MG	A076502	002	Apr 11, 2006	Mar	DISC
-----	---	--	------	---------	-----	--------------	-----	------

>D>	AB		180MG	A076502	003	Apr 11, 2006	Mar	DISC
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	@		180MG	A076502	003	Apr 11, 2006	Mar	DISC
-----	---	--	-------	---------	-----	--------------	-----	------

>D>	AB	RISING	60MG	A077081	003	Apr 11, 2008	Mar	DISC
-----	----	--------	------	---------	-----	--------------	-----	------

>A>	@		60MG	A077081	003	Apr 11, 2008	Mar	DISC
-----	---	--	------	---------	-----	--------------	-----	------

>D>	AB		180MG	A077081	001	Apr 16, 2007	Mar	DISC
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	@		180MG	A077081	001	Apr 16, 2007	Mar	DISC
-----	---	--	-------	---------	-----	--------------	-----	------

>D>	AB	TEVA	30MG	A076447	001	Sep 01, 2005	Mar	DISC
-----	----	------	------	---------	-----	--------------	-----	------

>A>	@		30MG	A076447	001	Sep 01, 2005	Mar	DISC
-----	---	--	------	---------	-----	--------------	-----	------

>D>	AB		60MG	A076447	002	Sep 01, 2005	Mar	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>	@		60MG	A076447	002	Sep 01, 2005	Mar	DISC
-----	---	--	------	---------	-----	--------------	-----	------

>D>	AB		180MG	A076447	003	Sep 01, 2005	Mar	DISC
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	@		180MG	A076447	003	Sep 01, 2005	Mar	DISC
-----	---	--	-------	---------	-----	--------------	-----	------

FIDAXOMICIN

TABLET;ORAL

FIDAXOMICIN

AB	APOTEX	200MG	A219559	001	Feb 02, 2026	Jan	NEWA
----	--------	-------	---------	-----	--------------	-----	------

AB	TORRENT	200MG	A220374	001	Jan 27, 2026	Jan	NEWA
----	---------	-------	---------	-----	--------------	-----	------

FLORBETABEN F-18SOLUTION; INTRAVENOUS
NEURACEQ

>A>	+	LANTHEUS	1.4-135mCi/ML	N204677	001	Mar 19, 2014	Mar CAHN
>D>	+	LIFE MOLECULAR	1.4-135mCi/ML	N204677	001	Mar 19, 2014	Mar CAHN

FLUCONAZOLETABLET; ORAL
FLUCONAZOLE

>D>	AB	THINQ PHARM-CRO PVT	50MG	A076957	001	Sep 28, 2005	Mar CAHN
>D>	AB		100MG	A076957	002	Sep 28, 2005	Mar CAHN
>D>	AB		150MG	A076957	004	Feb 27, 2017	Mar CAHN
>D>	AB		200MG	A076957	003	Sep 28, 2005	Mar CAHN
>A>	AB	UNIQUE	50MG	A076957	001	Sep 28, 2005	Mar CAHN
>A>	AB		100MG	A076957	002	Sep 28, 2005	Mar CAHN
>A>	AB		150MG	A076957	004	Feb 27, 2017	Mar CAHN
>A>	AB		200MG	A076957	003	Sep 28, 2005	Mar CAHN

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

@	+	CAPLIN ONE LABS	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan CAHN
---	---	-----------------	--------------------	---------	-----	--------------	----------

FLUDROCORTISONE ACETATETABLET; ORAL
FLUDROCORTISONE ACETATE

AB		HIBROW HLTHCARE	0.1MG	A220308	001	Feb 10, 2026	Jan NEWA
----	--	-----------------	-------	---------	-----	--------------	----------

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

>D>	AP	HIKMA	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Mar DISC
>A>	@		0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Mar DISC
>D>	AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Mar DISC
>A>	@		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Mar DISC

FLUOCINOLONE ACETONIDECREAM; TOPICAL
SYNALAR

AT	+	EUROFARMA	0.01%	N012787	004		Feb CAHN
AT	+		0.025%	N012787	002		Feb CAHN
AT	+		0.025%	N012787	005		Feb CAHN
		SYNALAR-HP					
@		EUROFARMA	0.2%	N016161	002		Feb CAHN

OINTMENT; TOPICAL
SYNALAR

AT	+	EUROFARMA	0.025%	N013960	001		Feb CAHN
----	---	-----------	--------	---------	-----	--	----------

SOLUTION; TOPICAL
SYNALAR

AT	+	EUROFARMA	0.01%	N015296	001		Feb CAHN
----	---	-----------	-------	---------	-----	--	----------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATECREAM; TOPICAL
NEO-SYNALAR

!		EUROFARMA	0.025%;EQ 3.5MG BASE/GM	A060700	001		Feb CAHN
---	--	-----------	-------------------------	---------	-----	--	----------

FLUOROMETHOLONESUSPENSION/DROPS; OPHTHALMIC
FLUOROMETHOLONE

AB		DIFGEN PHARMS	0.1%	A218819	001	Feb 12, 2026	Jan NEWA
----	--	---------------	------	---------	-----	--------------	----------

FLUOROURACILSOLUTION; INTRAVENOUS
FAVLYXA

+		AVYXA HOLDINGS	250MG/10ML (25MG/ML)	N220201	001	Feb 20, 2026	Feb NEWA
---	--	----------------	----------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1	SENORES PHARMS	EQ 10MG BASE	A 075049	001	Aug 02, 2001	Feb	CAHN
AB1		EQ 20MG BASE	A 075049	002	Jan 29, 2002	Feb	CAHN
AB		EQ 40MG BASE	A 075049	003	Jan 29, 2002	Feb	CAHN
	@ STRIDES PHARMA INTL	EQ 10MG BASE	A 076922	001	Dec 16, 2004	Jan	DISC
	@	EQ 20MG BASE	A 076922	002	Dec 16, 2004	Jan	DISC
	@	EQ 40MG BASE	A 076922	003	Dec 16, 2004	Jan	DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB	LUPIN LTD	EQ 60MG BASE	A 211632	001	Feb 08, 2019	Mar	DISC
>A>	@		EQ 60MG BASE	A 211632	001	Feb 08, 2019	Mar	DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

	@	BRECKENRIDGE	1MG	A 216891	001	Nov 15, 2022	Feb	DISC
	@		2.5MG	A 216891	002	Nov 15, 2022	Feb	DISC
	@		5MG	A 216891	003	Nov 15, 2022	Feb	DISC
	@		10MG	A 216891	004	Nov 15, 2022	Feb	DISC
AB	ZAMEER PHARMS	1MG	A 215141	001	Oct 20, 2021	Jan	CAHN	
AB		2.5MG	A 215141	002	Oct 20, 2021	Jan	CAHN	
AB		5MG	A 215141	003	Oct 20, 2021	Jan	CAHN	
AB		10MG	A 215141	004	Oct 20, 2021	Jan	CAHN	

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

	@	HIKMA INTL PHARMS	15MG	A 071108	002	Dec 08, 1986	Feb	CMS1
--	---	-------------------	------	----------	-----	--------------	-----	------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

	+	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N 204275	003	May 12, 2023	Jan	CHRS
--	---	---------------	--------------------------------	----------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

AB	+	GLAXO GRP LTD	0.044MG/INH	N 021433	003	May 14, 2004	Feb	CFTG
AB		GLENMARK SPECLT	0.044MG/INH	A 219602	001	Mar 03, 2026	Feb	NFTG

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO RESPICLICK

	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N 208799	001	Jan 27, 2017	Jan	CHRS
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N 208799	002	Jan 27, 2017	Jan	CHRS

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

>D>	AB	RESPIRENT PHARMS	0.1MG/INH;EQ 0.05MG BASE/INH	A 214464	001	Jan 12, 2026	Mar	DISC
>A>	@		0.1MG/INH;EQ 0.05MG BASE/INH	A 214464	001	Jan 12, 2026	Mar	DISC
	AB		0.1MG/INH;EQ 0.05MG BASE/INH	A 214464	001	Jan 12, 2026	Jan	NEWA
>D>	AB		0.25MG/INH;EQ 0.05MG BASE/INH	A 214464	002	Jan 12, 2026	Mar	DISC
>A>	@		0.25MG/INH;EQ 0.05MG BASE/INH	A 214464	002	Jan 12, 2026	Mar	DISC
	AB		0.25MG/INH;EQ 0.05MG BASE/INH	A 214464	002	Jan 12, 2026	Jan	NEWA

FOLIC ACID

SOLUTION;ORAL

QUIOFIC

>D>	+	CMP DEV LLC	0.2MG/ML	N 216395	001	Jan 26, 2026	Mar	CAHN
	+		0.2MG/ML	N 216395	001	Jan 26, 2026	Jan	NEWA
>A>	+	SOLUBIOMIX	0.2MG/ML	N 216395	001	Jan 26, 2026	Mar	CAHN

TABLET;ORAL

FOLIC ACID

AA	+	WATSON LABS	1MG	A 080680	001		Feb	CHRS
----	---	-------------	-----	----------	-----	--	-----	------

FONDAPARINUX SODIUM

SOLUTION; SUBCUTANEOUS

ARIXTRA

>D>	AP	+	MYLAN IRELAND LTD	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Mar	CPOT
>A>	AP	+		2.5MG/0.5ML (2.5MG/0.5ML)	N021345	001	Dec 07, 2001	Mar	CPOT
	AP	+		2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jan	CDFR
>D>	AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Mar	CPOT
>A>	AP	+		5MG/0.4ML (5MG/0.4ML)	N021345	002	May 28, 2004	Mar	CPOT
	AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Jan	CDFR
>D>	AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Mar	CPOT
>A>	AP	+		7.5MG/0.6ML (7.5MG/0.6ML)	N021345	003	May 28, 2004	Mar	CPOT
	AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jan	CDFR
>D>	AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Mar	CPOT
>A>	AP	+		10MG/0.8ML (10MG/0.8ML)	N021345	004	May 28, 2004	Mar	CPOT
	AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Jan	CDFR

FONDAPARINUX SODIUM

>D>	@		BRIGHTGENE	2.5MG/0.5ML	A218312	001	Dec 18, 2024	Mar	CPOT
>A>	@			2.5MG/0.5ML (2.5MG/0.5ML)	A218312	001	Dec 18, 2024	Mar	CPOT
	@			2.5MG/0.5ML	A218312	001	Dec 18, 2024	Jan	CDFR
>D>	AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011	Mar	CPOT
>A>	AP			2.5MG/0.5ML (2.5MG/0.5ML)	A091316	001	Jul 11, 2011	Mar	CPOT
	AP			2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jan	CDFR
>D>	AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Mar	CPOT
>A>	AP			5MG/0.4ML (5MG/0.4ML)	A091316	002	Jul 11, 2011	Mar	CPOT
	AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jan	CDFR
>D>	AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Mar	CPOT
>A>	AP			7.5MG/0.6ML (7.5MG/0.6ML)	A091316	003	Jul 11, 2011	Mar	CPOT
	AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jan	CDFR
>D>	AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Mar	CPOT
>A>	AP			10MG/0.8ML (10MG/0.8ML)	A091316	004	Jul 11, 2011	Mar	CPOT
	AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jan	CDFR
>D>	AP		EUGIA PHARMA	2.5MG/0.5ML	A206918	001	Dec 26, 2017	Mar	CPOT
>A>	AP			2.5MG/0.5ML (2.5MG/0.5ML)	A206918	001	Dec 26, 2017	Mar	CPOT
	AP			2.5MG/0.5ML	A206918	001	Dec 26, 2017	Jan	CDFR
>D>	AP			5MG/0.4ML	A206918	002	Dec 26, 2017	Mar	CPOT
>A>	AP			5MG/0.4ML (5MG/0.4ML)	A206918	002	Dec 26, 2017	Mar	CPOT
	AP			5MG/0.4ML	A206918	002	Dec 26, 2017	Jan	CDFR
>D>	AP			7.5MG/0.6ML	A206918	003	Dec 26, 2017	Mar	CPOT
>A>	AP			7.5MG/0.6ML (7.5MG/0.6ML)	A206918	003	Dec 26, 2017	Mar	CPOT
	AP			7.5MG/0.6ML	A206918	003	Dec 26, 2017	Jan	CDFR
>D>	AP			10MG/0.8ML	A206918	004	Dec 26, 2017	Mar	CPOT
>A>	AP			10MG/0.8ML (10MG/0.8ML)	A206918	004	Dec 26, 2017	Mar	CPOT
	AP			10MG/0.8ML	A206918	004	Dec 26, 2017	Jan	CDFR
>D>	@		HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Mar	CPOT
>A>	@			2.5MG/0.5ML (2.5MG/0.5ML)	A216493	001	Aug 19, 2024	Mar	CPOT
	@			2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jan	CDFR
>D>	@			5MG/0.4ML	A216493	002	Aug 19, 2024	Mar	CPOT
>A>	@			5MG/0.4ML (5MG/0.4ML)	A216493	002	Aug 19, 2024	Mar	CPOT
	@			5MG/0.4ML	A216493	002	Aug 19, 2024	Jan	CDFR
>D>	@			7.5MG/0.6ML	A216493	003	Aug 19, 2024	Mar	CPOT
>A>	@			7.5MG/0.6ML (7.5MG/0.6ML)	A216493	003	Aug 19, 2024	Mar	CPOT
	@			7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jan	CDFR
>D>	@			10MG/0.8ML	A216493	004	Aug 19, 2024	Mar	CPOT
>A>	@			10MG/0.8ML (10MG/0.8ML)	A216493	004	Aug 19, 2024	Mar	CPOT
	@			10MG/0.8ML	A216493	004	Aug 19, 2024	Jan	CDFR
>D>	AP		HENGRUI PHARMA	2.5MG/0.5ML	A206812	001	May 15, 2018	Mar	CPOT
>A>	AP			2.5MG/0.5ML (2.5MG/0.5ML)	A206812	001	May 15, 2018	Mar	CPOT
	AP			2.5MG/0.5ML	A206812	001	May 15, 2018	Jan	CDFR
>D>	AP			5MG/0.4ML	A206812	002	May 15, 2018	Mar	CPOT
>A>	AP			5MG/0.4ML (5MG/0.4ML)	A206812	002	May 15, 2018	Mar	CPOT
	AP			5MG/0.4ML	A206812	002	May 15, 2018	Jan	CDFR
>D>	AP			7.5MG/0.6ML	A206812	003	May 15, 2018	Mar	CPOT
>A>	AP			7.5MG/0.6ML (7.5MG/0.6ML)	A206812	003	May 15, 2018	Mar	CPOT
	AP			7.5MG/0.6ML	A206812	003	May 15, 2018	Jan	CDFR
>D>	AP			10MG/0.8ML	A206812	004	May 15, 2018	Mar	CPOT
>A>	AP			10MG/0.8ML (10MG/0.8ML)	A206812	004	May 15, 2018	Mar	CPOT
	AP			10MG/0.8ML	A206812	004	May 15, 2018	Jan	CDFR
>D>	AP		SCINOPHARM TAIWAN	2.5MG/0.5ML	A208615	001	Nov 14, 2018	Mar	CPOT
>A>	AP			2.5MG/0.5ML (2.5MG/0.5ML)	A208615	001	Nov 14, 2018	Mar	CPOT
	AP			2.5MG/0.5ML	A208615	001	Nov 14, 2018	Jan	CDFR
>D>	AP			5MG/0.4ML	A208615	002	Nov 14, 2018	Mar	CPOT
>A>	AP			5MG/0.4ML (5MG/0.4ML)	A208615	002	Nov 14, 2018	Mar	CPOT
	AP			5MG/0.4ML	A208615	002	Nov 14, 2018	Jan	CDFR

		SOLUTION;SUBCUTANEOUS							
		FONDAPARINUX SODIUM							
>D>	AP		7.5MG/0.6ML	A208615	003	Nov 14, 2018	Mar	CPOT	
>A>	AP		7.5MG/0.6ML (7.5MG/0.6ML)	A208615	003	Nov 14, 2018	Mar	CPOT	
	AP		7.5MG/0.6ML	A208615	003	Nov 14, 2018	Jan	CDFR	
>D>	AP		10MG/0.8ML	A208615	004	Nov 14, 2018	Mar	CPOT	
>A>	AP		10MG/0.8ML (10MG/0.8ML)	A208615	004	Nov 14, 2018	Mar	CPOT	
	AP		10MG/0.8ML	A208615	004	Nov 14, 2018	Jan	CDFR	
		<u>FOSAPREPITANT DIMEGLUMINE</u>							
		POWDER; INTRAVENOUS							
		FOSAPREPITANT DIMEGLUMINE							
	@	CAPLIN	EQ 150MG BASE/VIAL	A203939	001	Dec 08, 2020	Jan	CAHN	
		<u>FOSFOMYCIN TROMETHAMINE</u>							
		FOR SOLUTION;ORAL							
		FOSFOMYCIN TROMETHAMINE							
>A>	AA	AUCTA	EQ 3GM BASE/PACKET	A217772	001	Apr 09, 2026	Mar	NEWA	
		<u>FROVATRIPTAN SUCCINATE</u>							
		TABLET;ORAL							
		FROVA							
	@	+ ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Feb	DISC	
		FROVATRIPTAN SUCCINATE							
AB	!	RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Feb	CHRS	
		<u>FULVESTRANT</u>							
		SOLUTION;INTRAMUSCULAR							
		FULVESTRANT							
>D>	AO	EUGIA PHARMA	250MG/5ML (50MG/ML)	A215169	001	Jun 30, 2023	Mar	DISC	
>A>	@		250MG/5ML (50MG/ML)	A215169	001	Jun 30, 2023	Mar	DISC	
		<u>FUROSEMIDE</u>							
		INJECTABLE;INJECTION							
		FUROSEMIDE							
AP		MICRO LABS	10MG/ML	A218188	001	Jan 08, 2026	Jan	NEWA	
		<u>GABAPENTIN</u>							
		CAPSULE;ORAL							
		GABAPENTIN							
AB		PRINSTON INC	100MG	A219814	001	Mar 06, 2026	Feb	NEWA	
AB			300MG	A219814	002	Mar 06, 2026	Feb	NEWA	
AB			400MG	A219814	003	Mar 06, 2026	Feb	NEWA	
>D>	AB	SCIEGEN PHARMS	100MG	A204989	001	Feb 18, 2016	Mar	CTNA	
>D>			200MG	A204989	004	Mar 06, 2026	Mar	CTNA	
			200MG	A204989	004	Mar 06, 2026	Feb	NEWA	
>D>	AB		300MG	A204989	002	Feb 18, 2016	Mar	CTNA	
>D>	AB		400MG	A204989	003	Feb 18, 2016	Mar	CTNA	
>A>		RELGAABI							
>A>	AB	SCIEGEN PHARMS	100MG	A204989	001	Feb 18, 2016	Mar	CTNA	
>A>			200MG	A204989	004	Mar 06, 2026	Mar	CTNA	
>A>	AB		300MG	A204989	002	Feb 18, 2016	Mar	CTNA	
>A>	AB		400MG	A204989	003	Feb 18, 2016	Mar	CTNA	
		<u>GALANTAMINE HYDROBROMIDE</u>							
		TABLET;ORAL							
		GALANTAMINE HYDROBROMIDE							
AB		SENORES PHARMS	EQ 4MG BASE	A077593	001	Sep 11, 2008	Jan	CAHN	
AB			EQ 8MG BASE	A077593	002	Sep 11, 2008	Jan	CAHN	
AB			EQ 12MG BASE	A077593	003	Sep 11, 2008	Jan	CAHN	
		<u>GANAXOLONE</u>							
		SUSPENSION;ORAL							
		ZTALMY							
>A>		+! IMMEDICA PHARMA	50MG/ML	N215904	001	Jun 01, 2022	Mar	CAHN	
>D>		+! MARINUS	50MG/ML	N215904	001	Jun 01, 2022	Mar	CAHN	

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

>D>	AP	TRIS PHARMA INC	250MCG/0.5ML	A219454	001	Jun 27, 2025	Mar DISC
>A>	@		250MCG/0.5ML	A219454	001	Jun 27, 2025	Mar DISC

GEFITINIBTABLET; ORAL
GEFITINIB

@	APOTEX	250MG	A209532	001	Sep 23, 2022	Jan DISC
---	--------	-------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

@	NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb DISC
@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb DISC
@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb DISC

GENTAMICIN SULFATESOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

>D>	AT	PADAGIS US	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Mar DISC
>A>	@		EQ 0.3% BASE	A065121	001	Jan 30, 2004	Mar DISC

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
GLATIRAMER ACETATE

AP	HYBIO	20MG/ML	A213382	001	Feb 11, 2026	Jan NEWA
AP		40MG/ML	A214022	001	Feb 11, 2026	Jan NEWA

GLECAPREVIR; PIBRENTASVIRPELLETS; ORAL
MAVYRET

>D>	+!	ABBVIE	50MG; 20MG/PACKET	N215110	001	Jun 10, 2021	Mar CPOT
>A>	+!		50MG/PACKET; 20MG/PACKET	N215110	001	Jun 10, 2021	Mar CPOT

GLIPIZIDETABLET; ORAL
GLIPIZIDE

AB	GRAVITI PHARMS	5MG	A219159	001	Mar 04, 2026	Feb NEWA	
AB		10MG	A219159	002	Mar 04, 2026	Feb NEWA	
	!	RUBICON RESEARCH	15MG	A214874	004	Feb 04, 2026	Jan NFTG

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

>A>	AB	IMPAX	1.25MG; 250MG	A076345	001	Feb 18, 2004	Mar CAHN
>A>	AB		2.5MG; 500MG	A076345	002	Feb 18, 2004	Mar CAHN
>A>	AB		5MG; 500MG	A076345	003	Feb 18, 2004	Mar CAHN
>D>	AB	IMPAX LABS INC	1.25MG; 250MG	A076345	001	Feb 18, 2004	Mar CAHN
>D>	AB		2.5MG; 500MG	A076345	002	Feb 18, 2004	Mar CAHN
>D>	AB		5MG; 500MG	A076345	003	Feb 18, 2004	Mar CAHN

GLYCOPYRRONIUM TOSYLATECLOTH; TOPICAL
GLYCOPYRRONIUM TOSYLATE

>A>	AB	PADAGIS US	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Mar NFTG
		QBREXZA					
>D>	+!	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Mar CFTG
>A>	AB		EQ 2.4% BASE	N210361	001	Jun 28, 2018	Mar CFTG

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION/DROPS; OPHTHALMIC
NEOSPORIN

@	MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Jan DISC
---	----------------	---	---------	-----	--	----------

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

>A>	AB	ASCENT PHARMS INC	EQ 1MG BASE	A220675	001	Mar 24, 2026	Mar	NEWA
>A>	AB		EQ 2MG BASE	A220675	002	Mar 24, 2026	Mar	NEWA
>D>	BX	RUBICON RESEARCH	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar	CTEC
>A>	AB		EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar	CTEC
>D>	BX		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar	CTEC
>A>	AB		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar	CTEC

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

HALOBETASOL PROPIONATE

	AB	! PADAGIS ISRAEL	0.05%	A215266	001	Aug 11, 2023	Feb	CTEC
		! LEXETTE	0.05%	A215266	001	Aug 11, 2023	Feb	CHRS
		@ + MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Feb	DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A>	AB	AIPING PHARM INC	0.5MG	A071130	004	Apr 08, 2026	Mar	NEWA
>A>	AB		1MG	A071130	005	Apr 08, 2026	Mar	NEWA
>A>	AB		20MG	A071130	006	Apr 08, 2026	Mar	NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

		+! PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Feb	CMFD
--	--	-----------	----------------	---------	-----	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>D>	AA	PADAGIS US	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Mar	DISC
>A>		@	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA	HERITAGE	10MG	A086242	001	Feb 04, 2010	Mar	DISC
>A>		@	10MG	A086242	001	Feb 04, 2010	Mar	DISC
>D>	AA		25MG	A086242	003		Mar	DISC
>A>		@	25MG	A086242	003		Mar	DISC
>D>	AA		50MG	A086242	002		Mar	DISC
>A>		@	50MG	A086242	002		Mar	DISC
>D>	AA		100MG	A086242	004	Feb 04, 2010	Mar	DISC
>A>		@	100MG	A086242	004	Feb 04, 2010	Mar	DISC
		@ STRIDES PHARMA INTL	10MG	A087836	001	Oct 05, 1982	Jan	DISC
		@	25MG	A086961	002		Jan	DISC
		@	50MG	A086962	001		Jan	DISC
		@	100MG	A088391	001	Sep 27, 1983	Jan	DISC

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

		@ STRIDES PHARMA INTL	25MG; 25MG	A088957	001	Oct 21, 1985	Jan	DISC
		@	50MG; 50MG	A088946	001	Oct 21, 1985	Jan	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	37.5MG; 20MG	A215586	001	Apr 06, 2022	Feb	CAHN
----	--	--------------------	--------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

		@ STRIDES PHARMA INTL	15MG; 250MG	A070614	002	Feb 02, 1987	Jan	CMS1
		@	25MG; 250MG	A070614	003	Feb 02, 1987	Jan	CMS1
		@	30MG; 500MG	A070614	004	Feb 02, 1987	Jan	CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC	25MG;100MG	A202870	002	Nov 06, 2013	Feb	CHRS
AB	! MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Feb	CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A>	AB	SCIEGEN PHARMS	12.5MG;20MG	A208465	001	Mar 31, 2026	Mar	NEWA
>A>	AB		12.5MG;40MG	A208465	002	Mar 31, 2026	Mar	NEWA
>A>	AB		25MG;40MG	A208465	003	Mar 31, 2026	Mar	NEWA

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

AB	APPCO	5MG	A220329	001	Feb 25, 2026	Feb	NEWA
AB		10MG	A220329	002	Feb 25, 2026	Feb	NEWA
AB		20MG	A220329	003	Feb 25, 2026	Feb	NEWA

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE

AB	! TARO	0.1%	A076842	001	Dec 27, 2004	Feb	CTEC
AB	!	0.1%	A076842	001	Dec 27, 2004	Feb	CHRS
	LOCOID						
	@ + PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	Feb	DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

AP	APOTEX	EQ 100MG BASE/VIAL	A219856	001	Feb 05, 2026	Jan	NEWA
----	--------	--------------------	---------	-----	--------------	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

>D>	AB	PADAGIS ISRAEL	0.2%	A075666	001	May 24, 2000	Mar	DISC
>A>		@	0.2%	A075666	001	May 24, 2000	Mar	DISC

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

>A> ICOTROKINRA HYDROCHLORIDE

>A> TABLET; ORAL

>A> ICOTYDE

>A>	+!	JANSSEN BIOTECH	EQ 200MG BASE	N220149	001	Mar 17, 2026	Mar	NEWA
-----	----	-----------------	---------------	---------	-----	--------------	-----	------

IDELALISIB

TABLET; ORAL

IDELALISIB

AB	NATCO	100MG	A216921	001	Feb 17, 2026	Feb	NFTG
AB		150MG	A216921	002	Feb 17, 2026	Feb	NFTG

ZYDELIG

AB	+ GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Feb	CFTG
AB	+!	150MG	N205858	002	Jul 23, 2014	Feb	CFTG

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

>D>	AB	+ NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003	Mar	CHRS
>A>	AB	+!	EQ 100MG BASE	N021588	001	Apr 18, 2003	Mar	CHRS
>D>	AB	+!	EQ 400MG BASE	N021588	002	Apr 18, 2003	Mar	CHRS
>A>	AB	+	EQ 400MG BASE	N021588	002	Apr 18, 2003	Mar	CHRS

IMATINIB MESYLATE

@ SUN PHARM

@

		EQ 100MG BASE	A078340	001	Dec 03, 2015	Feb	DISC
		EQ 400MG BASE	A078340	002	Dec 03, 2015	Feb	DISC

IOMEPROL

SOLUTION; INTRA-ARTERIAL

IOMERVU

	+!	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Feb	CMFD
	+!		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Feb	CMFD
	+!		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Feb	CMFD
	+!		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Feb	CMFD

SOLUTION; INTRAVENOUS

IOMERVU

	+!	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Feb	CMFD
	+!		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Feb	CMFD
	+!		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Feb	CMFD
	+!		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Feb	CMFD

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

AB	+!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004	Feb	CFTG
AB		ARMSTRONG PHARMS	0.021MG/INH	A217953	001	Feb 23, 2026	Feb	NFTG

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

>D>	@	ANI PHARMS	20MG	A075147	001	Nov 27, 1998	Mar	CMFD
>A>	AB		20MG	A075147	001	Nov 27, 1998	Mar	CMFD

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS

ISOSULFAN BLUE

	!	MYLAN INSTITUTIONAL	10MG/ML (10MG/ML)	A090874	002	Jan 28, 2026	Jan	NFTG
	!		30MG/3ML (10MG/ML)	A090874	003	Jan 28, 2026	Jan	NFTG

ISOTRETINOIN

CAPSULE; ORAL

ISOTRETINOIN

>D>	AB2	AMNEAL PHARMS NY	10MG	A216097	001	Oct 07, 2025	Mar	DISC
>A>	@		10MG	A216097	001	Oct 07, 2025	Mar	DISC
>D>	AB2		20MG	A216097	002	Oct 07, 2025	Mar	DISC
>A>	@		20MG	A216097	002	Oct 07, 2025	Mar	DISC
>D>	AB2		25MG	A216097	003	Oct 07, 2025	Mar	DISC
>A>	@		25MG	A216097	003	Oct 07, 2025	Mar	DISC
>D>	AB2		30MG	A216097	004	Oct 07, 2025	Mar	DISC
>A>	@		30MG	A216097	004	Oct 07, 2025	Mar	DISC
>D>	AB2		35MG	A216097	005	Oct 07, 2025	Mar	DISC
>A>	@		35MG	A216097	005	Oct 07, 2025	Mar	DISC
>D>	AB2		40MG	A216097	006	Oct 07, 2025	Mar	DISC
>A>	@		40MG	A216097	006	Oct 07, 2025	Mar	DISC

IVABRADINE

SOLUTION; ORAL

CORLANOR

>D>	+!	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Mar	DISC
>A>	@ +		5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Mar	DISC

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

	@ +	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan	DISC
	@ +		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan	DISC
AB	!	INGENUS PHARMS LLC	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan	CHRS

IVERMECTINTABLET; ORAL
IVERMECTIN

>A>	AB	AJANTA PHARMA LTD	3MG	A218509	001	Apr 07, 2026	Mar	NEWA
	AB	E5 PHARMA	3MG	A216808	001	Mar 09, 2026	Feb	NEWA
	AB	ZYDUS LIFESCIENCES	3MG	A216863	001	Feb 26, 2026	Feb	NEWA

KETOCONAZOLECREAM; TOPICAL
KETOCONAZOLE

@	PADAGIS US	2%	A215185	001	Nov 17, 2021	Jan	DISC
---	------------	----	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDETABLET; ORAL
LABETALOL HYDROCHLORIDE

>D>	AP	APPCO	400MG	A209603	004	Oct 18, 2024	Mar	CTEC
>A>	AB		400MG	A209603	004	Oct 18, 2024	Mar	CTEC
>A>	AB	HERITAGE PHARMA	400MG	A074787	004	Mar 26, 2026	Mar	NEWA

LACOSAMIDESOLUTION; INTRAVENOUS
LACOSAMIDE

>D>	AP	ANTHEA PHARMA	200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Mar	CAHN
	AP		200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Jan	NEWA
>A>	AP	GLENMARK PHARMS	200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Mar	CAHN

SOLUTION; ORAL
LACOSAMIDE

@	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Feb	DISC
AA	INDOCO	10MG/ML	A220386	001	Jan 29, 2026	Jan	NEWA
AA	REGCON HOLDINGS	10MG/ML	A220386	001	Jan 29, 2026	Jan	CAHN

LAMIVUDINETABLET; ORAL
LAMIVUDINE

@	LUPIN LTD	150MG	A205217	001	Dec 18, 2014	Jan	DISC
@		300MG	A205217	002	Dec 18, 2014	Jan	DISC

LAMOTRIGINETABLET, ORALLY DISINTEGRATING; ORAL
LAMOTRIGINE

AB	ALEMBIC	25MG	A217278	001	Feb 25, 2026	Feb	NEWA
AB		50MG	A217278	002	Feb 25, 2026	Feb	NEWA
AB		100MG	A217278	003	Feb 25, 2026	Feb	NEWA
AB		200MG	A217278	004	Feb 25, 2026	Feb	NEWA
AB	TORRENT	25MG	A217100	001	Jan 08, 2026	Jan	NEWA
AB		50MG	A217100	002	Jan 08, 2026	Jan	NEWA
AB		100MG	A217100	003	Jan 08, 2026	Jan	NEWA
AB		200MG	A217100	004	Jan 08, 2026	Jan	NEWA

LATANOPROSTSOLUTION/DROPS; OPHTHALMIC
LATANOPROST

@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Feb	CAHN
---	----------	--------	---------	-----	--------------	-----	------

LENALIDOMIDECAPSULE; ORAL
LENALIDOMIDE

AB	ALVOGEN	2.5MG	A210480	005	Mar 06, 2023	Jan	CAHN	
AB		5MG	A210480	001	Aug 31, 2022	Jan	CAHN	
AB		10MG	A210480	002	Aug 31, 2022	Jan	CAHN	
AB		15MG	A210480	003	Aug 31, 2022	Jan	CAHN	
AB		20MG	A210480	006	Mar 06, 2023	Jan	CAHN	
AB		25MG	A210480	004	Aug 31, 2022	Jan	CAHN	
AB	CIPLA	5MG	A213165	001	Feb 02, 2026	Jan	NEWA	
AB		10MG	A213165	002	Feb 02, 2026	Jan	NEWA	
AB		15MG	A213165	003	Feb 02, 2026	Jan	NEWA	
AB		20MG	A213165	004	Feb 02, 2026	Jan	NEWA	
AB		25MG	A213165	005	Feb 02, 2026	Jan	NEWA	
>D>	AB	TORRENT	2.5MG	A213405	005	Feb 10, 2026	Mar	DISC
>A>	@	2.5MG	A213405	005	Feb 10, 2026	Mar	DISC	
	AB	2.5MG	A213405	005	Feb 10, 2026	Jan	NEWA	

CAPSULE;ORAL

LENALIDOMIDE

>D>	AB		5MG	A213405	006	Feb 10, 2026	Mar	DISC
>A>	@		5MG	A213405	006	Feb 10, 2026	Mar	DISC
	AB		5MG	A213405	006	Feb 10, 2026	Jan	NEWA
>D>	AB		15MG	A213405	004	Nov 04, 2025	Mar	DISC
>A>	@		15MG	A213405	004	Nov 04, 2025	Mar	DISC

LEUCOVORIN CALCIUM

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

@	INGENUS PHARMS LLC	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Feb	CAHN
---	--------------------	--------------------------------------	---------	-----	--------------	-----	------

VYKOURA

+	AVYXA HOLDINGS	EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N220406	001	Feb 03, 2026	Feb	NEWA
+		EQ 350MG BASE/35ML (EQ 10MG BASE/ML)	N220406	002	Feb 03, 2026	Feb	NEWA
+		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	N220406	003	Feb 03, 2026	Feb	NEWA

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS

LEUPROLIDE ACETATE

AP	SOMERSET THERAPS LLC	14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Feb	CAHN
----	----------------------	------------------------	---------	-----	--------------	-----	------

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI ETM

+	ACCORD	EQ 21MG BASE	N219745	001	Aug 25, 2025	Jan	CAHN
---	--------	--------------	---------	-----	--------------	-----	------

LEVETIRACETAM

SOLUTION;ORAL

LEVETIRACETAM

>A>	AA	ANDA REPOSITORY	100MG/ML	A218080	001	Nov 21, 2025	Mar	CAHN
>D>	AA	GUARDIAN DRUG	100MG/ML	A218080	001	Nov 21, 2025	Mar	CAHN

TABLET;ORAL

LEVETIRACETAM

	AB	SENORES PHARMS	250MG	A076920	001	Jan 15, 2009	Jan	CAHN
	AB		500MG	A076920	002	Jan 15, 2009	Jan	CAHN
	AB		750MG	A076920	003	Jan 15, 2009	Jan	CAHN
	AB		1GM	A078904	001	Jan 15, 2009	Jan	CAHN

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

>D>	AP	AMNEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Mar	DISC
>A>	@		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Mar	DISC

LIDOCAINE

PATCH;TOPICAL

LIDOCAINE

>D>	@	USPHARMA	5%	A207059	001	Feb 09, 2026	Mar	CMFD
>A>	AB		5%	A207059	001	Feb 09, 2026	Mar	CMFD
	@		5%	A207059	001	Feb 09, 2026	Feb	DISC
	AB		5%	A207059	001	Feb 09, 2026	Jan	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

	AP	ANTHEA PHARMA	2%	A219535	002	Feb 06, 2026	Jan	NEWA
>A>	AP	VIWIT PHARM	1%	A220071	001	Mar 19, 2026	Mar	NEWA
>A>	AP		2%	A220071	002	Mar 19, 2026	Mar	NEWA

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

>A>	AT	QUAGEN	2%	A218676	001	Mar 20, 2026	Mar	NEWA
-----	----	--------	----	---------	-----	--------------	-----	------

>A>	<u>LINERIXIBAT</u>								
>A>	TABLET;ORAL								
>A>	LYNAVOY								
>A>	+	GLAXOSMITHKLINE	40MG		N220295	001	Mar 17, 2026	Mar	NEWA
	<u>LIRAGLUTIDE</u>								
	SOLUTION;SUBCUTANEOUS								
	LIRAGLUTIDE								
	AP1	BIOCON PHARMA	18MG/3ML (6MG/ML)		A215245	001	Mar 11, 2026	Feb	NEWA
	AP2		18MG/3ML (6MG/ML)		A217063	001	Feb 24, 2026	Feb	NEWA
>A>	AP1	FRESENIUS KABI USA	18MG/3ML (6MG/ML)		A212552	001	Mar 30, 2026	Mar	NEWA
	AP2	ORBICULAR	18MG/3ML (6MG/ML)		A217234	001	Feb 24, 2026	Feb	NEWA
	AP1		18MG/3ML (6MG/ML)		A217590	001	Jan 14, 2026	Jan	NEWA
	<u>LITHIUM CITRATE</u>								
	SYRUP;ORAL								
	LITHIUM CITRATE								
>D>	@	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML		A070755	001	May 21, 1986	Mar	CMFD
>A>	AA		EQ 300MG CARBONATE/5ML		A070755	001	May 21, 1986	Mar	CMFD
	<u>LOMITAPIDE MESYLATE</u>								
	CAPSULE;ORAL								
	JUXTAPID								
	+	CHIESI	EQ 2MG BASE		N203858	007	Feb 25, 2026	Feb	NEWA
>D>	+		EQ 30MG BASE		N203858	004	Apr 23, 2015	Mar	CHRS
>A>	+		EQ 30MG BASE		N203858	004	Apr 23, 2015	Mar	CHRS
	<u>LOVASTATIN</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	ALTOPREV								
>A>	@	AZURITY	10MG		N021316	001	Jun 26, 2002	Mar	CAHN
>A>	@ +		20MG		N021316	002	Jun 26, 2002	Mar	CAHN
>A>	@ +		40MG		N021316	003	Jun 26, 2002	Mar	CAHN
>A>	@ +		60MG		N021316	004	Jun 26, 2002	Mar	CAHN
>D>	@	COVIS	10MG		N021316	001	Jun 26, 2002	Mar	CAHN
>D>	@ +		20MG		N021316	002	Jun 26, 2002	Mar	CAHN
>D>	@ +		40MG		N021316	003	Jun 26, 2002	Mar	CAHN
>D>	@ +		60MG		N021316	004	Jun 26, 2002	Mar	CAHN
	<u>LUBIPROSTONE</u>								
	CAPSULE;ORAL								
	LUBIPROSTONE								
AB		AMNEAL	8MCG		A209450	001	Nov 30, 2021	Jan	CMFD
AB			24MCG		A209450	002	Nov 30, 2021	Jan	CMFD
	<u>MACIMORELIN ACETATE</u>								
	FOR SOLUTION;ORAL								
	MACRILEN								
	@ +	AETERNA ZENTARIS	EQ 60MG BASE/POUCH		N205598	001	Dec 20, 2017	Jan	CAHN
	<u>MACITENTAN</u>								
	TABLET;ORAL								
	MACITENTAN								
>D>	@	APOTEX	10MG		A211195	001	Jan 09, 2024	Mar	CMFD
>A>	AB		10MG		A211195	001	Jan 09, 2024	Mar	CMFD
	<u>MAFENIDE ACETATE</u>								
	FOR SOLUTION;TOPICAL								
	MAFENIDE ACETATE								
	@	INGENUS PHARMS LLC	5%		A206716	001	Jul 31, 2017	Feb	CAHN
	<u>MAGNESIUM SULFATE</u>								
	INJECTABLE;INJECTION								
	MAGNESIUM SULFATE								
	!	BAXTER HLTHCARE CORP	3GM/100ML (30MG/ML)		A211966	004	Jan 08, 2026	Jan	NFTG
	MAGNESIUM SULFATE IN PLASTIC CONTAINER								
>D>	AP	MYLAN LABS LTD	2GM/50ML (40MG/ML)		A209911	001	Sep 14, 2018	Mar	DISC
>A>	@		2GM/50ML (40MG/ML)		A209911	001	Sep 14, 2018	Mar	DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	SENORES PHARMS	12.5MG	A 087128	002		Feb	CAHN
AA		25MG	A 087128	001		Feb	CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

>A>	AA	MEDLEY PHARMS	2MG/ML	A 210319	001	Aug 31, 2020	Mar	CAHN
>D>	AA	SETON PHARMS	2MG/ML	A 210319	001	Aug 31, 2020	Mar	CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

>D>	AB	DR REDDYS LABS LTD	10MG	A 090048	002	Apr 14, 2010	Mar	CHRS
>A>	AB	!	10MG	A 090048	002	Apr 14, 2010	Mar	CHRS
	AB	RENATA	5MG	A 209527	001	May 07, 2018	Feb	CAHN
	AB		10MG	A 209527	002	May 07, 2018	Feb	CAHN

NAMENDA

>D>	AB	+ ABBVIE	5MG	N 021487	001	Oct 16, 2003	Mar	DISC
>A>		@ +	5MG	N 021487	001	Oct 16, 2003	Mar	DISC
>D>	AB	+!	10MG	N 021487	002	Oct 16, 2003	Mar	DISC
>A>		@ +	10MG	N 021487	002	Oct 16, 2003	Mar	DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

!	FRESENIUS KABI USA	1%	A 089407	001	Dec 01, 1986	Jan	CHRS
!		2%	A 089410	001	Dec 01, 1986	Jan	CHRS

POLOCAINE-MPF

!	FRESENIUS KABI USA	1%	A 089406	001	Dec 01, 1986	Jan	CHRS
!		1.5%	A 089408	001	Dec 01, 1986	Jan	CHRS
!		2%	A 089409	001	Dec 01, 1986	Jan	CHRS

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

MESALAMINE

AB	DIFGEN PHARMS	250MG	A 219997	001	Mar 10, 2026	Feb	NFTG
AB		500MG	A 219997	002	Mar 10, 2026	Feb	NEWA

PENTASA

AB	+ TAKEDA PHARMS USA	250MG	N 020049	001	May 10, 1993	Feb	CFTG
----	---------------------	-------	----------	-----	--------------	-----	------

ENEMA; RECTAL

MESALAMINE

>A>	AB	KLM LABS PVT	4GM/60ML	A 220016	001	Mar 31, 2026	Mar	NEWA
-----	----	--------------	----------	----------	-----	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	EUGIA PHARMA	100MG/ML	A 220518	001	Jan 27, 2026	Jan	NEWA
----	--------------	----------	----------	-----	--------------	-----	------

TABLET; ORAL

MESNA

AB	INGENUS PHARMS LLC	400MG	A 218871	001	Jan 13, 2025	Feb	CAHN
----	--------------------	-------	----------	-----	--------------	-----	------

METAXALONE

TABLET; ORAL

METAXALONE

@	INGENUS PHARMS LLC	800MG	A 213836	001	Oct 21, 2020	Feb	CAHN
---	--------------------	-------	----------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	CHARTWELL	625MG	A 075972	005	Jan 24, 2002	Jan	CTEC
AB		750MG	A 075972	004	Jan 24, 2002	Jan	CTEC
AB	SCIEGEN PHARMS	625MG	A 203769	004	Feb 09, 2026	Jan	NEWA
AB		750MG	A 203769	005	Feb 09, 2026	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB1	AMNEAL PHARMS NY	500MG	A 078596	001	Jan 03, 2008	Mar	DISC
>A>		@	500MG	A 078596	001	Jan 03, 2008	Mar	DISC
>D>	AB		750MG	A 078596	002	Jan 03, 2008	Mar	DISC
>A>		@	750MG	A 078596	002	Jan 03, 2008	Mar	DISC
		@ APOTEX	500MG	A 213356	001	Dec 13, 2021	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

@		1GM	A213356	002	Dec 13, 2021	Feb	DISC
@	RK PHARMA	500MG	A215629	001	Jun 20, 2023	Jan	DISC
@		1GM	A215629	002	Jun 20, 2023	Jan	DISC

METHADONE HYDROCHLORIDE

SOLUTION;ORAL
METHADONE HYDROCHLORIDE

AA	VISTAPHARM LLC	5MG/5ML	A090707	001	Jun 30, 2010	Feb	CMFD
----	----------------	---------	---------	-----	--------------	-----	------

METHAZOLAMIDE

TABLET;ORAL
METHAZOLAMIDE

AB	AJANTA PHARMA LTD	25MG	A217408	001	Feb 09, 2026	Jan	NEWA
AB		50MG	A217408	002	Feb 09, 2026	Jan	NEWA

METHENAMINE HIPPURATE

TABLET;ORAL
METHENAMINE HIPPURATE

AB	INGENUS PHARMS LLC	1GM	A210068	001	Nov 27, 2020	Feb	CAHN
----	--------------------	-----	---------	-----	--------------	-----	------

METHOCARBAMOL

TABLET;ORAL
METHOCARBAMOL

>A>	AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Mar	CAHN
>A>	AA		750MG	A203550	002	Feb 08, 2017	Mar	CAHN
>D>	AA	HLTHCARE	500MG	A203550	001	Feb 08, 2017	Mar	CAHN
	AA		500MG	A203550	001	Feb 08, 2017	Feb	CAHN
>D>	AA		750MG	A203550	002	Feb 08, 2017	Mar	CAHN
	AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE

>D>	AP	CAPLIN ONE LABS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Mar	DISC
>A>	@		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Mar	DISC
	AP		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan	CAHN
>D>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Mar	DISC
>A>	@		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Mar	DISC
	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan	CAHN
>D>	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Mar	DISC
>A>	@		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Mar	DISC
	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan	CAHN

TABLET;ORAL
METHOTREXATE SODIUM

>D>	AB	DAITO	EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Mar	DISC
>A>	@		EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Mar	DISC

METHYLENE BLUE

SOLUTION;INTRAVENOUS
METHYLENE BLUE

>A>	!	ZYDUS LIFESCIENCES	5MG/ML (5MG/ML)	A215636	003	Feb 02, 2026	Jan	NFTG
	!		100MG/10ML (10MG/ML)	A215636	004	Mar 31, 2026	Mar	NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB1	DR REDDYS LABS SA	60MG	A078458	004	Jun 23, 2016	Feb	CHRS	
AB1	!	GRANULES	60MG	A211796	005	May 23, 2019	Feb	CHRS

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

	@	INGENUS PHARMS LLC	4MG	A210985	001	Jan 09, 2019	Feb CAHN
--	---	--------------------	-----	---------	-----	--------------	----------

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB		CAPLIN	40MG/ML	A220556	001	Jan 26, 2026	Jan NEWA
AB			80MG/ML	A220556	002	Jan 26, 2026	Jan NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SPRAY, METERED; NASAL

GIMOTI

	+	QOL MEDCL	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Feb CAHN
--	---	-----------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	@	STRIDES PHARMA INTL	EQ 10MG BASE	A070581	001	Oct 17, 1985	Jan DISC
--	---	---------------------	--------------	---------	-----	--------------	----------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

>D>	AB	MYLAN PHARMS INC	EQ 200MG TARTRATE	A202033	004	Dec 15, 2011	Mar DISC
>A>		@	EQ 200MG TARTRATE	A202033	004	Dec 15, 2011	Mar DISC

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

AB		ZYDUS LIFESCIENCES	0.75%	A220095	001	Feb 13, 2026	Feb NEWA
----	--	--------------------	-------	---------	-----	--------------	----------

INJECTABLE; INJECTION

METRO I.V. IN PLASTIC CONTAINER

	@	+	B BRAUN	500MG/100ML	N018900	001	Sep 29, 1983	Jan DISC
--	---	---	---------	-------------	---------	-----	--------------	----------

METRONIDAZOLE IN PLASTIC CONTAINER

AP		!	INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Jan CHRS
----	--	---	-----------	-------------	---------	-----	--------------	----------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	150MG	A214352	001	Jan 25, 2021	Feb CAHN
AB			200MG	A214352	002	Jan 25, 2021	Feb CAHN
AB			250MG	A214352	003	Jan 25, 2021	Feb CAHN
>A>	AB	MACLEODS PHARMS LTD	150MG	A219987	001	Mar 23, 2026	Mar NEWA
>A>	AB		200MG	A219987	002	Mar 23, 2026	Mar NEWA
>A>	AB		250MG	A219987	003	Mar 23, 2026	Mar NEWA

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

>A>	AP	ASPIRO	EQ 50MG BASE/VIAL	A220296	001	Mar 17, 2026	Mar NEWA
>A>	AP		EQ 100MG BASE/VIAL	A220296	002	Mar 17, 2026	Mar NEWA
	AP	HISUN PHARM HANGZHOU	EQ 50MG BASE/VIAL	A219712	001	Jan 21, 2026	Jan NEWA
	AP		EQ 100MG BASE/VIAL	A219712	002	Jan 21, 2026	Jan NEWA
	AP	YICHANG HUMANWELL	EQ 50MG BASE/VIAL	A219518	001	Feb 24, 2026	Feb NEWA
	AP		EQ 100MG BASE/VIAL	A219518	002	Feb 24, 2026	Feb NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

>D>	AB	THINQ PHARM-CRO PVT	2.5MG	A207613	001	Nov 02, 2018	Mar CAHN
>D>	AB		5MG	A207613	002	Nov 02, 2018	Mar CAHN
>D>	AB		10MG	A207613	003	Nov 02, 2018	Mar CAHN
>A>	AB	UNIQUE	2.5MG	A207613	001	Nov 02, 2018	Mar CAHN
>A>	AB		5MG	A207613	002	Nov 02, 2018	Mar CAHN
>A>	AB		10MG	A207613	003	Nov 02, 2018	Mar CAHN

MIGLITOL

TABLET;ORAL

MIGLITOL

>A>	!	ORIENT PHARMA	25MG	A203965	001	Feb 24, 2015	Mar CAHN
>A>			50MG	A203965	002	Feb 24, 2015	Mar CAHN
>A>			100MG	A203965	003	Feb 24, 2015	Mar CAHN
>D>	!	WESTMINSTER PHARMS	25MG	A203965	001	Feb 24, 2015	Mar CAHN
>D>			50MG	A203965	002	Feb 24, 2015	Mar CAHN
>D>			100MG	A203965	003	Feb 24, 2015	Mar CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Jan CMFD
AB			25MG	A205081	002	Apr 22, 2016	Jan CMFD
AB			50MG	A205081	003	Apr 22, 2016	Jan CMFD
AB			100MG	A205081	004	Apr 22, 2016	Jan CMFD
AB		BRECKENRIDGE	12.5MG	A205071	001	Jan 27, 2016	Jan CMFD
AB			25MG	A205071	002	Jan 27, 2016	Jan CMFD
AB			50MG	A205071	003	Jan 27, 2016	Jan CMFD
AB			100MG	A205071	004	Jan 27, 2016	Jan CMFD
AB		HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Feb CMFD
AB			25MG	A205147	002	Oct 03, 2024	Feb CMFD
AB			50MG	A205147	003	Oct 03, 2024	Feb CMFD
AB			100MG	A205147	004	Oct 03, 2024	Feb CMFD
		SAVELLA					
AB	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan CTEC
AB	+		25MG	N022256	002	Jan 14, 2009	Jan CTEC
AB	+		50MG	N022256	003	Jan 14, 2009	Jan CTEC
AB	+		100MG	N022256	004	Jan 14, 2009	Jan CTEC

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

>D>	AP	HIKMA	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Mar DISC
>A>	@		EQ 1MG BASE/ML	A075530	001	May 28, 2002	Mar DISC

MILSAPERIDONE

TABLET;ORAL

BYSANTI

	+	VANDA PHARMS INC	1MG	N220358	001	Feb 20, 2026	Feb NEWA
	+		2MG	N220358	002	Feb 20, 2026	Feb NEWA
	+		4MG	N220358	003	Feb 20, 2026	Feb NEWA
	+		6MG	N220358	004	Feb 20, 2026	Feb NEWA
	+		8MG	N220358	005	Feb 20, 2026	Feb NEWA
	+		10MG	N220358	006	Feb 20, 2026	Feb NEWA
	+		12MG	N220358	007	Feb 20, 2026	Feb NEWA

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MIRABEGRON

AB		ALKEM LABS LTD	8MG/ML	A219323	001	Jan 20, 2026	Jan NFTG
AB		MYRBETRIQ GRANULES					
AB	+	APGDI	8MG/ML	N213801	001	Mar 25, 2021	Jan CFTG

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		NOVITIUM PHARMA	7.5MG	A219919	001	Feb 02, 2026	Jan NEWA
AB			15MG	A219919	002	Feb 02, 2026	Jan NEWA
AB			30MG	A219919	003	Feb 02, 2026	Jan NEWA
AB			45MG	A219919	004	Feb 02, 2026	Jan NEWA

MITAPIVAT SULFATE

TABLET;ORAL

AQVESME

	+	AGIOS PHARMS INC	EQ 100MG BASE	N216196	004	Dec 23, 2025	Jan NEWA
--	---	------------------	---------------	---------	-----	--------------	----------

MOMETASONE FUROATE

IMPLANT; IMPLANTATION
SINUVA

>D>	+	INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017	Mar	CHRS
>A>	+	!	1.35MG	N209310	001	Dec 08, 2017	Mar	CHRS

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL
MONTELUKAST SODIUM

>D>	AB		AMNEAL PHARMS	EQ 4MG BASE	A205107	001	Sep 04, 2020	Mar	DISC
>A>		@		EQ 4MG BASE	A205107	001	Sep 04, 2020	Mar	DISC
>D>	AB			EQ 5MG BASE	A205107	002	Sep 04, 2020	Mar	DISC
>A>		@		EQ 5MG BASE	A205107	002	Sep 04, 2020	Mar	DISC
	AB		SENORES PHARMS	EQ 4MG BASE	A201581	001	Aug 06, 2012	Jan	CAHN
	AB			EQ 5MG BASE	A201581	002	Aug 06, 2012	Jan	CAHN

MORPHINE SULFATE

SOLUTION; ORAL
MORPHINE SULFATE

>D>	AA		PADAGIS US	100MG/5ML	A201574	001	Aug 06, 2012	Mar	DISC
>A>		@		100MG/5ML	A201574	001	Aug 06, 2012	Mar	DISC
>D>	AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	Mar	DISC
>A>		@		10MG/5ML	A203518	001	May 12, 2015	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

		@	STRIDES PHARMA INTL	15MG	A075295	001	Oct 28, 1998	Jan	DISC
		@		30MG	A075295	002	Oct 28, 1998	Jan	DISC
		@		60MG	A075295	003	Oct 28, 1998	Jan	DISC
		@		100MG	A075295	004	Sep 15, 2000	Jan	DISC
		@		200MG	A075295	005	Sep 15, 2000	Jan	DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

		@	FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Feb	DISC
--	--	---	---------	--------------	---------	-----	--------------	-----	------

TABLET; ORAL
MOXIFLOXACIN HYDROCHLORIDE

	AB		MACLEODS PHARMS LTD	EQ 400MG BASE	A209143	001	Mar 02, 2026	Feb	NEWA
--	----	--	---------------------	---------------	---------	-----	--------------	-----	------

MUPIROCIN

OINTMENT; TOPICAL
CENTANY

>D>	BX		PADAGIS US	2%	N050788	001	Dec 04, 2002	Mar	DISC
>A>		@		2%	N050788	001	Dec 04, 2002	Mar	DISC

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE; ORAL
MYCOPHENOLATE SODIUM

		@	RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Jan	DISC
		@		EQ 360MG BASE	A091248	001	Jan 08, 2014	Jan	DISC
>D>	AB		TWI PHARMS	EQ 180MG BASE	A214289	001	Nov 03, 2021	Mar	DISC
>A>		@		EQ 180MG BASE	A214289	001	Nov 03, 2021	Mar	DISC
>D>	AB			EQ 360MG BASE	A214289	002	Nov 03, 2021	Mar	DISC
>A>		@		EQ 360MG BASE	A214289	002	Nov 03, 2021	Mar	DISC

NABUMETONE

TABLET; ORAL
NABUMETONE

		!	LGM PHARMA	1GM	A203166	003	Aug 30, 2019	Jan	CHRS
--	--	---	------------	-----	---------	-----	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIFINE HYDROCHLORIDE

		@	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb	DISC
--	--	---	--------	----	---------	-----	--------------	-----	------

GEL; TOPICAL
NAFTIFINE HYDROCHLORIDE

>D>	AB		AMNEAL	1%	A206165	001	Mar 20, 2019	Mar	DISC
>A>		@		1%	A206165	001	Mar 20, 2019	Mar	DISC

NAFTIN

>D>	AB		! LEGACY PHARMA	1%	N019356	001	Jun 18, 1990	Mar	CTEC
>A>			!	1%	N019356	001	Jun 18, 1990	Mar	CTEC

NALOXONE HYDROCHLORIDESPRAY;NASAL
REZENOPY

+! SCIENATURE 10MG/SPRAY N215487 001 Apr 19, 2024 Jan CMFD

NAPROXENSUSPENSION;ORAL
NAPROXEN>D> AB AUROBINDO PHARMA 25MG/ML A216504 001 Oct 03, 2025 Mar DISC
>A> @ 25MG/ML A216504 001 Oct 03, 2025 Mar DISCNARATRIPTAN HYDROCHLORIDETABLET;ORAL
NARATRIPTAN>D> AB PADAGIS US EQ 1MG BASE A091326 001 Jul 08, 2010 Mar DISC
>A> @ EQ 1MG BASE A091326 001 Jul 08, 2010 Mar DISC
>D> AB EQ 2.5MG BASE A091326 002 Jul 08, 2010 Mar DISC
>A> @ EQ 2.5MG BASE A091326 002 Jul 08, 2010 Mar DISCNAVEPEGITIDEPOWDER;SUBCUTANEOUS
YUWIWEL+! ASCENDIS 1.3MG/VIAL N219164 001 Feb 27, 2026 Feb NEWA
+! 2.8MG/VIAL N219164 002 Feb 27, 2026 Feb NEWA
+! 5.5MG/VIAL N219164 003 Feb 27, 2026 Feb NEWANEBIVOLOL HYDROCHLORIDETABLET;ORAL
NEBIVOLOL HYDROCHLORIDE>D> AB TORRENT EQ 2.5MG BASE A203966 001 Mar 02, 2018 Mar DISC
>A> @ EQ 2.5MG BASE A203966 001 Mar 02, 2018 Mar DISC
>D> AB EQ 5MG BASE A203966 002 Mar 02, 2018 Mar DISC
>A> @ EQ 5MG BASE A203966 002 Mar 02, 2018 Mar DISC
>D> AB EQ 10MG BASE A203966 003 Mar 02, 2018 Mar DISC
>A> @ EQ 10MG BASE A203966 003 Mar 02, 2018 Mar DISC
>D> AB EQ 20MG BASE A203966 004 Mar 02, 2018 Mar DISC
>A> @ EQ 20MG BASE A203966 004 Mar 02, 2018 Mar DISCNEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION;IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATE@ WATSON LABS EQ 40MG BASE/ML;200,000 A062664 001 Apr 08, 1986 Jan DISC
UNITS/ML
! XGEN PHARMS EQ 40MG BASE/ML;200,000 A065106 001 Jan 31, 2006 Jan CTEC
UNITS/ML
AT ! EQ 40MG BASE/ML;200,000 A065106 001 Jan 31, 2006 Jan CHRS
UNITS/ML
! EQ 40MG BASE/ML;200,000 A065108 001 Jan 31, 2006 Jan CTEC
UNITS/ML
AT ! EQ 40MG BASE/ML;200,000 A065108 001 Jan 31, 2006 Jan CHRS
UNITS/ML
NEOSPORIN G.U. IRRIGANT
@ MONARCH PHARMS EQ 40MG BASE/ML;200,000 A060707 001 Jan DISC
UNITS/MLNEOSTIGMINE METHYLSULFATESOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE>D> AP HIKMA 3MG/3ML (1MG/ML) A216206 001 Jul 13, 2022 Mar DISC
>A> @ 3MG/3ML (1MG/ML) A216206 001 Jul 13, 2022 Mar DISC
>A> AP NIVAGEN PHARMS INC 5MG/10ML (0.5MG/ML) A212627 001 Nov 03, 2022 Mar CAHN
>A> AP 10MG/10ML (1MG/ML) A212627 002 Nov 03, 2022 Mar CAHN
>D> AP UMEDICA 5MG/10ML (0.5MG/ML) A212627 001 Nov 03, 2022 Mar CAHN
>D> AP 10MG/10ML (1MG/ML) A212627 002 Nov 03, 2022 Mar CAHNNICARDIPINE HYDROCHLORIDECAPSULE;ORAL
NICARDIPINE HYDROCHLORIDE>D> AB NAVINTA LLC 20MG A218638 001 Jun 25, 2025 Mar DISC
>A> @ 20MG A218638 001 Jun 25, 2025 Mar DISC
>D> AB 30MG A218638 002 Jun 25, 2025 Mar DISC
>A> @ 30MG A218638 002 Jun 25, 2025 Mar DISC
AB SENORES PHARMS 20MG A215377 001 Jul 17, 2023 Jan CAHN

	CAPSULE;ORAL							
	NICARDIPINE HYDROCHLORIDE							
AB		30MG		A215377	002	Jul 17, 2023	Jan	CAHN
	INJECTABLE;INJECTION							
	CARDENE							
AP	+	CHIESI	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Jan	CMFD
	NICARDIPINE HYDROCHLORIDE							
AP		SOMERSET THERAPS LLC	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Jan	CAHN
	<u>NIFEDIPINE</u>							
	CAPSULE;ORAL							
	NIFEDIPINE							
>D>	AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CHRS
>A>	AB	!	10MG	A202644	001	Apr 25, 2013	Mar	CHRS
	PROCARDIA							
>D>	AB	+!	PFIZER	N018482	001		Mar	DISC
>A>		@ +		N018482	001		Mar	DISC
	TABLET, EXTENDED RELEASE;ORAL							
	NIFEDIPINE							
>A>	@	PHARMADAX	30MG	A216019	001	Nov 18, 2022	Mar	CAHN
>A>	@		60MG	A216019	002	Nov 18, 2022	Mar	CAHN
>D>	@	SWISS PHARM	30MG	A216019	001	Nov 18, 2022	Mar	CAHN
>D>	@		60MG	A216019	002	Nov 18, 2022	Mar	CAHN
	<u>NINTEDANIB ESYLATE</u>							
	CAPSULE;ORAL							
>A>	NINTEDANIB ESYLATE							
>A>	AB	APOTEX	EQ 100MG BASE	A219227	001	Apr 02, 2026	Mar	NFTG
>A>	AB		EQ 150MG BASE	A219227	002	Apr 02, 2026	Mar	NFTG
>A>	AB	CIPLA	EQ 100MG BASE	A212609	001	Apr 02, 2026	Mar	NFTG
>A>	AB		EQ 150MG BASE	A212609	002	Apr 02, 2026	Mar	NFTG
>A>	AB	DEXCEL	EQ 100MG BASE	A219819	001	Apr 02, 2026	Mar	NFTG
>A>	AB		EQ 150MG BASE	A219819	002	Apr 02, 2026	Mar	NFTG
>A>	AB	DR REDDYS	EQ 100MG BASE	A219283	001	Apr 02, 2026	Mar	NFTG
>A>	AB		EQ 150MG BASE	A219283	002	Apr 02, 2026	Mar	NFTG
>A>	AB	SANDOZ	EQ 100MG BASE	A216915	001	Apr 02, 2026	Mar	NFTG
>A>	AB		EQ 150MG BASE	A216915	002	Apr 02, 2026	Mar	NFTG
	OFEV							
>D>	+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CFTG
>A>	AB	+	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CFTG
>D>	+	!	EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CFTG
>A>	AB	+	EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CFTG
	<u>NIROGACESTAT HYDROBROMIDE</u>							
	TABLET;ORAL							
	OGSIVEO							
>D>	+	SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Mar	DISC
>A>	@	+	EQ 50MG BASE	N217677	001	Nov 27, 2023	Mar	DISC
	<u>NISOLDIPINE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	NISOLDIPINE							
	@	MYLAN	34MG	A091001	004	Jan 26, 2011	Feb	DISC
	SULAR							
AB	+	AZURITY	8.5MG	N020356	008	Jan 02, 2008	Feb	CAHN
	@	+	10MG	N020356	001	Feb 02, 1995	Feb	CAHN
AB	+	!	17MG	N020356	007	Jan 02, 2008	Feb	CAHN
	@	+	20MG	N020356	002	Feb 02, 1995	Feb	CAHN
	@	+	25.5MG	N020356	006	Jan 02, 2008	Feb	CAHN
	@	+	30MG	N020356	003	Feb 02, 1995	Feb	CAHN
	+	!	34MG	N020356	005	Jan 02, 2008	Feb	CAHN
	@	+	40MG	N020356	004	Feb 02, 1995	Feb	CAHN
	+	!	COVIS	N020356	005	Jan 02, 2008	Feb	CTEC
	<u>NITRIC OXIDE</u>							
	GAS;INHALATION							
	NOXIVENT							
>D>	@	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Mar	CAHN
>D>	AA		800PPM	A207141	002	Oct 02, 2018	Mar	CAHN
>A>	@	VERO BIOTECH INC	100PPM	A207141	001	Oct 02, 2018	Mar	CAHN
>A>	AA		800PPM	A207141	002	Oct 02, 2018	Mar	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A>	AB	CREEKWOOD PHARMS	75MG;25MG	A220269	001	Apr 07, 2026	Mar	NEWA
-----	----	------------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

	+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jan	CHRS
	+		0.2MG/HR	N020145	002	Apr 04, 1995	Jan	CHRS
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Jan	CHRS
	+		0.6MG/HR	N020145	005	Apr 04, 1995	Jan	CHRS
	+		0.8MG/HR	N020145	006	Apr 04, 1995	Jan	CHRS

NITROGLYCERIN

AB2		MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Jan	CHRS
AB2			0.2MG/HR	A074559	003	Aug 30, 1996	Jan	CHRS
AB2			0.6MG/HR	A074559	001	Aug 30, 1996	Jan	CHRS

OINTMENT;INTRA-ANAL

NITROGLYCERIN

>D>	AB	COSETTE	0.4%	A216103	001	Feb 16, 2024	Mar	CHRS
>A>	AB	!	0.4%	A216103	001	Feb 16, 2024	Mar	CHRS
>D>		RECTIV						
>D>	AB	+! ABBVIE	0.4%	N021359	001	Jun 21, 2011	Mar	DISC
>A>		@ +	0.4%	N021359	001	Jun 21, 2011	Mar	DISC

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

	+	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	004	Feb 06, 2026	Feb	NEWA
	+		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	005	Feb 06, 2026	Feb	NEWA
	+		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	006	Feb 06, 2026	Feb	NEWA

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

>D>		+! BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	003	Nov 21, 2023	Mar	CFTG
>A>	AP	+!	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	003	Nov 21, 2023	Mar	CFTG
>A>	AP	SAGENT	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	A220483	001	Mar 26, 2026	Mar	NFTG

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB		INGENUS PHARMS LLC	5MG	A206490	001	Nov 05, 2018	Feb	CAHN
----	--	--------------------	-----	---------	-----	--------------	-----	------

NYSTATIN

SUSPENSION;ORAL

NILSTAT

>D>		@ + CHARTWELL MOLECULES	100,000 UNITS/ML	N050299	001		Mar	CMFD
>A>	AA	+	100,000 UNITS/ML	N050299	001		Mar	CMFD

NYSTATIN

AA		SCIEGEN PHARMS	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jan	CAHN
AA		STERANCO HLTHCARE	100,000 UNITS/ML	A220367	001	Feb 05, 2026	Jan	NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

>A>	AT	MICRO LABS	0.3%	A218557	001	Apr 08, 2026	Mar	NEWA
-----	----	------------	------	---------	-----	--------------	-----	------

OLANZAPINE

POWDER;INTRAMUSCULAR

OLANZAPINE

AP		AM REGENT	10MG/VIAL	A201741	001	Mar 20, 2012	Jan	CDFR
AP		ANTHEA PHARMA	10MG/VIAL	A220323	001	Mar 05, 2026	Feb	NEWA
AP		ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Jan	CDFR
AP		EUGIA PHARMA	10MG/VIAL	A210968	001	Oct 22, 2020	Jan	CDFR
AP		OMNIVIVUM PHARMS	10MG/VIAL	A219048	001	Jan 23, 2026	Jan	NEWA
AP		QILU	10MG/VIAL	A218116	001	May 16, 2025	Jan	CDFR
AP		SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Jan	CDFR
AP		UBI	10MG/VIAL	A211072	001	Jun 11, 2025	Jan	CDFR

POWDER; INTRAMUSCULAR							
ZYPREXA							
AP	+!	CHEPLAPHARM	10MG/VIAL	N021253	001	Mar 29, 2004	Jan CDFR
TABLET; ORAL							
OLANZAPINE							
AB		SUNSHINE	2.5MG	A206238	001	Nov 19, 2018	Feb CMFD
AB			5MG	A206238	002	Nov 19, 2018	Feb CMFD
AB			7.5MG	A206238	003	Nov 19, 2018	Feb CMFD
AB			10MG	A206238	004	Nov 19, 2018	Feb CMFD
AB			15MG	A206238	005	Nov 19, 2018	Feb CMFD
AB			20MG	A206238	006	Nov 19, 2018	Feb CMFD
AB		TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Jan CMFD
AB			5MG	A091434	002	Apr 23, 2012	Jan CMFD
AB			7.5MG	A091434	003	Apr 23, 2012	Jan CMFD
AB			10MG	A091434	004	Apr 23, 2012	Jan CMFD
AB			15MG	A091434	005	Apr 23, 2012	Jan CMFD
AB			20MG	A091434	006	Apr 23, 2012	Jan CMFD

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PRILOSEC

	+	AZURITY	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Feb CAHN
	+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Feb CAHN

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA		PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb CMFD
----	--	-------------	-----------------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB		UPSHER SMITH LABS	EQ 30MG BASE	A213437	001	Jan 22, 2026	Jan NEWA
AB			EQ 45MG BASE	A213437	002	Jan 22, 2026	Jan NEWA
AB			EQ 75MG BASE	A213437	003	Jan 22, 2026	Jan NEWA

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

AP		SHANDONG	50MG/10ML (5MG/ML)	A219765	001	Jan 15, 2026	Jan NEWA
AP			100MG/20ML (5MG/ML)	A219765	002	Jan 15, 2026	Jan NEWA

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB		STERANCO HLTHCARE	300MG/5ML	A220281	001	Mar 09, 2026	Feb NEWA
TABLET; ORAL							
OXCARBAZEPINE							
AB		EPIC PHARMA LLC	150MG	A219556	001	Mar 02, 2026	Feb NEWA
AB			300MG	A219556	002	Mar 02, 2026	Feb NEWA
AB			600MG	A219556	003	Mar 02, 2026	Feb NEWA

OXYBUTYNIN CHLORIDE

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB	!	NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017	Jan CHRS
AB	!	RISING	2.5MG	A209025	002	Feb 07, 2023	Feb CTEC
AB		STRIDES PHARMA INTL	2.5MG	A075079	002	Mar 10, 2026	Feb NEWA
AB			5MG	A075079	001	Oct 31, 1997	Jan CHRS

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	15MG	A207138	003	Feb 29, 2016	Jan CHRS
AB	!	ZYDUS PHARMS	15MG	A202332	003	Jun 26, 2017	Jan CHRS

OZENOXACIN

CREAM; TOPICAL

XEPI

	@	+	LNHC	1%	N208945	001	Dec 11, 2017	Jan CAHN
--	---	---	------	----	---------	-----	--------------	----------

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

>D>	@	DASH PHARMS	6MG/ML	A 091540	001	Sep 29, 2011	Mar	CAHN
>A>	@	NATCO PHARMA USA	6MG/ML	A 091540	001	Sep 29, 2011	Mar	CAHN

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL
PALIPERIDONE

>D>	@	AJANTA PHARMA LTD	3MG	A 218514	002	Jun 26, 2024	Mar	CMFD
>A>	AB		3MG	A 218514	002	Jun 26, 2024	Mar	CMFD
>D>	@		6MG	A 218514	003	Jun 26, 2024	Mar	CMFD
>A>	AB		6MG	A 218514	003	Jun 26, 2024	Mar	CMFD
>D>	@		9MG	A 218514	004	Jun 26, 2024	Mar	CMFD
>A>	AB		9MG	A 218514	004	Jun 26, 2024	Mar	CMFD
	AB	APOTEX	3MG	A 203279	001	Jan 26, 2026	Jan	NEWA
	AB		6MG	A 203279	002	Jan 26, 2026	Jan	NEWA
	AB		9MG	A 203279	003	Jan 26, 2026	Jan	NEWA
	@	RK PHARMA	1.5MG	A 203802	001	Sep 24, 2015	Jan	DISC
	@		3MG	A 203802	002	Sep 24, 2015	Jan	DISC
	@		6MG	A 203802	003	Sep 24, 2015	Jan	DISC
	@		9MG	A 203802	004	Sep 24, 2015	Jan	DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA HAFYERA

+	!	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N 207946	005	Aug 30, 2021	Jan	CHRS
+	!		1.560GM/5ML (312MG/ML)	N 207946	006	Aug 30, 2021	Jan	CHRS

INVEGA SUSTENNA

>D>	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N 022264	001	Jul 31, 2009	Mar	CHRS
>A>	+		39MG/0.25ML (39MG/0.25ML)	N 022264	001	Jul 31, 2009	Mar	CHRS
>D>	+		78MG/0.5ML (78MG/0.5ML)	N 022264	002	Jul 31, 2009	Mar	CHRS
>A>	+		78MG/0.5ML (78MG/0.5ML)	N 022264	002	Jul 31, 2009	Mar	CHRS
>D>	+		117MG/0.75ML (117MG/0.75ML)	N 022264	003	Jul 31, 2009	Mar	CHRS
>A>	+		117MG/0.75ML (117MG/0.75ML)	N 022264	003	Jul 31, 2009	Mar	CHRS
>D>	+		234MG/1.5ML (156MG/ML)	N 022264	005	Jul 31, 2009	Mar	CHRS
>A>	+		234MG/1.5ML (156MG/ML)	N 022264	005	Jul 31, 2009	Mar	CHRS

PANTOPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
PANTOPRAZOLE SODIUM

@		PHARMOBEDIANT	EQ 40MG BASE/VIAL	A 208580	001	May 04, 2018	Jan	CAHN
---	--	---------------	-------------------	----------	-----	--------------	-----	------

PARICALCITOLSOLUTION; INTRAVENOUS
PARICALCITOL

@		EUGIA PHARMA	0.002MG/ML (0.002MG/ML)	A 205982	001	Oct 09, 2018	Jan	DISC
@			0.005MG/ML (0.005MG/ML)	A 205982	002	Oct 09, 2018	Jan	DISC
@			0.01MG/2ML (0.005MG/ML)	A 205982	003	Oct 09, 2018	Jan	DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 10MG BASE/5ML	A 219954	001	Mar 05, 2026	Feb	NEWA
AB	!	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A 215003	001	Sep 03, 2021	Feb	CTEC

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

>A>	AB	ALEMBIC	EQ 12.5MG BASE	A 217280	003	Mar 26, 2026	Mar	NEWA
-----	----	---------	----------------	----------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@		INGENUS PHARMS LLC	37.5MG	A 091451	001	Sep 21, 2012	Feb	CAHN
---	--	--------------------	--------	----------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>A>	AP1	BAXTER HLTHCARE CORP	10MG/ML (10MG/ML)	A 217032	001	Apr 03, 2026	Mar	NEWA
>A>	AP1		50MG/5ML (10MG/ML)	A 217032	002	Apr 03, 2026	Mar	NEWA
>A>	AP1		100MG/10ML (10MG/ML)	A 217032	003	Apr 03, 2026	Mar	NEWA
	AP1	HAINAN POLY	10MG/ML (10MG/ML)	A 218412	001	Mar 14, 2024	Jan	CMFD

SOLUTION;INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Jan	CMFD
AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Jan	CMFD

PHYTONADIONE

INJECTABLE; INJECTION
PHYTONADIONE

>D>	AB	ALEMBIC	1MG/0.5ML	A216444	001	Sep 08, 2025	Mar	CTEC
>A>	AB1		1MG/0.5ML	A216444	001	Sep 08, 2025	Mar	CTEC
>D>	AB	AMNEAL	1MG/0.5ML	A216601	001	Nov 04, 2025	Mar	CTEC
>A>	AB1		1MG/0.5ML	A216601	001	Nov 04, 2025	Mar	CTEC
>D>	AB	BAXTER HLTHCARE CORP	1MG/0.5ML	A216852	001	Feb 26, 2026	Mar	CTEC
>A>	AB2		1MG/0.5ML	A216852	001	Feb 26, 2026	Mar	CTEC
	AB		1MG/0.5ML	A216852	001	Feb 26, 2026	Feb	NEWA
>D>	!	CIPLA	1MG/0.5ML	A214596	001	Apr 22, 2022	Mar	CTEC
>A>	AB2	!	1MG/0.5ML	A214596	001	Apr 22, 2022	Mar	CTEC
>D>	AB		1MG/0.5ML	A214966	001	Jan 03, 2025	Mar	CTEC
>A>	AB1		1MG/0.5ML	A214966	001	Jan 03, 2025	Mar	CTEC
>D>	AB	+!	INTL MEDICATION	A083722	001		Mar	CTEC
>A>	AB1	+!		A083722	001		Mar	CTEC
>A>	AB	ORBICULAR	1MG/0.5ML	A216298	001	Mar 13, 2026	Mar	NEWA
>A>	AB1		1MG/0.5ML	A216298	001	Mar 13, 2026	Mar	CTEC
	AB1	SUNNY	10MG/ML	A215090	001	Jan 09, 2026	Jan	NEWA

TABLET;ORAL
PHYTONADIONE

AB		SINOTHERAPEUTICS INC	5MG	A220454	001	Feb 26, 2026	Feb	NEWA
----	--	----------------------	-----	---------	-----	--------------	-----	------

PIFLUFOLASTAT F-18

>A>		SOLUTION;INTRAVENOUS							
>A>		PYLARIFY TRUVU							
>A>		+!	APHELION	1mCi/mL-120mCi/mL	N220089	001	Mar 06, 2026	Mar	NEWA

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL
PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	5MG	A212377	001	Aug 13, 2019	Jan	CAHN
AB			7.5MG	A212377	002	Aug 13, 2019	Jan	CAHN
>D>	AB	PADAGIS US	5MG	A076746	001	Nov 16, 2004	Mar	DISC
>A>	@		5MG	A076746	001	Nov 16, 2004	Mar	DISC

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL
PIVYA

		+!	ALEMBIC THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Jan	CAHN
--	--	----	----------------	---------------	---------	-----	--------------	-----	------

PLERIXAFOR

SOLUTION;SUBCUTANEOUS
PLERIXAFOR

>D>	AP	TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)	A205197	001	Jul 24, 2023	Mar	DISC
>A>	@		24MG/1.2ML (20MG/ML)	A205197	001	Jul 24, 2023	Mar	DISC

PODOFILOX

GEL;TOPICAL
CONDYLOX

	@ +	ALLERGAN	0.5%	N020529	001	Mar 13, 1997	Jan	DISC
	!	PADAGIS US	0.5%	A211871	001	Nov 22, 2023	Jan	CHRS
			0.5%	A211871	001	Nov 22, 2023	Jan	CTEC

SOLUTION;TOPICAL
CONDYLOX

AT		+!	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Feb	CAHN
----	--	----	--------------------	------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE;ORAL
POMALIDOMIDE

AB		APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	CMFD
AB			2MG	A210164	002	Jun 11, 2024	Jan	CMFD
AB			3MG	A210164	003	Jun 11, 2024	Jan	CMFD
AB			4MG	A210164	004	Jun 11, 2024	Jan	CMFD
AB		BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Jan	CMFD
AB			2MG	A210111	002	Oct 30, 2020	Jan	CMFD

CAPSULE;ORAL
POMALIDOMIDE

AB			3MG	A210111	003	Oct 30, 2020	Jan	CMFD
AB			4MG	A210111	004	Oct 30, 2020	Jan	CMFD
AB	EUGIA PHARMA		1MG	A210249	001	Oct 30, 2020	Jan	CMFD
AB			2MG	A210249	002	Oct 30, 2020	Jan	CMFD
AB			3MG	A210249	003	Oct 30, 2020	Jan	CMFD
AB			4MG	A210249	004	Oct 30, 2020	Jan	CMFD
AB	HETERO LABS LTD V		1MG	A210236	001	Sep 26, 2024	Jan	CMFD
AB			2MG	A210236	002	Sep 26, 2024	Jan	CMFD
AB			3MG	A210236	003	Sep 26, 2024	Jan	CMFD
AB			4MG	A210236	004	Sep 26, 2024	Jan	CMFD
AB	TEVA PHARMS USA		1MG	A209956	001	May 04, 2022	Jan	CMFD
AB			2MG	A209956	002	May 04, 2022	Jan	CMFD
AB			3MG	A209956	003	May 04, 2022	Jan	CMFD
AB			4MG	A209956	004	May 04, 2022	Jan	CMFD

POMALYST

AB	+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CTEC
AB	+		2MG	N204026	002	Feb 08, 2013	Jan	CTEC
AB	+		3MG	N204026	003	Feb 08, 2013	Jan	CTEC
AB	+		4MG	N204026	004	Feb 08, 2013	Jan	CTEC

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

	+	TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	Jan	CHRS
	+		EQ 45MG BASE	N203469	002	Dec 14, 2012	Jan	CHRS

POSACONAZOLE

SOLUTION;INTRAVENOUS

NOXAFIL

	@	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Jan	DISC
AP	!	GLAND	300MG/16.7ML (18MG/ML)	A217553	001	Dec 26, 2023	Jan	CHRS

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE

	@	EXELA PHARMA	2MEQ/ML	A206203	001	Dec 29, 2015	Jan	DISC
--	---	--------------	---------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>D>	AB	PADAGIS US	8MEQ	A200185	001	May 18, 2011	Mar	DISC
>A>	@		8MEQ	A200185	001	May 18, 2011	Mar	DISC
>D>	AB		10MEQ	A200185	002	May 18, 2011	Mar	DISC
>A>	@		10MEQ	A200185	002	May 18, 2011	Mar	DISC

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989	Mar	DISC
>A>	@	+	2.24GM/100ML	N019904	003	Dec 26, 1989	Mar	DISC

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

>A>	AP	CAPLIN	1.18GM/5ML (236MG/ML); 1.12GM/5ML	A220373	001	Mar 12, 2026	Mar	NEWA
>A>	AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML	A220373	002	Mar 12, 2026	Mar	NEWA
>A>	AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML	A220373	003	Mar 12, 2026	Mar	NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

	@	SENORES PHARMS	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan	CAHN
	@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan	CAHN

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	SENORES PHARMS	10MG	A 077491	002	Oct 23, 2006	Feb CAHN
AB		20MG	A 077491	003	Oct 23, 2006	Feb CAHN
AB		40MG	A 077491	004	Oct 23, 2006	Feb CAHN
AB		80MG	A 077491	001	Feb 11, 2008	Feb CAHN

PREGABALIN

CAPSULE; ORAL

PREGABALIN

AB	FOURRTS LABS	25MG	A 218529	001	Feb 24, 2026	Feb NEWA
AB		50MG	A 218529	002	Feb 24, 2026	Feb NEWA
AB		75MG	A 218529	003	Feb 24, 2026	Feb NEWA
AB		100MG	A 218529	004	Feb 24, 2026	Feb NEWA
AB		150MG	A 218529	005	Feb 24, 2026	Feb NEWA
AB		200MG	A 218529	006	Feb 24, 2026	Feb NEWA
AB		225MG	A 218529	007	Feb 24, 2026	Feb NEWA
AB		300MG	A 218529	008	Feb 24, 2026	Feb NEWA
AB	RENATA	50MG	A 210585	001	Dec 26, 2019	Feb CAHN
AB		75MG	A 210585	002	Dec 26, 2019	Feb CAHN
AB		100MG	A 210585	003	Dec 26, 2019	Feb CAHN
AB		150MG	A 210585	004	Dec 26, 2019	Feb CAHN
AB		200MG	A 210585	005	Dec 26, 2019	Feb CAHN
AB		300MG	A 210585	006	Dec 26, 2019	Feb CAHN

SOLUTION; ORAL

PREGABALIN

>D>	AA	ANDA REPOSITORY	20MG/ML	A 212604	001	Feb 18, 2022	Mar CAHN
>A>	AA	PATRIN	20MG/ML	A 212604	001	Feb 18, 2022	Mar CAHN

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS LLC	EQ 15MG BASE	A 206043	001	Jun 23, 2016	Feb CAHN
----	--------------------	--------------	----------	-----	--------------	----------

PRIMIDONE

TABLET; ORAL

PRIMIDONE

AB	CARNEGIE	50MG	A 218366	001	Jan 23, 2024	Feb CAHN
AB		250MG	A 218366	002	Jan 23, 2024	Feb CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	!	GLAND	100MG/ML	A 218135	001	Jul 22, 2024	Jan CHRS
AP	!		500MG/ML	A 218135	002	Jul 22, 2024	Jan CHRS
AP		HOSPIRA	100MG/ML	A 089069	001	Feb 12, 1986	Jan CHRS
	@		500MG/ML	A 089070	001	Feb 12, 1986	Jan DISC

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

@ AMNEAL

EQ 5MG BASE/ML

A 214192	001	Nov 28, 2022	Feb DISC
----------	-----	--------------	----------

PROGESTERONE

INSERT; VAGINAL

PROGESTERONE

>A>	AB	GLENMARK PHARMS LTD	100MG	A 216363	001	Apr 08, 2026	Mar NEWA
-----	----	---------------------	-------	----------	-----	--------------	----------

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL

HEMANGEOL

>A>		+! ETON	4.28MG/ML	N 205410	001	Mar 14, 2014	Mar CAHN
>D>		+! PIERRE	4.28MG/ML	N 205410	001	Mar 14, 2014	Mar CAHN

PROPRANOLOL HYDROCHLORIDE

! HIKMA

20MG/5ML

A 070690	002	May 15, 1987	Feb CMS1
----------	-----	--------------	----------

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	MANKIND PHARMA	10MG	A 216663	001	Jan 27, 2026	Jan NEWA
AB		20MG	A 216663	002	Jan 27, 2026	Jan NEWA
AB		40MG	A 216663	003	Jan 27, 2026	Jan NEWA

		TABLET;ORAL								
		PROPRANOLOL HYDROCHLORIDE								
AB			60MG	A216663	004	Jan 27, 2026	Jan	NEWA		
AB			80MG	A216663	005	Jan 27, 2026	Jan	NEWA		
		<u>PRUCALOPRIDE SUCCINATE</u>								
		TABLET;ORAL								
		PRUCALOPRIDE SUCCINATE								
AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219220	001	Jan 16, 2026	Jan	NEWA		
AB			EQ 2MG BASE	A219220	002	Jan 16, 2026	Jan	NEWA		
AB		TEVA PHARMS INC	EQ 1MG BASE	A219071	001	Feb 05, 2026	Jan	NEWA		
AB			EQ 2MG BASE	A219071	002	Feb 05, 2026	Jan	NEWA		
		<u>PYRIDOSTIGMINE BROMIDE</u>								
		TABLET, EXTENDED RELEASE;ORAL								
		PYRIDOSTIGMINE BROMIDE								
	@	IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Jan	DISC		
		<u>RABEPRAZOLE SODIUM</u>								
		TABLET, DELAYED RELEASE;ORAL								
		RABEPRAZOLE SODIUM								
AB		AUROBINDO PHARMA USA	20MG	A205761	001	Feb 17, 2017	Jan	CAHN		
		<u>RAMELTEON</u>								
		TABLET;ORAL								
		RAMELTEON								
AB		AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Feb	CTEC		
>D>	BX	XIROMED	8MG	A216209	001	Nov 25, 2022	Mar	CTEC		
>A>	AB		8MG	A216209	001	Nov 25, 2022	Mar	CTEC		
		<u>RAMIPRIL</u>								
		CAPSULE;ORAL								
		RAMIPRIL								
AB		SENORES PHARMS	1.25MG	A078191	001	Jun 18, 2008	Jan	CAHN		
AB			2.5MG	A078191	002	Jun 18, 2008	Jan	CAHN		
AB			5MG	A078191	003	Jun 18, 2008	Jan	CAHN		
AB			10MG	A078191	004	Jun 18, 2008	Jan	CAHN		
		SOLUTION;ORAL								
		VOSTALLY								
	+	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Feb	CAHN		
		<u>RANITIDINE HYDROCHLORIDE</u>								
		CAPSULE;ORAL								
		RANITIDINE HYDROCHLORIDE								
>D>	@	PHARMOBEDIENT	EQ 150MG BASE	A075564	001	Oct 27, 2000	Mar	CAHN		
>D>	@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Mar	CAHN		
>A>	@	RISING	EQ 150MG BASE	A075564	001	Oct 27, 2000	Mar	CAHN		
>A>	@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Mar	CAHN		
		<u>RANOLAZINE</u>								
		TABLET, EXTENDED RELEASE;ORAL								
		RANOLAZINE								
AB		PIRAMAL	500MG	A213085	001	Jul 25, 2023	Feb	CMFD		
AB			1GM	A213085	002	Jul 25, 2023	Feb	CMFD		
		<u>REGADENOSON</u>								
		SOLUTION;INTRAVENOUS								
		REGADENOSON								
	@	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Feb	DISC		
>A>	<u>RELACORILANT</u>									
>A>	CAPSULE;ORAL									
>A>	LIFYORLI (COPACKAGED)									
>A>	+	CORCEPT THERAP	100MG;25MG	N220641	001	Mar 25, 2026	Mar	NEWA		
		<u>REPAGLINIDE</u>								
		TABLET;ORAL								
		REPAGLINIDE								
>D>	AB	PADAGIS US	0.5MG	A201189	001	Jul 17, 2013	Mar	DISC		
>A>	@		0.5MG	A201189	001	Jul 17, 2013	Mar	DISC		
>D>	AB		1MG	A201189	002	Jan 22, 2014	Mar	DISC		
>A>	@		1MG	A201189	002	Jan 22, 2014	Mar	DISC		

	TABLET;ORAL								
	REPAGLINIDE								
>D>	AB		2MG	A201189	003	Jan 22, 2014	Mar	DISC	
>A>	@		2MG	A201189	003	Jan 22, 2014	Mar	DISC	
	<u>RIBAVIRIN</u>								
	FOR SOLUTION;INHALATION								
	RIBAVIRIN								
>D>	!	NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016	Mar	DISC	
>A>	@		6GM/VIAL	A207366	001	Oct 06, 2016	Mar	DISC	
	<u>RIFABUTIN</u>								
	CAPSULE;ORAL								
	RIFABUTIN								
>A>	AB	I3 PHARMS	150MG	A212430	001	Mar 19, 2026	Mar	NEWA	
	<u>RIFAXIMIN</u>								
	TABLET;ORAL								
>A>		RIFAXIMIN							
>A>	AB	ACTAVIS LABS FL INC	550MG	A208959	001	Mar 19, 2026	Mar	NFTG	
		XIFAXAN							
>D>	+	SALIX PHARMS	550MG	N021361	002	Mar 24, 2010	Mar	CFTG	
>A>	AB	+	550MG	N021361	002	Mar 24, 2010	Mar	CFTG	
	<u>RILPIVIRINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	EDURANT								
AB	+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Jan	CFTG	
	RILPIVIRINE HYDROCHLORIDE								
AB		SOMERSET THERAPS LLC	EQ 25MG BASE	A218798	001	Jan 29, 2026	Jan	NFTG	
	<u>RILUZOLE</u>								
	TABLET;ORAL								
	RILUTEK								
>A>	@ +	AZURITY	50MG	N020599	001	Dec 12, 1995	Mar	CAHN	
>D>	@ +	COVIS	50MG	N020599	001	Dec 12, 1995	Mar	CAHN	
	<u>RISPERIDONE</u>								
	POWDER;INTRAMUSCULAR								
	RISPERDAL CONSTA								
AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CHRS	
AB	+		12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CDFR	
AB	+		25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CDFR	
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CHRS	
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CDFR	
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CHRS	
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CDFR	
	RISPERIDONE								
AB		AMNEAL	12.5MG/VIAL	A218586	001	Sep 02, 2025	Jan	CDFR	
AB			25MG/VIAL	A218586	002	Sep 02, 2025	Jan	CDFR	
AB			37.5MG/VIAL	A218586	003	Sep 02, 2025	Jan	CDFR	
AB			50MG/VIAL	A218586	004	Sep 02, 2025	Jan	CDFR	
AB		NANOMI	25MG/VIAL	A211220	001	Sep 02, 2025	Jan	CDFR	
AB			37.5MG/VIAL	A211220	002	Sep 02, 2025	Jan	CDFR	
AB			50MG/VIAL	A211220	003	Sep 02, 2025	Jan	CDFR	
AB		TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CDFR	
AB			25MG/VIAL	A214068	002	Dec 05, 2023	Jan	CDFR	
AB			37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan	CDFR	
AB			50MG/VIAL	A214068	004	Dec 05, 2023	Jan	CDFR	
	TABLET;ORAL								
	RISPERIDONE								
>D>	@	DASH PHARMS	0.25MG	A076288	001	Sep 15, 2008	Mar	CAHN	
>D>	@		0.5MG	A076288	002	Sep 15, 2008	Mar	CAHN	
>D>	@		1MG	A076288	003	Sep 15, 2008	Mar	CAHN	
>D>	@		2MG	A076288	004	Sep 15, 2008	Mar	CAHN	
>D>	@		3MG	A076288	005	Sep 15, 2008	Mar	CAHN	
>D>	@		4MG	A076288	006	Sep 15, 2008	Mar	CAHN	
>A>	@	NATCO PHARMA USA	0.25MG	A076288	001	Sep 15, 2008	Mar	CAHN	
>A>	@		0.5MG	A076288	002	Sep 15, 2008	Mar	CAHN	
>A>	@		1MG	A076288	003	Sep 15, 2008	Mar	CAHN	
>A>	@		2MG	A076288	004	Sep 15, 2008	Mar	CAHN	
>A>	@		3MG	A076288	005	Sep 15, 2008	Mar	CAHN	

TABLET;ORAL		RISPERIDONE						
>A>	@		4MG	A076288	006	Sep 15, 2008	Mar	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL		RISPERIDONE						
>D>	@	DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013	Mar	CAHN
>D>	@		0.5MG	A091537	001	Mar 30, 2011	Mar	CAHN
>D>	@		1MG	A091537	002	Mar 30, 2011	Mar	CAHN
>D>	@		2MG	A091537	003	Mar 30, 2011	Mar	CAHN
>D>	@		3MG	A091537	004	Mar 30, 2011	Mar	CAHN
>D>	@		4MG	A091537	005	Mar 30, 2011	Mar	CAHN
>A>	@	NATCO PHARMA USA	0.25MG	A091537	006	Feb 12, 2013	Mar	CAHN
>A>	@		0.5MG	A091537	001	Mar 30, 2011	Mar	CAHN
>A>	@		1MG	A091537	002	Mar 30, 2011	Mar	CAHN
>A>	@		2MG	A091537	003	Mar 30, 2011	Mar	CAHN
>A>	@		3MG	A091537	004	Mar 30, 2011	Mar	CAHN
>A>	@		4MG	A091537	005	Mar 30, 2011	Mar	CAHN

RITONAVIR

TABLET;ORAL		NORVIR						
AB	+	ABBVIE	100MG	N022417	001	Feb 10, 2010	Jan	CHRS
TABLET;ORAL		RITONAVIR						
>D>	AB	AMNEAL	100MG	A208890	001	Sep 17, 2018	Mar	DISC
>A>	@		100MG	A208890	001	Sep 17, 2018	Mar	DISC
AB	!	AUROBINDO PHARMA LTD	100MG	A206614	001	Sep 17, 2018	Jan	CHRS

RIVAROXABAN

FOR SUSPENSION;ORAL		RIVAROXABAN						
AB		APOTEX	1MG/ML	A218427	001	Mar 02, 2026	Feb	NEWA
TABLET;ORAL		RIVAROXABAN						
BX		BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	Feb	CTEC
BX			10MG	A218107	002	May 14, 2025	Feb	CTEC
BX			15MG	A218107	003	May 14, 2025	Feb	CTEC
BX			20MG	A218107	004	May 14, 2025	Feb	CTEC
AB		INVAGEN PHARMS	2.5MG	A218768	001	Feb 20, 2026	Feb	NEWA

RIZATRIPTAN BENZOATE

FILM;ORAL		RIZAFILM						
	+	GENSCO	EQ 5MG BASE	N205394	002	Feb 26, 2026	Feb	NEWA
TABLET;ORAL		RIZATRIPTAN BENZOATE						
	@	PHARMOBEDIANT	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	DISC
	@		EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION		ROCURONIUM BROMIDE						
AP		ASPIRO	50MG/5ML (10MG/ML)	A220124	001	Mar 04, 2026	Feb	NEWA
AP			100MG/10ML (10MG/ML)	A220124	002	Mar 04, 2026	Feb	NEWA

ROFLUMILAST

TABLET;ORAL		ROFLUMILAST						
	@	PHARMOBEDIANT	500MCG	A208257	001	Jul 13, 2018	Feb	DISC
AB		SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb	CMFD
AB			500MCG	A208236	001	Oct 03, 2018	Feb	CMFD

ROSUVASTATIN CALCIUM

TABLET;ORAL		ROSUVASTATIN CALCIUM						
>A>	@	ANVI	EQ 5MG BASE	A079161	001	Jul 19, 2016	Mar	CAHN
>A>	@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Mar	CAHN
>A>	@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Mar	CAHN
>A>	@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Mar	CAHN
>D>	@	STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Mar	CAHN
>D>	@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Mar	CAHN
>D>	@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Mar	CAHN
>D>	@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Mar	CAHN

SACUBITRIL; VALSARTAN

TABLET; ORAL

SACUBITRIL AND VALSARTAN

AB	SOMERSET THERAPS LLC	24MG;26MG	A219983	001	Jan 20, 2026	Jan	NEWA
AB		49MG;51MG	A219983	002	Jan 20, 2026	Jan	NEWA
AB		97MG;103MG	A219983	003	Jan 20, 2026	Jan	NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

AB	+! BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Jan	CHRS
AB	MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jan	NEWA
AB		500MG/PACKET	A219511	002	Jan 08, 2026	Jan	NEWA

SELENIOS ACID

SOLUTION; INTRAVENOUS

SELENIOS ACID

	@ CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jan	DISC
	@	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jan	DISC
AP	KINDOS	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219472	001	Feb 03, 2026	Jan	NEWA

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS

WEGOVY HD

>A>	+! NOVO	7.2MG/0.75ML (7.2MG/0.75ML)	N215256	006	Mar 19, 2026	Mar	NEWA
>A>	OZEMPIC						
>A>	+! NOVO	1.5MG	N213051	004	Dec 09, 2024	Mar	CTNA
>A>	+!	4MG	N213051	005	Dec 09, 2024	Mar	CTNA
>A>	+!	9MG	N213051	006	Dec 09, 2024	Mar	CTNA
>D>	RYBELSUS						
>D>	+! NOVO	1.5MG	N213051	004	Dec 09, 2024	Mar	CTNA
>D>	+!	4MG	N213051	005	Dec 09, 2024	Mar	CTNA
>D>	+!	9MG	N213051	006	Dec 09, 2024	Mar	CTNA
>D>	WEGOVY						
>D>	+ NOVO	1.5MG	N218316	001	Dec 22, 2025	Mar	CHRS
>A>	+!	1.5MG	N218316	001	Dec 22, 2025	Mar	CHRS
>D>	+	4MG	N218316	002	Dec 22, 2025	Mar	CHRS
>A>	+!	4MG	N218316	002	Dec 22, 2025	Mar	CHRS
>D>	+	9MG	N218316	003	Dec 22, 2025	Mar	CHRS
>A>	+!	9MG	N218316	003	Dec 22, 2025	Mar	CHRS

SERTRALINE HYDROCHLORIDE

CAPSULE; ORAL

SERTRALINE HYDROCHLORIDE

>A>	AB	AMNEAL	EQ 150MG BASE	A219655	001	Jan 28, 2026	Mar	CAHN
>A>	AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Mar	CAHN
	AB	APPCO	EQ 150MG BASE	A218712	001	Jan 20, 2026	Jan	NEWA
	AB		EQ 200MG BASE	A218712	002	Jan 20, 2026	Jan	NEWA
	AB	NOVITIUM PHARMA	EQ 150MG BASE	A219714	001	Jan 20, 2026	Jan	NEWA
	AB		EQ 200MG BASE	A219714	002	Jan 20, 2026	Jan	NEWA
>D>	AB	SKG PHARMA	EQ 150MG BASE	A219655	001	Jan 28, 2026	Mar	CAHN
	AB		EQ 150MG BASE	A219655	001	Jan 28, 2026	Jan	NEWA
>D>	AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Mar	CAHN
	AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Jan	NEWA
	AB	UMEDICA	EQ 150MG BASE	A218342	001	Jan 20, 2026	Jan	NEWA
	AB		EQ 200MG BASE	A218342	002	Jan 20, 2026	Jan	NEWA
	AB	ZYDUS LIFESCIENCES	EQ 150MG BASE	A220275	001	Jan 29, 2026	Jan	NEWA
	AB		EQ 200MG BASE	A220275	002	Jan 29, 2026	Jan	NEWA

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@ APPCO

@

@

	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan	CAHN
	EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan	CAHN
	EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan	CAHN

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

>D>		REVATIO							
>D>	AB	+!	VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Mar	DISC
>A>		@ +		EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Mar	DISC
			SILDENAFIL CITRATE						
>D>	AB		AUROBINDO PHARMA LTD	EQ 10MG BASE/ML	A214773	001	Dec 23, 2022	Mar	CHRS
>A>	AB	!		EQ 10MG BASE/ML	A214773	001	Dec 23, 2022	Mar	CHRS

SIPONIMOD

TABLET; ORAL

MAYZENT

>D>	AB	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Mar	CTEC
>A>		+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Mar	CTEC
	AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Feb	CTEC
>D>	AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Mar	CTEC
>A>		+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Mar	CTEC
	AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Feb	CTEC
>D>	AB	+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	Mar	CTEC
>A>		+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	Mar	CTEC
	AB	+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	Feb	CTEC

SIPONIMOD

>D>	AB		AUROBINDO PHARMA LTD	EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Mar	DISC
>A>		@		EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Mar	DISC
	AB			EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Feb	NEWA
>D>	AB			EQ 1MG BASE	A218459	002	Mar 06, 2026	Mar	DISC
>A>		@		EQ 1MG BASE	A218459	002	Mar 06, 2026	Mar	DISC
	AB			EQ 1MG BASE	A218459	002	Mar 06, 2026	Feb	NEWA
>D>	AB			EQ 2MG BASE	A218459	003	Mar 06, 2026	Mar	DISC
>A>		@		EQ 2MG BASE	A218459	003	Mar 06, 2026	Mar	DISC
	AB			EQ 2MG BASE	A218459	003	Mar 06, 2026	Feb	NEWA

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

SITAGLIPTIN PHOSPHATE

AB			APOTEX	EQ 25MG BASE	A202425	001	Jan 20, 2026	Jan	NEWA
AB				EQ 50MG BASE	A202425	002	Jan 20, 2026	Jan	NEWA
AB				EQ 100MG BASE	A202425	003	Jan 20, 2026	Jan	NEWA
AB			SANDOZ	EQ 25MG BASE	A202387	001	Jan 14, 2026	Jan	NEWA
AB				EQ 50MG BASE	A202387	002	Jan 14, 2026	Jan	NEWA
AB				EQ 100MG BASE	A202387	003	Jan 14, 2026	Jan	NEWA

SODIUM ACETATE

SOLUTION; INTRAVENOUS

SODIUM ACETATE

AP			AMNEAL	40MEQ/20ML (2MEQ/ML)	A218469	003	Mar 02, 2026	Feb	NEWA
----	--	--	--------	----------------------	---------	-----	--------------	-----	------

SODIUM BICARBONATE

SOLUTION; INTRAVENOUS

SODIUM BICARBONATE

AP			AMNEAL	50MEQ/50ML (1MEQ/ML)	A217523	001	Jan 13, 2026	Jan	NEWA
----	--	--	--------	----------------------	---------	-----	--------------	-----	------

SODIUM PHENYL BUTYRATE

POWDER; ORAL

BUPHENYL

		@ +	HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan	DISC
			SODIUM PHENYL BUTYRATE						
AB		!	PH HEALTH	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jan	CHRS

TABLET; ORAL

BUPHENYL

		@ +	HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan	DISC
			SODIUM PHENYL BUTYRATE						
AB			NAVINTA LLC	500MG	A220418	001	Feb 17, 2026	Feb	NEWA
AB		!	PH HEALTH	500MG	A204395	001	Apr 15, 2016	Jan	CHRS

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION; INTRAVENOUS

SODIUM PHOSPHATES

AP			CAPLIN	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A220683	001	Feb 23, 2026	Feb	NEWA
AP				4.02GM/15ML; 4.14GM/15ML	A220683	002	Feb 23, 2026	Feb	NEWA

SOLUTION;INTRAVENOUS
SODIUM PHOSPHATES

		(268MG/ML; 276MG/ML)					
AP		13.4GM/50ML;13.8GM/50ML	A220683	003	Feb 23, 2026	Feb	NEWA
		(268MG/ML; 276MG/ML)					

SUCCINYLCHOLINE CHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
SUCCINYLCHOLINE CHLORIDE

>D>	AP	FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Mar	CHRS
>A>	AP	!	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Mar	CHRS
>D>	AP	+! HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Mar	DISC
>A>		@ +	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Mar	DISC

SUFENTANIL CITRATE

INJECTABLE;INJECTION
SUFENTANIL CITRATE

>D>	AP	HIKMA	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Mar	DISC
>A>		@	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Mar	DISC

SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

>D>		SULFACETAMIDE SODIUM						
>D>		! PADAGIS US	10%	A080029	001		Mar	DISC
>A>		@	10%	A080029	001		Mar	DISC

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP		ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb	CMFD
----	--	---------------------	-------------------------------------	---------	-----	--------------	-----	------

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL
VYNDAQEL

@ +	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	Jan	DISC
-----	---------------	------	---------	-----	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL
TAPENTADOL HYDROCHLORIDE
NOVITIUM PHARMA

EQ 20MG BASE/ML	A219119	001	Jan 26, 2026	Jan	NFTG
-----------------	---------	-----	--------------	-----	------

TABLET;ORAL
NUCYNTA

AB	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Jan	CFTG
AB	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Jan	CFTG
AB	+!		EQ 100MG BASE	N022304	003	Nov 20, 2008	Jan	CFTG

TAPENTADOL HYDROCHLORIDE

AB		HIKMA	EQ 50MG BASE	A205057	001	Feb 10, 2026	Jan	NEWA
AB			EQ 75MG BASE	A205057	002	Feb 10, 2026	Jan	NEWA
AB			EQ 100MG BASE	A205057	003	Feb 10, 2026	Jan	NEWA
AB		HUMANWELL	EQ 50MG BASE	A214378	001	Jan 27, 2026	Jan	NFTG
AB			EQ 75MG BASE	A214378	002	Jan 27, 2026	Jan	NFTG
AB			EQ 100MG BASE	A214378	003	Jan 27, 2026	Jan	NFTG

TAVABOROLE

SOLUTION;TOPICAL
TAVABOROLE

@	CIPLA	5%	A212224	001	Feb 09, 2021	Jan	DISC	
@	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Feb	DISC	
>D>	AB	PADAGIS US	5%	A211848	001	Oct 13, 2020	Mar	DISC
>A>		@	5%	A211848	001	Oct 13, 2020	Mar	DISC

TAZAROTENE

CREAM;TOPICAL
TAZAROTENE

AB		SOLARIS PHARMA CORP	0.05%	A214560	001	Nov 24, 2025	Jan	CAHN
----	--	---------------------	-------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M BICISATE KITINJECTABLE; INJECTION
NEUROLITE

	+	!	SHINE	N/A	N020256	001	Nov 23, 1994	Feb	CAHN
--	---	---	-------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION
CARDIOLITE

AP		+	!	SHINE	N/A	N019785	001	Dec 21, 1990	Feb	CAHN
				MIRALUMA						
		@		SHINE	N/A	N019785	003	May 23, 1997	Feb	CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS
TECHNELITE

		+	!	SHINE	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	Feb	CAHN
		@			0.0083-2.7 CI/GENERATOR	N017771	001		Feb	CAHN

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

AB				AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Jan	CMFD
AB					15MG	A203482	002	May 23, 2016	Jan	CMFD
AB					22.5MG	A203482	003	May 23, 2016	Jan	CMFD
AB					30MG	A203482	004	May 23, 2016	Jan	CMFD

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB				SENORES PHARMS	EQ 1MG BASE	A074823	001	Mar 30, 1998	Feb	CAHN
AB					EQ 2MG BASE	A074823	002	Mar 30, 1998	Feb	CAHN
AB					EQ 5MG BASE	A074823	003	Mar 30, 1998	Feb	CAHN
AB					EQ 10MG BASE	A074823	004	Mar 30, 1998	Feb	CAHN

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB				CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Feb	CMFD
AB					14MG	A218663	002	Apr 07, 2025	Feb	CMFD

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

>D>	AO			CAPLIN ONE LABS	100MG/ML	A040615	001	Aug 10, 2006	Mar	DISC
>A>		@			100MG/ML	A040615	001	Aug 10, 2006	Mar	DISC
	AO				100MG/ML	A040615	001	Aug 10, 2006	Jan	CAHN
>D>	AO				200MG/ML	A040615	002	Aug 10, 2006	Mar	DISC
>A>		@			200MG/ML	A040615	002	Aug 10, 2006	Mar	DISC
	AO				200MG/ML	A040615	002	Aug 10, 2006	Jan	CAHN

THEOPHYLLINE

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

	@	+		SOLIS PHARMS	80MG/15ML	A085186	001		Jan	DISC
--	---	---	--	--------------	-----------	---------	-----	--	-----	------

THEOPHYLLINE

		!		PHARM ASSOC	80MG/15ML	A206344	001	Dec 16, 2016	Jan	CHRS
					80MG/15ML	A206344	001	Dec 16, 2016	Jan	CTEC

THIOTEPA

POWDER; INTRAVENOUS

TEPADINA AND SODIUM CHLORIDE

		+	!	ADIENNE SA	400MG	N208264	004	Jan 15, 2026	Jan	NEWA
--	--	---	---	------------	-------	---------	-----	--------------	-----	------

TICAGRELOR

TABLET; ORAL

TICAGRELOR

>D>	AB			AMNEAL	60MG	A208531	002	Oct 28, 2025	Mar	DISC
>A>		@			60MG	A208531	002	Oct 28, 2025	Mar	DISC
	AB			MANKIND PHARMA	60MG	A217679	001	Feb 06, 2026	Jan	NEWA
	AB				90MG	A217679	002	Feb 06, 2026	Jan	NEWA
>A>	AB			ZHEJIANG JINGXIN	60MG	A219006	001	Mar 24, 2026	Mar	NEWA

TABLET;ORAL
TICAGRELOR

>A> AB 90MG A219006 002 Mar 24, 2026 Mar NEWA

TIGECYCLINE

POWDER; INTRAVENOUS
TIGECYCLINE

>D> AP +! FRESENIUS KABI USA 50MG/VIAL N205645 001 Dec 01, 2016 Mar DISC
>A> @ + 50MG/VIAL N205645 001 Dec 01, 2016 Mar DISC

TIMOLOL MALEATE

TABLET;ORAL
TIMOLOL MALEATE

>D> AB MYLAN 5MG A072668 002 Jun 08, 1990 Mar DISC
>A> @ 5MG A072668 002 Jun 08, 1990 Mar DISC
>D> AB ! 20MG A072668 001 Jun 08, 1990 Mar DISC
>A> @ 20MG A072668 001 Jun 08, 1990 Mar DISC
>D> AB RISING 5MG A207556 001 May 02, 2019 Mar CTEC
>A> 5MG A207556 001 May 02, 2019 Mar CTEC
>D> AB 20MG A207556 003 May 02, 2019 Mar CTEC
>A> 20MG A207556 003 May 02, 2019 Mar CTEC
>A> ! 20MG A207556 003 May 02, 2019 Mar CHRS

TINIDAZOLE

TABLET;ORAL
TINIDAZOLE

>D> AB THINQ PHARM-CRO PVT 250MG A202489 001 Oct 09, 2013 Mar CAHN
>D> AB 500MG A202489 002 Oct 09, 2013 Mar CAHN
>A> AB UNIQUE 250MG A202489 001 Oct 09, 2013 Mar CAHN
>A> AB 500MG A202489 002 Oct 09, 2013 Mar CAHN

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL
TIOPRONIN

>D> AB AMNEAL 100MG A216278 002 Aug 29, 2025 Mar DISC
>A> @ 100MG A216278 002 Aug 29, 2025 Mar DISC
>D> AB 300MG A216278 001 Aug 15, 2023 Mar DISC
>A> @ 300MG A216278 001 Aug 15, 2023 Mar DISC

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS
MOUNJARO

+! ELI LILLY AND CO 10MG/2.4ML (4.17MG/ML) N215866 013 Jan 07, 2026 Jan NEWA
+! 20MG/2.4ML (8.33MG/ML) N215866 014 Jan 07, 2026 Jan NEWA
+! 30MG/2.4ML (12.5MG/ML) N215866 015 Jan 07, 2026 Jan NEWA
+! 40MG/2.4ML (16.7MG/ML) N215866 016 Jan 07, 2026 Jan NEWA
+! 50MG/2.4ML (20.8MG/ML) N215866 017 Jan 07, 2026 Jan NEWA
+! 60MG/2.4ML (25MG/ML) N215866 018 Jan 07, 2026 Jan NEWA

MOUNJARO KWIKPEN

+! ELI LILLY AND CO 10MG/2.4ML (4.17MG/ML) N215866 019 Jan 20, 2026 Jan NEWA
+! 20MG/2.4ML (8.33MG/ML) N215866 020 Jan 20, 2026 Jan NEWA
+! 30MG/2.4ML (12.5MG/ML) N215866 021 Jan 20, 2026 Jan NEWA
+! 40MG/2.4ML (16.7MG/ML) N215866 022 Jan 20, 2026 Jan NEWA
+! 50MG/2.4ML (20.8MG/ML) N215866 023 Jan 20, 2026 Jan NEWA
+! 60MG/2.4ML (25MG/ML) N215866 024 Jan 20, 2026 Jan NEWA

ZEPBOUND

+! ELI LILLY AND CO 10MG/2.4ML (4.17MG/ML) N217806 013 Jan 07, 2026 Jan NEWA
+! 20MG/2.4ML (8.33MG/ML) N217806 014 Jan 07, 2026 Jan NEWA
+! 30MG/2.4ML (12.5MG/ML) N217806 015 Jan 07, 2026 Jan NEWA
+! 40MG/2.4ML (16.7MG/ML) N217806 016 Jan 07, 2026 Jan NEWA
+! 50MG/2.4ML (20.8MG/ML) N217806 017 Jan 07, 2026 Jan NEWA
+! 60MG/2.4ML (25MG/ML) N217806 018 Jan 07, 2026 Jan NEWA

ZEPBOUND KWIKPEN

+! ELI LILLY AND CO 10MG/2.4ML (4.17MG/ML) N217806 019 Jan 20, 2026 Jan NEWA
+! 20MG/2.4ML (8.33MG/ML) N217806 020 Jan 20, 2026 Jan NEWA
+! 30MG/2.4ML (12.5MG/ML) N217806 021 Jan 20, 2026 Jan NEWA
+! 40MG/2.4ML (16.7MG/ML) N217806 022 Jan 20, 2026 Jan NEWA
+! 50MG/2.4ML (20.8MG/ML) N217806 023 Jan 20, 2026 Jan NEWA
+! 60MG/2.4ML (25MG/ML) N217806 024 Jan 20, 2026 Jan NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb CAHN
AB			EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb CAHN
AB			EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb CAHN
AB		SENORES PHARMS	EQ 4MG BASE	A213365	001	May 13, 2024	Jan CAHN
AB			EQ 6MG BASE	A213365	002	May 13, 2024	Jan CAHN
ZANAFLEX							
>D>	AB	+ LEGACY PHARMA USA	EQ 4MG BASE	N021447	002	Aug 29, 2002	Mar CHRS
>A>	AB	+!	EQ 4MG BASE	N021447	002	Aug 29, 2002	Mar CHRS
>D>	AB	+!	EQ 6MG BASE	N021447	003	Aug 29, 2002	Mar CHRS
>A>	AB	+	EQ 6MG BASE	N021447	003	Aug 29, 2002	Mar CHRS

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

@		AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Jan DISC
---	--	-------------------	--------------	---------	-----	--------------	----------

TOLCAPONE

TABLET;ORAL

TASMAR

>D>	AB	+! BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar CTEC
>A>		+!	100MG	N020697	001	Jan 29, 1998	Mar CTEC
TOLCAPONE							
>D>	AB	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Mar DISC
>A>		@	100MG	A208937	001	Aug 07, 2018	Mar DISC
	AB		100MG	A208937	001	Aug 07, 2018	Feb CAHN

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

>D>	AB	PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar CAHN
>D>	AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN
>A>	AB	UNIQUE	1MG	A204721	001	Jan 24, 2020	Mar CAHN
>A>	AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB		SENORES PHARMS	15MG	A218642	001	Oct 10, 2024	Jan CAHN
AB			25MG	A218642	002	Oct 10, 2024	Jan CAHN
AB		STRIDES PHARMA	50MG	A078418	003	Feb 02, 2026	Jan NEWA

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

AB1		ASCENT PHARMS INC	25MG	A217443	001	Jan 12, 2026	Jan NEWA
AB1			50MG	A217443	002	Jan 12, 2026	Jan NEWA
AB1			100MG	A217443	003	Jan 12, 2026	Jan NEWA
AB1			200MG	A217443	004	Jan 12, 2026	Jan NEWA

TABLET;ORAL

TOPIRAMATE

@		SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	Jan CAHN
@			50MG	A090353	002	Sep 01, 2010	Jan CAHN
@			100MG	A090353	003	Sep 01, 2010	Jan CAHN
@			200MG	A090353	004	Sep 01, 2010	Jan CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP		INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Feb CAHN
----	--	--------------------	------------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

>D>		@ DASH PHARMS	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar CAHN
>A>		@ NATCO PHARMA USA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar CAHN

TRAMADOL HYDROCHLORIDE

SOLUTION; ORAL

QDOLO

>D>	@ +	ATHENA	5MG/ML	N214044	001	Sep 01, 2020	Mar	CAHN
>A>	@ +	ROSEMONT	5MG/ML	N214044	001	Sep 01, 2020	Mar	CAHN

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB	RUBICON	25MG	A208708	003	Nov 27, 2023	Mar	CTEC
>D>		RUBICON RESEARCH	25MG	A208708	003	Nov 27, 2023	Mar	CTEC
>A>	AB	STRIDES PHARMA	25MG	A202075	002	Mar 23, 2026	Mar	NEWA

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@ SENORES PHARMS

@

@

A078493	001	Aug 25, 2008	Jan	CAHN
A078493	002	Aug 25, 2008	Jan	CAHN
A078493	003	Aug 25, 2008	Jan	CAHN

TRANEXAMIC ACID

TABLET; ORAL

TRANEXAMIC ACID

AB		I 3 PHARMS	650MG	A219702	001	Jan 26, 2026	Jan	NEWA
----	--	------------	-------	---------	-----	--------------	-----	------

TRETINOIN

CREAM; TOPICAL

TRETINOIN

>A>	AB1	ENCUBE	0.05%	A217832	001	Mar 25, 2026	Mar	NEWA
	AB		0.1%	A217833	001	Feb 10, 2026	Jan	NEWA

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10

AB		+! APOTHECON	10MG/ML	N012041	001		Jan	CHRS
----	--	--------------	---------	---------	-----	--	-----	------

TRIAMCINOLONE ACETONIDE

@ CAPLIN

10MG/ML	A090166	001	May 27, 2009	Jan	CAHN
---------	---------	-----	--------------	-----	------

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ BRECKENRIDGE

@

AB		INGENUS PHARMS LLC	0.125MG	A214219	001	Oct 20, 2020	Feb	CAHN
AB			0.25MG	A216890	002	Nov 08, 2022	Feb	DISC
			0.25MG	A216890	001	Nov 08, 2022	Feb	DISC
			0.25MG	A214219	002	Oct 20, 2020	Feb	CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

! RISING

500MG	A212238	002	Sep 22, 2023	Jan	CHRS
-------	---------	-----	--------------	-----	------

TROSPIMUM CHLORIDE

TABLET; ORAL

TROSPIMUM CHLORIDE

AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Jan	CAHN
----	--	---------------	------	---------	-----	--------------	-----	------

URSODIOL

CAPSULE; ORAL

URSODIOL

STRIDES PHARMA

150MG	A210344	002	Jan 16, 2026	Jan	NFTG
-------	---------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		! HETERO LABS LTD V	EQ 1GM BASE	A203047	002	Apr 08, 2015	Feb	CHRS
----	--	---------------------	-------------	---------	-----	--------------	-----	------

VALTREX

AB		+ GLAXOSMITHKLINE	EQ 1GM BASE	N020487	002	Jun 23, 1995	Feb	CHRS
----	--	-------------------	-------------	---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDEFOR SOLUTION;ORAL
VALGANCICLOVIR HYDROCHLORIDE

>A>	AB	MICRO LABS	50MG/ML	A218838	001	Mar 19, 2026	Mar	NEWA
-----	----	------------	---------	---------	-----	--------------	-----	------

VALSARTANTABLET;ORAL
VALSARTAN

	@	RENATA	40MG	A218169	001	Aug 05, 2024	Feb	CAHN
	@		80MG	A218169	002	Aug 05, 2024	Feb	CAHN
	@		160MG	A218169	003	Aug 05, 2024	Feb	CAHN
	@		320MG	A218169	004	Aug 05, 2024	Feb	CAHN

VANCOMYCIN HYDROCHLORIDECAPSULE;ORAL
VANCOMYCIN HYDROCHLORIDE

>D>		@	PAI HOLDINGS	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	CMFD
>A>	AB			EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	CMFD
>D>		@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	CMFD
>A>	AB			EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	CMFD

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

AP			EUROFARMA	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	CAHN
AP				EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	CAHN

POWDER;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

	!	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan	CHRS
			EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan	CTNA

VARENICLINE TARTRATETABLET;ORAL
VARENICLINE TARTRATE

AB			PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jan	CMFD
AB				EQ 1MG BASE	A217115	002	Jul 23, 2024	Jan	CMFD
AB			UMEDICA	EQ 0.5MG BASE	A218985	001	Jan 09, 2026	Jan	NEWA
AB				EQ 1MG BASE	A218985	002	Jan 09, 2026	Jan	NEWA

VASOPRESSINSOLUTION;INTRAVENOUS
VASOPRESSIN

>D>	AP		EAGLE PHARMS	20UNITS/ML (20UNITS/ML)	A211538	001	Dec 15, 2021	Mar	DISC
>A>		@		20UNITS/ML (20UNITS/ML)	A211538	001	Dec 15, 2021	Mar	DISC

VENLAFAXINE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

>D>	AB		ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Mar	DISC
>A>		@		EQ 75MG BASE	A213927	001	Jan 21, 2021	Mar	DISC
>A>		@	PHARMADAX	EQ 75MG BASE	A214423	001	Jan 04, 2022	Mar	CAHN
>A>		@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Mar	CAHN
>D>		@	SWISS PHARM	EQ 75MG BASE	A214423	001	Jan 04, 2022	Mar	CAHN
>D>		@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Mar	CAHN

VERAPAMIL HYDROCHLORIDESOLUTION;INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

>D>	AP		AMNEAL	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Mar	DISC
>A>		@		5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Mar	DISC
>D>	AP			10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Mar	DISC
>A>		@		10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Mar	DISC

VIGABATRINFOR SOLUTION;ORAL
VIGABATRIN

	@	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Jan	DISC
--	---	-----------------	--------------	---------	-----	--------------	-----	------

XENON XE-133GAS; INHALATION
XENON XE 133

SHINE

10mCi/VIAL
20mCi/VIALN017284 001
N017284 002Feb CAHN
Feb CAHNZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

AP

GLAND
@ HOSPIRA INCEQ 4MG BASE/100ML
EQ 5MG BASE/100MLA219984 001 Feb 05, 2026
A202837 001 Apr 05, 2013Jan NEWA
Jan DISCZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ SENORES PHARMS
@5MG
10MGA077985 001 Apr 23, 2007
A077985 002 Apr 23, 2007Jan CAHN
Jan CAHNTABLET, EXTENDED RELEASE; ORAL
ZOLPIDEM TARTRATE

AB

BRECKENRIDGE

6.25MG
12.5MGA213592 001 Jun 04, 2020
A213592 002 Jun 04, 2020Jan CMFD
Jan CMFD

AB

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE

@	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	Feb	DISC
---	--------	----------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

>D>		AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010	Mar	DISC
>A>	@		5MG	A078780	001	Jan 21, 2010	Mar	DISC
>D>			10MG	A078780	004	Jan 21, 2010	Mar	DISC
>A>	@		10MG	A078780	004	Jan 21, 2010	Mar	DISC

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D>		AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010	Mar	DISC
>A>	@		5MG	A078780	003	Jan 21, 2010	Mar	DISC
>D>			10MG	A078780	002	Jan 21, 2010	Mar	DISC
>A>	@		10MG	A078780	002	Jan 21, 2010	Mar	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL
DYNA-HEX 2

+!	XTTRIUM	2%	N019422	001	Dec 17, 1985	Feb	CTNA
----	---------	----	---------	-----	--------------	-----	------

DYNA-HEX 4

	XTTRIUM	4%	N019125	001	Dec 24, 1984	Feb	CTNA
--	---------	----	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

>D>		AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018	Mar	DISC
>A>	@		25MG;220MG	A209726	001	Oct 23, 2018	Mar	DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

>D>		TEVA	30MG	A076447	004	Apr 13, 2011	Mar	DISC
>A>	@		30MG	A076447	004	Apr 13, 2011	Mar	DISC
>A>		TIME CAP LABS	30MG	A079112	002	Feb 08, 2012	Mar	CAHN
>D>		WOCKHARDT	30MG	A079112	002	Feb 08, 2012	Mar	CAHN

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

>D>		TEVA	30MG	A076447	005	Apr 13, 2011	Mar	DISC
>A>	@		30MG	A076447	005	Apr 13, 2011	Mar	DISC
>A>		TIME CAP LABS	30MG	A079112	001	Feb 08, 2012	Mar	CAHN
>D>		WOCKHARDT	30MG	A079112	001	Feb 08, 2012	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE ALLERGY

>D>		RISING	60MG	A077081	006	Jul 21, 2011	Mar	DISC
>A>	@		60MG	A077081	006	Jul 21, 2011	Mar	DISC
>D>			180MG	A077081	008	Jul 21, 2011	Mar	DISC
>A>	@		180MG	A077081	008	Jul 21, 2011	Mar	DISC
>D>		TEVA	60MG	A076447	006	Apr 13, 2011	Mar	DISC
>A>	@		60MG	A076447	006	Apr 13, 2011	Mar	DISC
>D>			180MG	A076447	008	Apr 13, 2011	Mar	DISC
>A>	@		180MG	A076447	008	Apr 13, 2011	Mar	DISC
>A>		TIME CAP LABS	60MG	A079112	004	Feb 08, 2012	Mar	CAHN
>A>			180MG	A079112	006	Feb 08, 2012	Mar	CAHN
>D>		WOCKHARDT	60MG	A079112	004	Feb 08, 2012	Mar	CAHN
>D>			180MG	A079112	006	Feb 08, 2012	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE HIVES

>D>		RISING	60MG	A077081	007	Jul 21, 2011	Mar	DISC
>A>	@		60MG	A077081	007	Jul 21, 2011	Mar	DISC
>D>			180MG	A077081	009	Jul 21, 2011	Mar	DISC
>A>	@		180MG	A077081	009	Jul 21, 2011	Mar	DISC
>D>		TEVA	60MG	A076447	007	Apr 13, 2011	Mar	DISC
>A>	@		60MG	A076447	007	Apr 13, 2011	Mar	DISC
>A>		TIME CAP LABS	60MG	A079112	003	Feb 08, 2012	Mar	CAHN
>A>			180MG	A079112	005	Feb 08, 2012	Mar	CAHN
>D>		WOCKHARDT	60MG	A079112	003	Feb 08, 2012	Mar	CAHN
>D>			180MG	A079112	005	Feb 08, 2012	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 180MG;240MG A215232 001 Apr 17, 2025 Feb CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

>A> GLENMARK PHARMS LTD 0.05MG/SPRAY A218742 001 Mar 16, 2026 Mar NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

RUBICON RESEARCH 100MG/5ML A220239 001 Mar 05, 2026 Feb NEWA

TABLET;ORAL

IBUPROFEN

>D> AMNEAL PHARMS NY 200MG A071333 001 Feb 17, 1987 Mar DISC

>A> @ 200MG A071333 001 Feb 17, 1987 Mar DISC

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

INSTAPILL 5MG A212795 001 Sep 18, 2020 Feb CAHN

10MG A213294 001 Oct 30, 2020 Feb CAHN

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

>D> + HISAMITSU PHARM CO 3%;10% N022029 002 Nov 05, 2012 Mar CHRS

>A> +! 3%;10% N022029 002 Nov 05, 2012 Mar CHRS

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ FDC LTD EQ 0.2% BASE A217051 001 Jul 14, 2025 Feb DISC

PERMETHRIN

LOTION;TOPICAL

PERMETHRIN

@ FERRIGO NEW YORK 1% A076090 001 Dec 20, 2001 Feb DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D> @ PHARMOBEDIANT EQ 75MG BASE A075497 001 Jan 14, 2000 Mar CAHN

>A> @ RISING EQ 75MG BASE A075497 001 Jan 14, 2000 Mar CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2026

NO MARCH 2026 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2026 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11207311	Jul 28, 2037			I-980	Dec 12, 2028
	11207311	Jul 28, 2037				
	11673877	Mar 27, 2038	DS DP	U-2830		
	11673877	Mar 27, 2038	DS DP	U-4368		
	11986468	Jul 28, 2037		U-2830		
	11986468	Jul 28, 2037		U-4368		
	11986469	Jul 28, 2037		U-2830		
	11986469	Jul 28, 2037		U-4368		
	11986470	Jul 28, 2037		U-4368		
	11992486	Jul 28, 2037		U-2830		
	11992486	Jul 28, 2037		U-4368		
	12383543	Jul 28, 2037		U-2830		
	12383543	Jul 28, 2037		U-4368		
	8071579	Aug 12, 2027		U-2830		
	8071579	Aug 12, 2027		U-4368		
	8143241	Aug 12, 2027		U-2830		
	8143241	Aug 12, 2027		U-4368		
	8859562	Aug 04, 2031		U-2830		
	8859562	Aug 04, 2031		U-4368		
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11207311	Jul 28, 2037			I-980	Dec 12, 2028
	11207311	Jul 28, 2037		U-4368		
	11673877	Mar 27, 2038	DS DP	U-2830		
	11673877	Mar 27, 2038	DS DP	U-4368		
	11986468	Jul 28, 2037		U-2830		
	11986468	Jul 28, 2037		U-4368		
	11986469	Jul 28, 2037		U-2830		
	11986469	Jul 28, 2037		U-4368		
	11986470	Jul 28, 2037		U-4368		
	11992486	Jul 28, 2037		U-2830		
	11992486	Jul 28, 2037		U-4368		
	12383543	Jul 28, 2037		U-2830		
	12383543	Jul 28, 2037		U-4368		
	8071579	Aug 12, 2027		U-2830		
	8071579	Aug 12, 2027		U-4368		
	8143241	Aug 12, 2027		U-2830		
	8143241	Aug 12, 2027		U-4368		
	8859562	Aug 04, 2031		U-2830		
	8859562	Aug 04, 2031		U-4368		
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	>A> 11166951	Aug 11, 2035		U-4426		
	>A> 11166951	Aug 11, 2035		U-4427		
	>A> 11166951	Aug 11, 2035		U-4428		
	>A> 11166951	Aug 11, 2035		U-4429		
	>A> 11166951	Aug 11, 2035		U-4430		
	>A> 11166951	Aug 11, 2035		U-4431		
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	>A> 11166951	Aug 11, 2035		U-4426		
	>A> 11166951	Aug 11, 2035		U-4427		
	>A> 11166951	Aug 11, 2035		U-4428		
	>A> 11166951	Aug 11, 2035		U-4429		
	>A> 11166951	Aug 11, 2035		U-4430		
	>A> 11166951	Aug 11, 2035		U-4431		
<u>ACECLIDINE HYDROCHLORIDE - VIZZ</u>						
N 218585 001	12533347	Oct 08, 2039		U-3741		
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	12539290	Aug 16, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFICAMTEN - MYOORZO</u>						
N 219083 001	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 002	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 003	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 004	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001	7977488	Apr 10, 2030	DS			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	>A> 11723898	Jan 14, 2041	U-4449			
	>A> 12303497	Jan 30, 2040	U-4201			
	>A> 12303497	Jan 30, 2040	U-4448			
	>A> RE50642	Sep 23, 2033	U-4450			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	>A> 11723898	Jan 14, 2041	U-4449			
	>A> 12303497	Jan 30, 2040	U-4201			
	>A> 12303497	Jan 30, 2040	U-4448			
	>A> RE50642	Sep 23, 2033	U-4450			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001	>A> 12390442	Feb 16, 2044	U-4433			
<u>ARTICAINE HYDROCHLORIDE - CYKLX</u>						
N 218643 001	11096922	Mar 27, 2039	DP U-4423			
	11826347	Mar 27, 2039	DP U-4423			
	12403126	Mar 27, 2039	DP U-4423			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	12521369	Feb 23, 2041	U-3980			
	>A> 12582631	Mar 25, 2043	U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2027	DS			
	9617546	Feb 14, 2027	DS U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	8906938	Jan 06, 2034	DS DP			
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAFKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	12509450	Dec 29, 2042	DP			
<u>AXITINIB - INLYTA</u>						
N 202324 001	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
<u>AXITINIB - INLYTA</u>						
N 202324 002	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	8987441	Oct 24, 2032	DS DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12551491	Jul 23, 2045		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12551491	Jul 23, 2045		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12551491	Jul 23, 2045		U-713		
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545645*PED	May 01, 2040				
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545646*PED	May 01, 2040				
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12545647*PED	May 01, 2040				
	>A> 12552750	Nov 01, 2039	DS DP			
	>A> 12552750*PED	May 01, 2040				
	>A> 12590068	Nov 01, 2039	DS DP			
	>A> 12590069	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545645*PED	May 01, 2040				
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545646*PED	May 01, 2040				
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12545647*PED	May 01, 2040				
	>A> 12552750	Nov 01, 2039	DS DP			
	>A> 12552750*PED	May 01, 2040				
	>A> 12590068	Nov 01, 2039	DS DP			
	>A> 12590069	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 001	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545645*PED	May 01, 2040				
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545646*PED	May 01, 2040				
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12545647*PED	May 01, 2040				
	>A> 12552750	Nov 01, 2039	DS DP			
	>A> 12552750*PED	May 01, 2040				
	>A> 12590068	Nov 01, 2039	DS DP			
	>A> 12590069	Nov 01, 2039	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 002	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545645*PED	May 01, 2040				
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545646*PED	May 01, 2040				
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12545647*PED	May 01, 2040				
	>A> 12552750	Nov 01, 2039	DS DP			
	>A> 12552750*PED	May 01, 2040				
	>A> 12590068	Nov 01, 2039	DS DP			
	>A> 12590069	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545645*PED	May 01, 2040				
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545646*PED	May 01, 2040				
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12545647*PED	May 01, 2040				
	>A> 12552750	Nov 01, 2039	DS DP			
	>A> 12552750*PED	May 01, 2040				
	>A> 12590068	Nov 01, 2039	DS DP			
	>A> 12590069	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 004	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545645*PED	May 01, 2040				
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545646*PED	May 01, 2040				
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12545647*PED	May 01, 2040				
	>A> 12552750	Nov 01, 2039	DS DP			
	>A> 12552750*PED	May 01, 2040				
	>A> 12590068	Nov 01, 2039	DS DP			
	>A> 12590069	Nov 01, 2039	DS DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	>A> 7777050	Mar 13, 2027	DS DP			
<u>BRIMONIDINE TARTRATE; CARBACHOL - YUVEZZI</u>						
N 220142 001	12268662	Nov 10, 2042	DP U-3741		NP	Jan 28, 2029
	12268662	Nov 10, 2042	DP U-4419			
	12268662	Nov 10, 2042	DP U-4420			
	8455494	May 24, 2030	U-3741			
	8455494	May 24, 2030	U-4419			
	8455494	May 24, 2030	U-4420			
<u>BUMETANIDE - ENBUMYST</u>						
N 219500 001	>A> 12558330	May 14, 2045	DP U-4279			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10583110*PED	Apr 27, 2031				
	10716777	Oct 27, 2030	U-2856			
	10716777*PED	Apr 27, 2031				
	12453712	Oct 27, 2030	U-4334			
	12453712*PED	Apr 27, 2031				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		>A> M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		>A> NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		>A> PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		>A> PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		>A> M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		>A> NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		>A> PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		>A> PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750		>A> M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		>A> NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		>A> PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030			>A> PED	Jun 18, 2029
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750		>A> M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		>A> PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 005	7737142	Sep 17, 2029	DS DP U-2543		>A> M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		>A> NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		>A> PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		>A> PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 006	7737142	Sep 17, 2029	DS DP U-2543		>A> M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		>A> NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		>A> PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		>A> PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
<u>CITALOPRAM HYDROBROMIDE - CITALOPRAM HYDROBROMIDE</u>						
A 219985 001					>A> CGT	Sep 16, 2026
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	12533408	Sep 10, 2041	U-4395			
	12539329	Sep 10, 2041	U-4399			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	11179465	Aug 31, 2030	DP U-1858			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	>A> 12576032	Jul 28, 2041	U-2357			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12514819	Nov 22, 2036	U-2814			
<u>COPPER HISTIDINATE - ZYCUBO</u>						
N 211241 001					NCE	Jan 12, 2031
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150		PED	Sep 30, 2028
	10028912*PED	Apr 15, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-3149			
	10166184*PED	Apr 15, 2033				
	10835492	Oct 15, 2032	U-3150			
	10835492*PED	Apr 15, 2033				
	7850990	Jan 23, 2027	DP U-3147			
	7850990*PED	Jul 23, 2027				
	8022279	Sep 14, 2027	DP U-3147			
	8022279*PED	Mar 14, 2028				
	8092828	Apr 01, 2029	U-3147			
	8092828*PED	Oct 01, 2029				
	9271931	Jan 23, 2027	DP			
	9271931*PED	Jul 23, 2027				
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	12329742	Jun 17, 2042	DP			
<u>DASATINIB - PHYRAGO</u>						
N 216099 001	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 002	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 003	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 004	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 005	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	12529052	Jun 22, 2032	DP			
	12534722	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001 >A>	12558349	Mar 14, 2034	U-3967			
<u>DESMOPRESSIN ACETATE - DESMODA</u>						
N 219873 001 >A>	12214010	Apr 03, 2044	DP			
	>A> 12343372	Apr 03, 2044	DP U-4432			
<u>DEUCRAVACITINIB - SOTYKTU</u>						
N 214958 001 >A>	12521390	Feb 11, 2043	DP U-3434			
	>A> 12521390	Feb 11, 2043	DP U-4451			
	>A> RE47929	Nov 07, 2033	DS DP U-3434			
	>A> RE47929	Nov 07, 2033	DS DP U-4452			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM - MUCINEX 12HR COLD & FEVER MULTI-SYMP TOM</u>						
N 217338 001 >A>	11278506	Oct 11, 2036	DP			
	>A> 12257218	Oct 11, 2036	DP			
	>A> 12370189	Oct 11, 2036	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12521400	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12521400	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12521400	Mar 27, 2029	DP			
<u>DIFAMILAST - ADOUEY</u>						
N 219474 001 >A>	10588893	Dec 31, 2036	DS DP		NCE	Feb 12, 2031
	>A> RE46792	Mar 01, 2028	DS DP U-4445			
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	12533351	Feb 26, 2039	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001 >A>	8193182	Sep 24, 2032	DS			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002 >A>	8193182	Sep 24, 2032	DS			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12527769	Nov 12, 2041	U-4111			
	>A> 12569469	Nov 12, 2041	U-4111			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001 >A>	12582625	Feb 12, 2036	U-4444			
<u>ELAMIPRETIDE HYDROCHLORIDE - FORZINITY</u>						
N 215244 001	7576061	Jan 20, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELINZANETANT - LYNKUET</u>						
N 219469 001	12533358	May 14, 2045	U-4402			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	>A> 10005761	Aug 27, 2030	U-2335			
	>A> 10005761	Aug 27, 2030	U-2802			
	>A> 10005761	Aug 27, 2030	U-2803			
	>A> 10005761	Aug 27, 2030	U-3738			
	>A> 10005761	Aug 27, 2030	U-4051			
	>A> 10005761	Aug 27, 2030	U-4440			
	>A> 10258622	Nov 21, 2032	U-2802			
	>A> 10258622	Nov 21, 2032	U-4051			
	>A> 10258622	Nov 21, 2032	U-4439			
	>A> 8541575	Feb 26, 2030	DS DP U-2335			
	>A> 8541575	Feb 26, 2030	DS DP U-2802			
	>A> 8541575	Feb 26, 2030	DS DP U-2803			
	>A> 8541575	Feb 26, 2030	DS DP U-3738			
	>A> 8541575	Feb 26, 2030	DS DP U-4051			
	>A> 8541575	Feb 26, 2030	DS DP U-4440			
	>A> 9314464	Jul 04, 2031	U-2336			
	>A> 9314464	Jul 04, 2031	U-2802			
	>A> 9314464	Jul 04, 2031	U-2803			
	>A> 9314464	Jul 04, 2031	U-3738			
	>A> 9314464	Jul 04, 2031	U-4051			
	>A> 9314464	Jul 04, 2031	U-4440			
	>A> 9474754	Aug 05, 2033	U-2802			
	>A> 9474754	Aug 05, 2033	U-4051			
	>A> 9474754	Aug 05, 2033	U-4440			
	>A> 9850230	Aug 27, 2030	U-2334			
	>A> 9850230	Aug 27, 2030	U-2802			
	>A> 9850230	Aug 27, 2030	U-2803			
	>A> 9850230	Aug 27, 2030	U-3738			
	>A> 9850230	Aug 27, 2030	U-4051			
	>A> 9850230	Aug 27, 2030	U-4440			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 215425 001	12539283	Jan 17, 2045	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	12551447	Nov 05, 2042	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002				D-199	Jan 16, 2029
<u>ETRIPAMIL - CARDAMYST</u>						
N 218571	001	10010522	Jun 19, 2028	U-38		
		10010523	Jun 19, 2028	DS		
		10117848	Apr 13, 2036	DP	U-4370	
		12257224	Jul 15, 2042		U-4370	
		9227918	Jun 19, 2028	DP		
		9463179	Jun 19, 2028		U-4370	
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565	001	7612109	Feb 05, 2027	DS DP		
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565	002	7612109	Feb 05, 2027	DS DP		
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565	003	7612109	Feb 05, 2027	DS DP		
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565	004	7612109	Feb 05, 2027	DS DP		
<u>FINERENONE - KERENDIA</u>						
N 215341	001	8436180	Aug 26, 2033	DS DP		
<u>FINERENONE - KERENDIA</u>						
N 215341	002	8436180	Aug 26, 2033	DS DP		
<u>FINERENONE - KERENDIA</u>						
N 215341	003	8436180	Aug 26, 2033	DS DP		
<u>FLIBANSERIN - ADDYI</u>						
N 022526	001				I-983	Dec 13, 2028
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168	001	12527884	May 13, 2042	DP	U-4406	
<u>FLUTICASONE PROPIONATE - FLUTICASONE PROPIONATE</u>						
A 219602	001				>A> CGT	Sep 20, 2026
<u>FOSFOMYCIN DISODIUM - CONTEPO</u>						
N 212271	001				NP GAIN	Oct 22, 2028 Oct 22, 2033
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986	001	12064487	Jan 17, 2040	U-4424	>A> NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986	002	12064487	Jan 17, 2040	U-4424	>A> NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986	003	12064487	Jan 17, 2040	U-4424	>A> NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986	004	12064487	Jan 17, 2040	U-4424	>A> NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986	005	12064487	Jan 17, 2040	U-4424	>A> NPP	Feb 20, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	12064487	Jan 17, 2040	U-4424		>A> NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007					>A> NPP	Feb 20, 2029
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	8318714	Nov 28, 2031	DP			
<u>GEMCITABINE HYDROCHLORIDE - INLEXZO</u>						
N 219683 001	>A> 12576253	Dec 17, 2030	DP			
<u>GEPOTIDACIN MESYLATE - BLUJEPÄ</u>						
N 218230 001	12528809	Dec 13, 2042	DS DP U-4361			
	12528809	Dec 13, 2042	DS DP U-4408			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	7329689	Jan 15, 2027	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	8148401	Apr 14, 2029	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	8148401	Apr 14, 2029	DS DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 12551448	Mar 03, 2036	DP			
<u>ICOTROKINRA HYDROCHLORIDE - ICOTYDE</u>						
N 220149 001	>A> 11845808	Jan 14, 2041	DS U-4447			
	>A> 11939361	Nov 19, 2041	DP U-4447			
	>A> 12552836	Jul 12, 2039	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2026	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2026	DS DP			
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-4249		I-985	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4413		NPP	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4414			
	10131907	Aug 24, 2028	DS DP U-4249			
	10131907	Aug 24, 2028	DS DP U-4413			
	10131907	Aug 24, 2028	DS DP U-4414			
	10851377	Aug 25, 2036	U-4249			
	10851377	Aug 25, 2036	U-4413			
	10851377	Aug 25, 2036	U-4414			
	8106022	Dec 12, 2029	DS DP U-4249			
	8106022	Dec 12, 2029	DS DP U-4413			
	8106022	Dec 12, 2029	DS DP U-4414			
	8222222	Dec 29, 2027	U-4249			
	8222222	Dec 29, 2027	U-4413			
	8222222	Dec 29, 2027	U-4414			
	8809292	May 10, 2027	DS DP U-4249			
	8809292	May 10, 2027	DS DP U-4413			
	8809292	May 10, 2027	DS DP U-4414			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	8828956	Dec 04, 2028	DS DP U-4249			
	8828956	Dec 04, 2028	DS DP U-4413			
	8828956	Dec 04, 2028	DS DP U-4414			
	9370582	Dec 04, 2028	DS DP U-4249			
	9370582	Dec 04, 2028	DS DP U-4413			
	9370582	Dec 04, 2028	DS DP U-4414			
<u>IOHEXOL - IOHEXOL</u>						
A 217737 001					CGT	Jul 26, 2026
<u>LANDIOLOL HYDROCHLORIDE - RAPIBLYK</u>						
N 217202 001				>A> NPP		Feb 13, 2029
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	12544380	Aug 07, 2034	U-3264			
	12544380	Aug 07, 2034	U-3998			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 001	12564592	Dec 23, 2044	DP			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 002	12564592	Dec 23, 2044	DP			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 003	12564592	Dec 23, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 011	>A> 12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 012	>A> 12564565	Sep 26, 2044	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 013 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 014 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 015 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 016 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 001 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 002 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 003 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 004 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 005 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 006 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 007 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 008 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 009 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 010 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 011 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 012 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 013 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 014 >A>	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 015 >A>	12564565	Sep 26, 2044	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u> N 021717 001	12558328	Jan 14, 2031	U-4421			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001					NPP PED	Nov 04, 2028 May 04, 2029
<u>LINERIXIBAT - LYNAVOY</u>						
N 220295 001	>A> 9040518	Sep 06, 2031	DS DP			
<u>LISDEXAMFETAMINE DIMESYLATE - ARYNTE</u>						
N 219847 001	>A> 12582620	Apr 16, 2040	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	>A> 12472172	Jul 29, 2041			U-4438	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	>A> 12472172	Jul 29, 2041			U-4438	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	>A> 12472172	Jul 29, 2041			U-4438	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	>A> 12472172	Jul 29, 2041			U-4438	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 007	>A> 12472172 >A> 7932268	Jul 29, 2041 Aug 19, 2027			U-4438 U-1316	
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 001					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 002					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 003					CGT	May 19, 2026
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - LOTEPREDNOL ETABONATE AND TOBRAMYCIN</u>						
A 217597 001					CGT	Jul 14, 2026
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12527771	Oct 11, 2043	DS DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	12544383	Mar 10, 2045			U-1719	
	12551488	May 28, 2040			U-1719	
	12551489	May 28, 2040			U-1719	
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	12533342	May 20, 2039			U-3421	
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 001	>A> 10563259	Jul 24, 2030			U-4436	
	>A> 10563259	Jul 24, 2030			U-4437	
	>A> 10570453	Mar 28, 2028			U-4436	
	>A> 10570453	Mar 28, 2028			U-4437	
	>A> 12478619	May 31, 2044			U-4434	
	>A> 12478619	May 31, 2044			U-4435	
	>A> 8999638	Oct 28, 2030			U-4436	
	>A> 8999638	Oct 28, 2030			U-4437	
	>A> 9072742	Jan 16, 2031			U-4436	
	>A> 9072742	Jan 16, 2031			U-4437	
	>A> 9074254	Dec 28, 2031			U-4436	
	>A> 9074254	Dec 28, 2031			U-4437	
	>A> 9074255	Dec 17, 2030			U-4436	
	>A> 9074255	Dec 17, 2030			U-4437	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 001	>A> 9074256	Feb 10, 2031	U-4436			
	>A> 9074256	Feb 10, 2031	U-4437			
	>A> 9157121	Apr 05, 2030	U-4436			
	>A> 9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 002	>A> 10563259	Jul 24, 2030	U-4436			
	>A> 10563259	Jul 24, 2030	U-4437			
	>A> 10570453	Mar 28, 2028	U-4436			
	>A> 10570453	Mar 28, 2028	U-4437			
	>A> 12478619	May 31, 2044	U-4434			
	>A> 12478619	May 31, 2044	U-4435			
	>A> 8999638	Oct 28, 2030	U-4436			
	>A> 8999638	Oct 28, 2030	U-4437			
	>A> 9072742	Jan 16, 2031	U-4436			
	>A> 9072742	Jan 16, 2031	U-4437			
	>A> 9074254	Dec 28, 2031	U-4436			
	>A> 9074254	Dec 28, 2031	U-4437			
	>A> 9074255	Dec 17, 2030	U-4436			
	>A> 9074255	Dec 17, 2030	U-4437			
	>A> 9074256	Feb 10, 2031	U-4436			
	>A> 9074256	Feb 10, 2031	U-4437			
	>A> 9157121	Apr 05, 2030	U-4436			
	>A> 9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 003	>A> 10563259	Jul 24, 2030	U-4436			
	>A> 10563259	Jul 24, 2030	U-4437			
	>A> 10570453	Mar 28, 2028	U-4436			
	>A> 10570453	Mar 28, 2028	U-4437			
	>A> 12478619	May 31, 2044	U-4434			
	>A> 12478619	May 31, 2044	U-4435			
	>A> 8999638	Oct 28, 2030	U-4436			
	>A> 8999638	Oct 28, 2030	U-4437			
	>A> 9072742	Jan 16, 2031	U-4436			
	>A> 9072742	Jan 16, 2031	U-4437			
	>A> 9074254	Dec 28, 2031	U-4436			
	>A> 9074254	Dec 28, 2031	U-4437			
	>A> 9074255	Dec 17, 2030	U-4436			
	>A> 9074255	Dec 17, 2030	U-4437			
	>A> 9074256	Feb 10, 2031	U-4436			
	>A> 9074256	Feb 10, 2031	U-4437			
	>A> 9157121	Apr 05, 2030	U-4436			
	>A> 9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 004	>A> 10563259	Jul 24, 2030	U-4436			
	>A> 10563259	Jul 24, 2030	U-4437			
	>A> 10570453	Mar 28, 2028	U-4436			
	>A> 10570453	Mar 28, 2028	U-4437			
	>A> 12478619	May 31, 2044	U-4434			
	>A> 12478619	May 31, 2044	U-4435			
	>A> 8999638	Oct 28, 2030	U-4436			
	>A> 8999638	Oct 28, 2030	U-4437			
	>A> 9072742	Jan 16, 2031	U-4436			
	>A> 9072742	Jan 16, 2031	U-4437			
	>A> 9074254	Dec 28, 2031	U-4436			
	>A> 9074254	Dec 28, 2031	U-4437			
	>A> 9074255	Dec 17, 2030	U-4436			
	>A> 9074255	Dec 17, 2030	U-4437			
	>A> 9074256	Feb 10, 2031	U-4436			
	>A> 9074256	Feb 10, 2031	U-4437			
	>A> 9157121	Apr 05, 2030	U-4436			
	>A> 9157121	Apr 05, 2030	U-4437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 005	>A> 10563259	Jul 24, 2030	U-4436			
	>A> 10563259	Jul 24, 2030	U-4437			
	>A> 10570453	Mar 28, 2028	U-4436			
	>A> 10570453	Mar 28, 2028	U-4437			
	>A> 12478619	May 31, 2044	U-4434			
	>A> 12478619	May 31, 2044	U-4435			
	>A> 8999638	Oct 28, 2030	U-4436			
	>A> 8999638	Oct 28, 2030	U-4437			
	>A> 9072742	Jan 16, 2031	U-4436			
	>A> 9072742	Jan 16, 2031	U-4437			
	>A> 9074254	Dec 28, 2031	U-4436			
	>A> 9074254	Dec 28, 2031	U-4437			
	>A> 9074255	Dec 17, 2030	U-4436			
	>A> 9074255	Dec 17, 2030	U-4437			
	>A> 9074256	Feb 10, 2031	U-4436			
	>A> 9074256	Feb 10, 2031	U-4437			
	>A> 9157121	Apr 05, 2030	U-4436			
	>A> 9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 006	>A> 10563259	Jul 24, 2030	U-4436			
	>A> 10563259	Jul 24, 2030	U-4437			
	>A> 10570453	Mar 28, 2028	U-4436			
	>A> 10570453	Mar 28, 2028	U-4437			
	>A> 12478619	May 31, 2044	U-4434			
	>A> 12478619	May 31, 2044	U-4435			
	>A> 8999638	Oct 28, 2030	U-4436			
	>A> 8999638	Oct 28, 2030	U-4437			
	>A> 9072742	Jan 16, 2031	U-4436			
	>A> 9072742	Jan 16, 2031	U-4437			
	>A> 9074254	Dec 28, 2031	U-4436			
	>A> 9074254	Dec 28, 2031	U-4437			
	>A> 9074255	Dec 17, 2030	U-4436			
	>A> 9074255	Dec 17, 2030	U-4437			
	>A> 9074256	Feb 10, 2031	U-4436			
	>A> 9074256	Feb 10, 2031	U-4437			
	>A> 9157121	Apr 05, 2030	U-4436			
	>A> 9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 007	>A> 10563259	Jul 24, 2030	U-4436			
	>A> 10563259	Jul 24, 2030	U-4437			
	>A> 10570453	Mar 28, 2028	U-4436			
	>A> 10570453	Mar 28, 2028	U-4437			
	>A> 12478619	May 31, 2044	U-4434			
	>A> 12478619	May 31, 2044	U-4435			
	>A> 8999638	Oct 28, 2030	U-4436			
	>A> 8999638	Oct 28, 2030	U-4437			
	>A> 9072742	Jan 16, 2031	U-4436			
	>A> 9072742	Jan 16, 2031	U-4437			
	>A> 9074254	Dec 28, 2031	U-4436			
	>A> 9074254	Dec 28, 2031	U-4437			
	>A> 9074255	Dec 17, 2030	U-4436			
	>A> 9074255	Dec 17, 2030	U-4437			
	>A> 9074256	Feb 10, 2031	U-4436			
	>A> 9074256	Feb 10, 2031	U-4437			
	>A> 9157121	Apr 05, 2030	U-4436			
	>A> 9157121	Apr 05, 2030	U-4437			
<u>MITAPIVAT SULFATE - AOVESME</u>						
N 216196 004	10632114	May 03, 2032	U-4391		NCE	Feb 17, 2027
	11254652	Nov 21, 2038	DS DP		NP	Dec 23, 2028
	11878049	Jul 31, 2041	U-4390			
	9193701	Oct 26, 2032	U-4393			
	9682080	May 03, 2032	U-4392			
	RE49582	Feb 24, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	>A> 12576089	Aug 21, 2039	U-4441			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	>A> 12576089	Aug 21, 2039	U-4441			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	>A> 12576089	Aug 21, 2039	U-4441			
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001	12514854	Feb 05, 2041	U-4397			
<u>NAVEPEGTRITIDE - YUWIWEL</u>						
N 219164 001	>A> 10835578	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	>A> 11154593	Jan 05, 2037	DS DP U-4425			
	>A> 11224661	Jan 05, 2037	DS DP			
	>A> 11311604	Jan 05, 2037	DS DP U-4425			
	>A> 11389510	Jan 05, 2037	DS DP			
	>A> 11389511	Jan 05, 2037	DP U-4425			
	>A> 11413351	Jan 05, 2037	DS DP			
	>A> 12083182	Jan 05, 2037	U-4425			
	>A> 12156917	Jan 05, 2037	U-4425			
	>A> 12239689	Jan 05, 2037	U-4425			
	>A> 12377133	Nov 12, 2042	DP U-4425			
	>A> 8906847	Apr 30, 2031	DS DP U-4425			
<u>NAVEPEGTRITIDE - YUWIWEL</u>						
N 219164 002	>A> 10835578	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	>A> 11154593	Jan 05, 2037	DS DP U-4425			
	>A> 11224661	Jan 05, 2037	DS DP			
	>A> 11311604	Jan 05, 2037	DS DP U-4425			
	>A> 11389510	Jan 05, 2037	DS DP			
	>A> 11389511	Jan 05, 2037	DP U-4425			
	>A> 11413351	Jan 05, 2037	DS DP			
	>A> 12083182	Jan 05, 2037	U-4425			
	>A> 12156917	Jan 05, 2037	U-4425			
	>A> 12239689	Jan 05, 2037	U-4425			
	>A> 12377133	Nov 12, 2042	DP U-4425			
	>A> 8906847	Apr 30, 2031	DS DP U-4425			
<u>NAVEPEGTRITIDE - YUWIWEL</u>						
N 219164 003	>A> 10835578	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	>A> 11154593	Jan 05, 2037	DS DP U-4425			
	>A> 11224661	Jan 05, 2037	DS DP			
	>A> 11311604	Jan 05, 2037	DS DP U-4425			
	>A> 11389510	Jan 05, 2037	DS DP			
	>A> 11389511	Jan 05, 2037	DP U-4425			
	>A> 11413351	Jan 05, 2037	DS DP			
	>A> 12083182	Jan 05, 2037	U-4425			
	>A> 12156917	Jan 05, 2037	U-4425			
	>A> 12239689	Jan 05, 2037	U-4425			
	>A> 12377133	Nov 12, 2042	DP U-4425			
	>A> 8906847	Apr 30, 2031	DS DP U-4425			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 001	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373			
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 002	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373			
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 004	10888534	Apr 26, 2039	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 001					CGT	Aug 02, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 002					CGT	Jul 27, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 003					CGT	Jul 27, 2026
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	12509684	May 01, 2034	U-4050			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	12514899	Aug 29, 2029	U-4398			
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	12514899	Aug 29, 2029	U-4398			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7771707	Oct 09, 2028	DP			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	12528836	Oct 07, 2036	U-4394			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	>A> 12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	>A> 12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	>A> 12552792	Oct 03, 2040	DS DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
N 216830 001	>A> 12564561	Aug 08, 2044	DP			
<u>PIFLUFOLASTAT F-18 - PYLARIFY TRUVU</u>						
N 220089 001	>A> 10947197	Jun 09, 2037	DS DP U-3317			
	>A> 11851407	Jun 09, 2037	DS DP U-3317			
	>A> 12070513	Jul 31, 2029	DS DP U-3317			
	>A> 8487129	Nov 07, 2027	DS DP			
	>A> 8778305	Sep 21, 2030	DS DP U-3317			
	>A> 9861713	Jul 31, 2029	DS DP U-3317			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	>A> 7601740	Apr 29, 2030	DS DP			
	>A> 7601740*PED	Oct 29, 2030				
	>A> 7732615	Jun 03, 2028	DS DP			
	>A> 7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	>A> 10517860	Mar 23, 2037	U-1974			
	>A> 10517860*PED	Sep 23, 2037				
	>A> 10953000	Mar 23, 2037	U-1974			
	>A> 10953000*PED	Sep 23, 2037				
	>A> 7601740	Apr 29, 2030	DS DP			
	>A> 7601740*PED	Oct 29, 2030				
	>A> 7732615	Jun 03, 2028	DS DP			
	>A> 7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	>A> 10449185	Aug 27, 2038	DP			
	>A> 10449185*PED	Feb 27, 2039				
	>A> 10646480	Aug 27, 2038	DP			
	>A> 10646480*PED	Feb 27, 2039				
	>A> 10849891	Aug 27, 2038	DP U-1974			
	>A> 10849891*PED	Feb 27, 2039				
	>A> 11452721	Aug 27, 2038	DP			
	>A> 11452721*PED	Feb 27, 2039				
	>A> 7601740	Apr 29, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	>A> 7601740*PED	Oct 29, 2030				
	>A> 7732615	Jun 03, 2028	DS DP			
	>A> 7732615*PED	Dec 03, 2028				
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					I-981	Dec 02, 2028
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					I-981	Dec 02, 2028
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 001					>A> PC	Aug 30, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 002					>A> PC	Aug 30, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 003					>A> PC	Aug 30, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 004					>A> PC	Aug 30, 2026
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP	Jan 27, 2029
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698		NPP	Jan 27, 2029
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9023790	Jul 04, 2031	DP U-4415			
	9023790	Jul 04, 2031	DP U-4416			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-4415			
	9358297	Jun 24, 2031	DP U-4416			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					I-984	Jan 27, 2029
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 001	12539314	Mar 07, 2039	DP			
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 002	12539314	Mar 07, 2039	DP			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	12448366	Jul 07, 2042	DS			
	12539303	Apr 03, 2039			U-2828	
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972 001	12544337	Dec 23, 2039	DP U-4026			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001	>A> 12564590	Dec 18, 2042	DP U-4045			
	>A> 12564590	Dec 18, 2042	DP U-4327			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002	>A> 12564590	Dec 18, 2042	DP U-4045			
	>A> 12564590	Dec 18, 2042	DP U-4327			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003	>A> 12564590	Dec 18, 2042	DP U-4045			
	>A> 12564590	Dec 18, 2042	DP U-4327			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	12544379	Aug 07, 2034	U-3975			
	12544380	Aug 07, 2034	U-4404			
	12544380	Aug 07, 2034	U-4405			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001					I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002					I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003					I-982	Dec 17, 2028
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12544381	May 20, 2031	DP			
	>A> 12564593	May 20, 2031	DP			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001 >A>	9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002 >A>	12569543	Apr 28, 2037		U-4446		
	>A> 9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003 >A>	12569543	Apr 28, 2037		U-4446		
	>A> 9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004 >A>	12569543	Apr 28, 2037		U-4446		
	>A> 9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	12514822	May 02, 2034		U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	12514822	May 02, 2034		U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	12514822	May 02, 2034		U-2628		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 004	12514822	May 02, 2034		U-2628		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 005	12514822	May 02, 2034		U-2628		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 006	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001 >A>	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002 >A>	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003 >A>	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004 >A>	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12551536	Oct 10, 2038	U-4418			
	>A> 12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY HD</u>						
N 215256 006 >A>	10888605	Aug 24, 2038	DP U-4418			
	>A> 11318191	Feb 17, 2041	DP U-4418			
	>A> 11752198	Aug 24, 2038	DP U-4418			
	>A> 12029779	Oct 10, 2038	U-4418			
	>A> 12214017	Aug 24, 2038	DP U-4418			
	>A> 12551536	Oct 10, 2038	U-4418			
	>A> 12569543	Apr 28, 2037	U-4443			
	>A> 8129343	Dec 05, 2031	DS DP			
	>A> 9764003	Jun 21, 2033	U-4418			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 001	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 002	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 003	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	9278123	Dec 16, 2031	DP U-4389			
<u>SEVABERTINIB - HYRNUO</u>						
N 219972 001	10428063	Oct 10, 2035	DS DP			
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 001	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 002	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 003	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 004	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	12533340	Apr 23, 2036	U-4407			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	>A> 10195160	May 23, 2036	DP			
	>A> 12569453	Dec 18, 2039	U-4048			
<u>TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT</u>						
N 022335 001	>A> 7722856	Feb 24, 2031	U-4442			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12539299	Nov 26, 2042	DP			
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 004	9931458	May 31, 2037	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 013	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 014	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 015	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 015	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 016	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 017	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 018	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 019	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 020	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 021	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 021	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 022	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 023	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 024	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 013	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 014	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 014	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 015	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 016	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 017	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 018	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 019	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 020	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 020	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 021	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 022	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 023	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 024	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TRADIPITANT - NEREUS</u>						
N 220152 001	10772880	Mar 04, 2036	U-4396			
	10821099	Mar 04, 2036	U-4396			
	11324735	Mar 04, 2036	U-4396			
	12318375	Aug 09, 2036	U-4396			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	7199162	Oct 12, 2026	U-4142			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	7199162	Oct 12, 2026	U-4142			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001	12551461	Nov 14, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12527798	Dec 05, 2037	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE-425	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 002	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 003	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 001 >A>	12558317	Oct 29, 2039	DP			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 002 >A>	12558317	Oct 29, 2039	DP			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 003 >A>	12558317	Oct 29, 2039	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	8648087	Jan 14, 2031	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	8648087	Jan 14, 2031	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001 >A>	12569474	Jun 04, 2034	U-3876			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002 >A>	12569474	Jun 04, 2034	U-3876			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003 >A>	12569474	Jun 04, 2034	U-3876			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003					D-198	Jan 21, 2029
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001 >A>	12576054	Jun 08, 2043	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
>A>	12582655	Dec 23, 2039	U-4145			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
>A>	12582655	Dec 23, 2039	U-4145			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
>A>	12582655	Dec 23, 2039	U-4145			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2027	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001	7977488	Apr 10, 2030	DS			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002	7977488	Apr 10, 2030	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12514906	Aug 01, 2036	DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12514906	Aug 01, 2036	DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12514906	Aug 01, 2036	DP U-3927			
<u>ZIFTOMENIB - KOMZIFTI</u>						
N 220305 001	12521396	Jul 16, 2044	DP			
<u>ZOLIFLODACIN - NUZOLVENCE</u>						
N 219491 001	8658641	Jun 20, 2030	DS			
	8889671	Jan 21, 2034	DS		U-4369	
	9040528	Oct 13, 2029			U-4369	
	9187495	Jan 21, 2034	DS		U-4369	
	9540394	Jan 21, 2034			U-4369	
	9839641	Jan 21, 2034			U-4369	

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 46TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm